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ABSTRACT 
Methylglyoxal (MG), a metabolite of glucose, causes non-enzymatic glycation 
of proteins to form irreversible advanced glycation end products (AGEs). Increased MG 
production, which in turn gives rise to AGEs, has been linked to the development of 
complications in diabetes.  However, the role of MG and AGEs in hypertension has not 
been investigated widely. The previous study from our laboratory showed that the 
cellular levels of MG and MG-induced AGE formation are significantly higher in 
cultured aortic smooth muscle cells from spontaneously hypertensive rats (SHR) than 
those from normotensive Wistar-Kyoto rats (WKY). Using immunofluorescence 
staining with specific monoclonal antibodies against MG-induced AGEs, the present 
studies show a strong association of MG and its AGE products (Nε-carboxyethyl-lysine 
and Nε-carboxymethyl-lysine) with hypertension in SHR. The blood pressure of SHR 
was not different from that of WKY rats at 5 wks of age. From 8 wks onwards, blood 
pressure was significantly elevated compared to age-matched WKY rats. Importantly, 
this increase in blood pressure coincided with an elevated MG level in plasma and aorta 
of SHR in an age-dependent fashion compared to age-matched WKY rats, although no 
difference was observed in blood glucose levels between these two strains. Our data 
showed an increased MG level in plasma and aorta, but not in kidney or heart, in SHR at 
an early age of 8 wks, suggesting, in addition to diabetes/hyperglycemic or 
hyperlipidemic conditions, the accumulation of MG in blood vessel walls plays an 
 ii
important role in the development of hypertension or its complications even in the 
absence of diabetes. Moreover, we observed increased blood pressure and vascular 
remodeling in Sprague Dawley rats which had been treated to increase endogenous MG 
and related AGEs. After inhibiting MG and MG-induced AGE generation in SHR, 
hypertension development in this genetic hypertension model was delayed and vascular 
remodeling was reversed. Our data indicate that increased MG and AGE formation may 
play an important role in the development of hypertension. 
.  
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INTRODUCTION AND LITERATURE REVIEW 
 1
1.  Hypertension 
 
Hypertension, commonly known as high blood pressure, is a medical condition in 
which the blood pressure is chronically elevated. Medical guidelines state that a normal 
blood pressure for most adults is less than 120/80 mm Hg. Drug treatment is 
recommended when the blood pressure is at or above 140/90 mm Hg (Chobanian et al. 
2003). Persistent hypertension is a major risk factor for vascular morbidity and mortality 
and is a leading cause of chronic renal failure, heart failure and coronary heart disease. 
Stroke is also one of the most devastating consequences of hypertension. Hypertension 
is an important public-health challenge worldwide, which affects almost one third of the 
adult population. In 2000, the estimated total number of adults with hypertension was 
972 million, 60% of which was in economically developing countries. It is predicted that 
the total number of adults with hypertension in 2025 will increase to 1.56 billion 
(Kearney et al. 2005). Hence hypertension is a significant health problem and will 
become a greater global burden in the next 20 years. Prevention, detection, treatment 
and control of this condition are very critical. 
 
1.1 Types of hypertension 
There are two categories of hypertension, primary (essential) hypertension and 
secondary hypertension. Essential hypertension, hypertension of unknown cause, is 
responsible for 90 to 95 percent of diagnosed hypertension. This type of hypertension is 
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a heterogeneous disorder, with different patients having different causal factors that lead 
to high blood pressure. Secondary hypertension is responsible for the rest of the 
percentage. It is most often due to some identifiable cause such as renal diseases or 
endocrine abnormalities like increased estrogen, catecholamine or aldosterone levels. It 
can also be caused by other preexisting medical conditions such as thyroid dysfunction, 
tumors or overactivity of the adrenal gland, pregnancy-related conditions. Secondary 
hypertension can often be corrected by treating the primary condition with medication or 
surgery. 
 
1.2 Hypertension and lifestyle 
The lifestyle has a significant impact on blood pressure. In some cases of borderline 
hypertension, changes of lifestyle may produce a reduction in blood pressure sufficient 
to avoid the need for the introduction of drug therapy. 
1.2.1 Weight 
Obesity increases the risk of developing hypertension. One possible mechanism is 
that sympathetic drive is increased in overweight people, thus contributing to 
vasoconstriction and increased renin production. Blood pressure falls with weight 
reduction (He et al. 2000; Stevens et al. 2001). Therefore body weight control is an 
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obvious early lifestyle intervention in many people. This becomes especially critical as 
the body mass index of individual in Western countries has increased to epidemic levels. 
For example, in United States, 32.9% of adults 20-74 years old are obese and more than 
17% of teenagers are overweight, which contributes to the rise in blood pressure and 
related complications (Ogden et al. 2007). 
1.2.2 Salt intake 
The relationship between salt intake and blood pressure has been controversial over 
the past 50 years. Several clinical trials have shown that reduction of dietary salt intake 
is successful in reducing blood pressure (Midgley et al. 1996; Sacks et al. 2001). 
It has been demonstrated that the reduction of sodium intake significantly lowered 
systolic and diastolic blood pressure in a stepwise fashion, and there was a greater 
response of blood pressure to progressively lower levels of sodium intake (Sacks et al. 
2001). Salt restriction induces greater reduction in blood pressure in hypertensive 
patients than that in normotensive subjects (Midgley et al. 1996). Therefore, limitation 
of salt intake is a useful adjunct to pharmacological treatment of hypertension. 
1.2.3 Alcohol 
There is a positive linear relationship between alcohol consumption and blood 
pressure in both men and women (Maheswaran et al. 1992; Xin et al. 2001). Both the 
chronic and acute alcohol intake increase blood pressure. Clinical trials have shown that 
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67% reduction in heavy alcohol consumption (3-6 drinks/day) leads to a 3.31 mmHg 
decrease in systolic blood pressure and 2.04 mmHg in diastolic blood pressure (Xin et al. 
2001). In general, it is recommended that hypertensive patients should limit alcohol 
consumption to no more than 2 drinks per day. 
1.2.4 Exercise 
Physical activity has been associated with reduced blood pressure. It has been 
reported that moderately intense aerobic exercise lowers resting blood pressure. In 
addition, progressive resistance exercise may also reduce resting blood pressure, 
possibly by reducing peripheral resistance at rest (Kelley and Kelley 2000; Whelton et al. 
2002). 
1.3 Pathogenesis of essential hypertension 
Although the cause of essential hypertension in any specific patient is usually 
unclear, numerous pathophysiologic factors have been associated with it. These include 
increased sympathetic nervous system activity, overproduction of sodium-retaining 
hormones and vasoconstrictors, increased renin secretion, lifestyle, insulin resistance, 
deficiencies of vasodilators such as NO and prostacyclin, altered cellular ion transport 
and abnormalities of resistance vessels (Fig. 1-1) (Oparil et al. 2003). Recently, 
compelling evidence has shown that structural and functional abnormalities in the 
vasculature, including increased oxidative stress, endothelial dysfunction and vascular 
 5
remodeling may contribute to the pathogenesis of hypertension (Koller 2002; Mulvany 
2000; de Champlain et al. 2004). Many of the antihypertensive drugs interfere with one 
or more of the above factors. 
 
Fig.1-1. Pathophysiologic mechanisms of hypertension. (Adopted from Ann. Intern. 
Med. 139:761-776, 2003)  
 
1.3.1 Oxidative stress 
Oxidative stress is a situation of serious imbalance between the production of 
reactive oxygen species (ROS) and antioxidant defense mechanisms. ROS include 
superoxide anions (O2.-), hydroxyl radicals (OH·), and hydrogen peroxide (H2O2). The 
primary sources for ROS generation include the mitochondrial electron transport chain 
and oxidase enzymes such as NAD(P)H oxidase, xanthine oxidase, cytochrome P450 
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enzymes and lipoxygenases (Mueller et al. 2005). Under normal conditions, only small 
quantities of ROS are generated and ROS are safely neutralized by the antioxidant 
system which consists of numerous enzymes and antioxidant molecules. Under 
pathological conditions, the rate of ROS generation exceeds the neutralizing capacity of 
the antioxidant defense system, leading to oxidative stress. Nearly all animal studies 
performed in various models of hereditary and acquired hypertension have provided 
evidence to support the causative role of oxidative stress to the pathogenesis of 
hypertension. For example, a progressive increase in the production of superoxide anion 
in vascular and cardiac tissues during the development of hypertension has been 
demonstrated in various models of hypertension such as DOCA-salt, SHR, and the 
angiotensin or glucose-induced model of hypertension (de Champlain et al. 2004). There 
are three lines of evidence for the causal contribution of oxidative stress to hypertension. 
First, oxidative stress is present in various animal models of hypertension (Vaziri and 
Rodriguez-Iturbe 2006). Second, chronic treatment with potent antioxidant can prevent 
or attenuate the development of hypertension (de Champlain et al. 2004). Finally, 
induction of oxidative stress causes hypertension in genetically normal and healthy 
animals (Vaziri et al. 2000; Zhou et al. 2002). 
 
1.3.2 Endothelial dysfunction 
Vascular endothelial cells play an essential role in cardiovascular regulation by 
producing a number of potent local vasoactive agents, such as the vasodilator molecule 
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nitric oxide (NO), and the vasoconstrictor peptide endothelin. Dysfunction of the 
endothelium has been implicated in human essential hypertension (MacGregor and 
Kaplan 2006; Quyyumi 1998). It is clear that antihypertensive drugs that interrupt the 
renin-angiotensin system, including ACE inhibitors, angiotensin-receptor blockers and 
mineralocorticoid receptor antagonists, are effective in restoring endothelial dysfunction 
(MacGregor and Kaplan 2006). This action may at least partly account for their 
cardioprotective effects. 
Endothelial dysfunction is a functional and reversible alteration of endothelial cells, 
resulting from impairment in NO availability. Endothelial cells release NO in response 
to several stimuli including increased shear stress during increased blood flow or 
muscarinic receptor stimulation (MacGregor and Kaplan 2006). Numerous studies have 
demonstrated a beneficial effect of acute and chronic L-arginine supplementation on NO 
production and endothelial function, and L-arginine has been shown to reduce systemic 
blood pressure in some forms of experimental hypertension (Gokce 2004). Endothelin-1 
(ET-1), the main endothelin generated in the endothelium, acts in a paracrine or 
autocrine manner on ETA and ETB receptors on adjacent endothelial or smooth muscle 
cells (Pollock and Pollock 2005). An interaction of the NO and ET-1 systems may 
participate in the pathogenesis of endothelial dysfunction. It was found that the 
vasoconstrictor activity of ET-1 is increased along with diminished availability of NO 
(Haynes and Webb 1998).  The imbalance between the two systems may enhance the 
vasoconstrictor and protrophic activity of ET-1, leading to the increase of blood 
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pressure. 
 
1.3.3 Vascular remodeling 
Peripheral resistance is consistently increased in hypertensive conditions 
(MacGregor and Kaplan 2006). Peripheral resistance is determined mainly by resistance 
vessels which consist of the small arteries (lumen diameters < 300 μm) and arterioles. 
Examination of gluteal skin biopsy specimens obtained from patients with untreated 
essential hypertension revealed that essential hypertension is associated with reduced 
lumen areas and increased media-lumen ratios without an increase in medial area in 
resistance vessels (Mulvany 2000). This remodeling is known as inward eutrophic 
remodeling. Mulvany M (Mulvany 2002) suggests that essential hypertension is 
associated only with eutrophic, not hypertrophic, remodeling in small arteries. Although 
the mechanisms by which cause eutrophic remodeling is not clear, the following process 
is proposed: increased neurohumoral activity leads to vasoconstriction and increased 
blood pressure. On the basis of the Laplace relation, the wall stress remains normal by 
decreasing the diameter and increasing the wall thickness of the vessels (Mulvany 2002). 
With time, the active vasoconstriction changes to a passive eutrophic remodeling as 
demonstrated by in vitro experiments (Bakker et al. 2000).  
Several classes of antihypertensive agents such as ACE inhibitors, 
angiotensin-receptor blockers and calcium-channel blockers normalize the vascular 
remodeling (Schiffrin 2001). But not all effective antihypertensive treatments are able to 
 9
correct the abnormal vessel structure. For example, a β-blocker does not reverse 
resistance artery remodeling even it effectively lowers blood pressure (Thybo et al. 
1995).  
 
2. Rat models of hypertension   
Hypertension is a multifactorial and polygenic disease that involves complex 
interactions between genetically determined homeostatic control mechanisms and 
environmental factors; currently no species can meet the requirement for an ideal animal 
model of hypertension. The choice of animal models for specific research is determined 
by experimental design and other constraints. There are two categories of rat models for 
hypertension research, nongenetic and genetic models. Nongenetic models include 
2K1C and DOCA-salt rats, whereas genetic models include SHR, SHRsp and Dhal 
salt-sensitive rats. 
 
2.1 Two-kidney one-clip (2K1C) 
2K1C, the first animal model of hypertension was developed in dogs by clipping 
the renal artery in 1934 (Goldblatt et al. 1934). Five years later, this model was 
developed in rats (Wilson and Byrom 1939). In rats, 2K1C leads to a gradual and 
chronic increase in blood pressure, which plateaus after 2 weeks (Leenen and de Jong 
1971). This model has some sensitivity to diet. For example, sodium restriction 
attenuates development of hypertension in young rats (Miksche et al. 1970). Circulating 
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renin and aldosterone levels are increased in 2K1C model (Koletsky et al. 1971). The 
blood pressure in 2K1C is very sensitive to the inhibition of the renin-angiotensin 
system. Calcium antagonists and direct vasodilators are also effective, but this model 
does not respond to β-blocker, endothelin antagonists and diuretics (Pinto et al. 1998). 
 
2.2 Deoxycorticosterone acetate (DOCA)-salt rats 
The most common endocrine method to induce hypertension is administration of 
mineralocorticoid, particularly DOCA (Terris et al. 1976). In rats, the development of 
hypertension with DOCA requires a high salt diet (Lawler et al. 1987). DOCA-salt rats 
have impaired endothelium dependent relaxation, increased cardiac output, proteinuria 
and glomerulosclerosis (Pinto et al. 1998). DOCA-salt is the only model in which 
renin-angiotensin inhibition does not decrease blood pressure.  This model is sensitive 
to endothelin antagonists and diuretics (Pinto et al. 1998). 
 
2.3 Spontaneously hypertensive rats (SHR) and stroke prone SHR (SHRsp) 
SHR was obtained by inbreeding Wistar Kyoto rats with the highest blood pressure 
(Okamoto and Aoki 1963). The genetic mechanisms of hypertension in SHR have been 
attributed to both neural and vascular alterations. At least three major genes contribute to 
the early development of hypertension, and additional one to the development and 
maintenance of hypertension during aging in SHR (Yamori 1999). The blood pressure in 
SHR rises around 6 weeks of age and steadily increases with age until it reaches 200 
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mmHg. By far, SHR is the most widely used animal model of hypertension. Endothelial 
dysfunction is consistently found in SHR. This model has many features of hypertensive 
end-organ damage like cardiac hypertrophy, cardiac failure and renal dysfunction (Pinto 
et al. 1998). Blood pressure in this model responds to calcium antagonists, direct 
vasodilators and the inhibition of renin-angiotensin system (Pinto et al. 1998).  
Stroke-prone SHR is a further developed substrain from SHR with even higher 
levels of blood pressure and a strong tendency to die from stroke. The blood pressure of 
SHRsp increases rapidly at a young age and finally reaches around 240 mmHg. SHRsp 
rats die with stroke from a few days to 24 weeks after initial symptoms of stroke or 
hypertension. The average life span of this model is 33 to 41 weeks in males and far 
longer in females (Okamoto et al. 1974). 
 
2.4 Dahl salt-sensitive rats 
Dahl salt-sensitive rats were developed by Dr. Lewis K. Dahl in 1950s (Dahl et al. 
1962). The salt sensitive Dahl rats rapidly develop hypertension when treated with high 
salt (8% NaCl) diets at weaning and all died by the 16th week of salt feeding. The 
magnitude of the blood pressure response in this model is partly determined by the age 
at which high salt diet is started. For example, when given high salt at weaning, the rats 
developed fulminating hypertension (above 200 mm Hg) within 6 weeks. If high salt 
feeding was given at 3 months of age, the hypertension developed less rapidly and blood 
pressure went to about 185 mm Hg by 16-20 weeks (Dahl et al. 1968). Dahl 
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salt-sensitive rats have a moderately increased blood pressure even on normal rat chow 
containing 1% NaCl, but it takes a longer time (months instead of weeks) to develop 
(Sustarsic et al. 1981). Inhibition of the renin-angiotensin system, diuretics and 
vasodilators can attenuate the increase of blood pressure in this model, while calcium 
antagonists and β-blockers are less effective (Pinto et al. 1998). 
 
2.5 Fructose-induced hypertensive rats 
It was first demonstrated by Hwang et al that a high-fructose diet can not only 
cause insulin resistance and hyperinsulinemia, but also induce hypertension in 
non-genetic Sprague-Dawley (SD) rats (Hwang et al. 1987). In Wistar rats, treatment 
with 10% fructose in drinking water (equivalent to a diet containing 48-57% fructose) 
for one week or longer is appropriate for the rapid production of fructose-induced 
hypertension (Dai and McNeill 1995). Fructose induced hypertension is a relatively mild 
hypertension compared to genetic hypertension in SHR or DOCA-induced hypertension. 
Irrespective of the concentration of fructose solution given or the duration of treatment, 
the maximum increase in systolic blood pressure is no more than 50 mmHg (Dai and 
McNeill 1995). The mechanism of fructose-induced hypertension is not fully understood. 
It is clear that fructose- induced hypertension is not related to the 
renin-angiotensin-aldosterone system (Hwang et al. 1989). A number of studies 
(Takagawa et al. 2001; Verma et al. 1996) have shown that the endothelium-dependent 
vascular relaxation is impaired in fructose-fed rats. Vasdev et al proposed that aldehydes, 
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especially methylglyoxal, may be the cause of fructose-induced hypertension (Vasdev et 
al. 2000). 
 
3. Gender differences in hypertension 
The incidence and the progression rate of hypertension are markedly higher in men 
than in age-matched, premenopausal women, and very comparable in men and 
age-matched menopausal women (Reckelhoff 2001). This suggests the gender 
differences in vascular tone and possible vascular protective effects of the female sex 
hormone, estrogen. Experimental and clinical data have suggested that hormone 
replacement therapy may reduce cardiovascular disease in postmenopausal women. 
Gender differences in hypertension have also been found in hypertensive animal models, 
such as SHR (Reckelhoff et al. 1999), Dahl salt-sensitive rats (Rowland and Fregly 1992) 
and DOCA-salt rats (Ouchi et al. 1987). It has been reported that estrogen can also lower 
total and low density lipoprotein cholesterol, increase high density lipoprotein 
cholesterol and reduce fibrinogen and factor VII, which may contribute to its 
cardioprotective effect (Knopp et al. 1994; Riedel et al. 1993). A recent study 
demonstrated that the expression of angiotensin II type 2 receptors, a receptor that has 
antiproliferative, anti-inflammatory and antioxidative effects in injured vessels, was 
lower in the injured arteries of male rats compared to female rats (Okumura et al. 2005). 
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This might be the underlying cause for the sex differences in the degree of vascular 
injury, being more pronounced in males than females. The receptors of sex hormone are 
also critical determinants of cardiovascular gender differences. For example, a recent 
work found that activation and expression of estrogen receptor-α, a receptor that reduces 
smooth muscle cell differentiation and induces microvessel dysfunction, were increased 
in women compared to men, which partly explains why women are at high risk of dying 
from cardiovascular disease after menopause (Montague et al. 2006). 
Hormone-dependent gender differences exist in vascular function. Vascular 
contraction is greater in blood vessels of intact male than intact female rats (Crews and 
Khalil 1999). Moreover, the increase in vascular contraction is prevented by estrogen 
replacement in ovariectomized female rats (Tsang et al. 2004). It has also been 
demonstrated that endothelium-dependent vascular relaxation is greater in female SHR 
compared with male SHR (Kauser and Rubanyi 1995). In addition, endothelial 
dysfunction is improved by selective estrogen receptor agonists in ovariectomized SHR 
(Widder et al. 2003). Considerable evidence indicates that sex hormone modifies the 
synthesis/bioactivity of NO, an important vasodilator (Moncada et al. 1991). The gender 
of the animal has been shown to have an important influence on the expression/activity 
of endothelial nitric oxide synthase (eNOS) in the blood vessels (Ellison et al. 1989; 
Kauser and Rubanyi 1994) and the kidney (Neugarten et al. 1997). It has been shown in 
humans and animals that NO level is greater in females than in males because estrogen 
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not only stimulates NO production (Hayashi et al. 1992; Kauser and Rubanyi 1994) but 
also decreases inactivation of NO by oxygen radicals (Mendelsohn and Karas 1999). 
Post-menopausal females has reduced arterial NO activity which was restored to 
premenopausal level after two weeks of estrogen replacement therapy (Majmudar et al. 
2000).  
 
4. Methylglyoxal  
Methylglyoxal (MG), also known as acetlyformaldehyde, pyruvic aldehyde, 
2-ketoproprion-aldehyde etc. is a reactive α-oxoaldehyde. As shown in Fig. 1-2, MG has 
a simple structure with a ketone bond and an aldehyde bond. The aldehyde group is 
more reactive than the ketonic group. In aqueous solution, MG is present mostly in the 
monohydrate (71%) form, while the unhydrate (1%) and dihydrate (28%) forms account 
for the rest part (Creighton et al. 1988). Chemically prepared MG is a yellow liquid with 
a pungent odor.  
 
Fig. 1-2. Structure of methylglyoxal 
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4.1 Formation of MG 
4.1.1 Main pathways of MG formation 
4.1.1.1 Enzymatic MG formation 
Endogenous MG is mainly formed spontaneously during glycolysis as a result of 
fragmentation and elimination of phosphate from glyceraldehydes-3-phosphate (G3P) 
and dihydroxyacetonephosphate (DHAP) (Thornalley 1996) (Fig. 1-3). Normally, 
40-67% of MG is formed from G3P and 33-60% from DHAP, depending on the 
DHAP/G3P molar ratio (Phillips and Thornalley 1993). G3P and DHAP can be 
converted to MG enzymatically (Pompliano et al. 1990; Ray and Ray 1981) and 
nonenzymatically (Richard 1991).  Triosephosphate isomerase (EC.5.3.1.1) can convert 
both G3P and DHAP to MG (Pompliano et al. 1990). Triosephosphate isomerase is a 
very effective catalyst of isomerization and is present at very high cellular 
concentrations (Albery and Knowles 1976). Therefore, a significant concentration of 
cellular MG might be generated by triosephosphate isomerase even though its catalysis 
of degradation of G3P and DHAP to MG is very slow. DHAP can also be catalyzed to 
MG by methylglyoxal synthase in goat liver (Ray and Ray 1981). Methylglyoxal 
synthase (EC.4.2.99.11.) cannot catalyze G3P, fructose 1,6-bisphosphate, 
dihydroxyacetone, and glyceraldehydes. Its activity is regulated by inorganic phosphate 
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which suggests that its role in the control of glycolysis depends on the availability of 
intracellular inorganic phosphate (Ray and Ray 1981).  
 
4.1.1.2 Nonenzymatic MG formation 
The instability of G3P at physiological pH was first reported in 1969 (Mel'nichenko 
et al. 1969). This was followed by a study which found two reaction products, inorganic 
phosphate and MG, from nonenzymatic G3P reaction at pH 7.7, in the presence of 
increasing concentrations of the buffer catalyst lysine (Bonsignore et al. 1973). 
Currently, it is accepted that the deprotonation of G3P or DHAP to an enediolate 
phosphate followed by the cleavage of phosphate group from the carbon skeleton results 
in the formation of MG (Richard 1993). An estimated rate of nonenzymatic MG 
formation is 0.1 mmol/L/day (Richard 1991). 
4.1.2 Minor pathway of MG formation 
Under physiological conditions, minor sources of MG formation include 
metabolism of acetone from lipolysis and metabolism of threonine from protein 
catabolism (Casazza et al. 1984; Lyles and Chalmers 1992). The conversion of acetone 
to MG involves two enzymes, acetone monooxygenase which converts acetone to acetol 
and acetol monooxygenase (AMO) which converts acetol to methylglyoxal. O2 and 
NADPH are required for both enzyme activities. Agents like acetone and ethanol induce 
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the expression of acetone and acetol monooxygenases (Casazza et al. 1984). Their 
activities are also increased under pathological conditions such as diabetes mellitus 
(Gonzalez 1988). Semicarbazide-sensitive amine oxidase (SSAO, EC.1.4.3.6) is a group 
of enzymes containing quinine and copper. Because SSAO contains a cofactor having 
carbonyls, it is sensitive to semicarbazide inhibition (Lyles 1996). This enzyme is 
present in two forms, a soluble form in plasma and a membrane-bound form in tissues. 
Both forms can convert amino acetone to MG (Lyles 1996). SSAO is located only in 
some tissues like vascular wall, retina, kidney and the cartilage tissues, and seems to be 
specific to mammals (Lyles 1996; Yu 1998). Increased SSAO activities are associated 
with diabetic complications, vascular disorders and heart disease. Under physiological 
conditions vascular endothelial cells are the major source of circulating SSAO (Stolen et 
al. 2004). Increased activities of plasma SSAO and AMO have been suggested to be 
responsible for the increased circulating MG levels and diabetic vascular complications 
in animals (Yu et al. 2003). Increased SSAO in transgenic mice are associated with an 
increased endothelial cell capacity for lymphocyte binding and altered expression of 
redox-sensitive proteins (Stolen et al. 2004). 
 
4.2 Exogenous formation of MG 
Exogenous sources of MG include many food products, beverages, alcohol and 
coffee (Nemet et al. 2006). During food processing and storage, MG is formed as a 
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by-product. For example, MG level in honey is in the range of 0.4-5.4 mg/kg, which 
comes from sugar degradation during the heating processes applied in manufacturing 
and storage (Nemet et al. 2006). MG formation was also observed during the heating of 
glucose, fructose and maltulose.  There are different amounts of MG in dairy products 
and alcoholic drinks coming from fermentation. Take wine process as an example; MG 
is released by Saccharomyces cerevisiae during alcoholic fermentation and by 
Oenococcus oeni during malolactic fermentation (Marchand et al. 2000).  
In addition, cigarette smoking is also an exogenous source of MG. Gas 
chromatographic measurement revealed MG levels of 13.5-59.6 μg/cigarette (Fujioka 
and Shibamoto 2006). MG is found in plants, too. It has been reported that MG 
concentration is 30-75 micromolar in various plant species and it can be increased up to 
6-fold by stress conditions such as salinity, drought, and cold (Yadav et al. 2005).   
4.3 Metabolism of MG 
4.3.1 Glyoxalase metabolism of MG   
MG is mainly degraded to D-lactate via glyoxalase system (Fig 1-3). The 
glyoxalase system consists of two enzymes, glyoxalase I and glyoxalase II, and a 
cofactor, reduced glutathione (GSH) (Racker 1951). It is a relatively simple pathway 
comprising two consecutive enzymatic reactions. First reaction is the generation of 
S-D-lactoylglutathione from the hemithioacetal formed non-enzymatically from MG and 
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GSH, which is catalyzed by glyoxalase I (S-lactoylglutathione lysase, EC 4.4.1.5). The 
second reaction is the hydrolysis of S-D-lactoylglutathione to D-lactate catalyzed by 
glyoxalase II (hydroxyacylglutathione hydrolase, EC 3.1.2.6). It has been reported that 
both the maximal velocity and the affinity for its substrate of glyoxalase I are three fold 
greater than those of glyoxalase II (Rae et al. 1990).  
Glyoxalase I activity is found in all tissues of prokaryotic and eukaryotic organisms. 
In human tissues, glyoxalase I activity is highest in the pancreas, kidney, lung and brain 
and lowest in the liver and adipose tissue (Thornalley 1993). The concentration of 
glyoxalase I in most human tissues is approximately 0.2 mg/mg protein (Larsen et al. 
1985). Human glyoxalase I is a dimer and its molecular mass is 44,000Da. GSH is 
essential for glyoxalase I reaction. It not only provides specific binding to the active site 
of glyoxalase I, but also activates the C1 protein of the aldehydic group of MG by 
hemithioacetal formation (Thornalley 1993). GSH is a weak competitive inhibitor of 
glyoxalase I, and its estimated Ki value is 7.9 mM (Rae et al. 1990). Glyoxalase II 
activity is found in the cytosol and mitochondria of cells (Talesa et al. 1988). In human, 
glyoxalase II is a monomer and its molecular mass is 29,200 (Allen and Thornalley 
1993). In cytosol the physiological substrate for glyoxalase is S-D-lactoylglutathione, 
but in mitochondria other substrates such as S-succinylglutathione, may be available 
substrate for this enzyme (Allen et al. 1993a).   
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4.3.2 Non-glyoxalase metabolism of MG 
4.3.2.1 Aldose reductase 
Aldose reductase catalyzes the conversion of MG to acetol (95%) and 
D-lactaldehyde (5%), with NADPH as a cofactor (Vander Jagt et al. 1992). Aldose 
reductase also catalyses the further reduction of acetol and D-lactaldehyde to 
L-1,2-propanediol and D-propanediol respectively. In most human tissues, the ratio of 
the rate of detoxification of MG by glyoxalase I to that by aldose reductase is ca. 10-40 
(Allen et al. 1993b). 
 
4.3.2.2 MG reductase 
MG reductase catalyzes the reduction of MG to L-lactaldehyde. It has been found 
in rat liver homogenates (Ting et al. 1965) and purified from goat liver (Ray and Ray 
1984). In mammals, the molecular weight of MG reductase is 89,000 Da. It requires 
NADH as cofactor and has broad substrate specificity for α-oxoaldehydes and other 
aldehydes, with MG the best substrate (Ray and Ray 1984). MG reductase is highly 
sensitive to sulfhydryl group reagents, and the pH optimum of this enzyme is 6.5. In 
yeast, the molecular weight of this enzyme is 43,000 Da, and it requires NADPH as a 
cofactor and is specific for α-oxoaldehydes (Murata et al. 1986).  
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4.3.2.3 MG dehydrogenase 
MG dehydrogenase catalyzes the oxidation of MG to pyruvate. Two MG 
dehydrogenases have been purifed from goat liver, one requiring NAD and the other 
needing NADP as a cofactor (Ray and Ray 1982). Subsequent studies revealed that MG 
dehydrogenase requires an activator for its activity. Vicinal aminoalcohols have been 
shown to be the best activators. In human liver, this enzyme is an important 
detoxification enzyme for protection against MG (Vander Jagt and Hunsaker 2003). 
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Fig. 1-3. Methylglyoxal formation and detoxification 
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AGE, advanced glycation endproducts;  
AMO, acetol monooxygenase;  
DHAP, dihydroxyacetone phosphate;  
F-1-P, fructose-1-phosphate;  
G3P, glyceraldehyde-3-phosphate;  
Gly, glyoxalase;  
GSH, reduced glutathione;  
MG, methylglyoxal;  
SSAO, semicarbadize-sensitive amine oxidase;  
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4.4 Determination of MG in biological systems 
It is difficult to determine MG content in biological systems. There are several 
major problems with MG quantification. One difficulty is that MG can react with other 
components of the biological matrix. Therefore, it is impossible to detect MG directly. 
Most high performance liquid chromatography (HPLC) methods for MG measurement 
are based on MG derivatization into more stable compounds. Another difficulty with 
MG analysis is interferences from other metabolites. During sample processing 
involving alkalinization, glyceraldehyde-3-phosphate and dihydroxyacetone phosphate 
are converted to MG through spontaneous phosphate elimination (Richard 1991). 
Moreover, the low concentration of MG in biological samples also makes MG difficult 
to detect.   
To date, various techniques have been worked out to detect MG levels in biological 
systems. An early approach for MG determination involved derivatization with 
2,4-dinitrophenylhydrazine, with or without chromatographic separation of the resultant 
osazone and spectrophotometric detection (Fodor et al. 1978; Riddle and Lorenz 1968). 
This method was used to measure non-enzymic formation of MG from glyceraldehydes 
(Riddle and Lorenz 1968) and to detect the presence of MG in beef liver (Fodor et al. 
1978). A disadvantage of this approach is the interference from glycolytic metabolites 
which react with 2,4-dinitrophenylhydrazine to form the same osazone as MG.  
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In the last two decades, several types of derivatization methods for MG have been 
developed with the use of HPLC.  The most common technique is the generation of 
quinoxaline derivatives. In 1980s, 1, 2-diamino-4, 5-dimethoxybenzene was used to 
derivatize MG, and this quinoxaline adduct formed by derivatization has a high 
extinction coefficient and is fluorescent (Hara et al. 1988; Ohmori et al. 1987; 
Yamaguchi et al. 1989). It can be easily detected by UV or fluorescent detectors of 
HPLC or by a mass spectrometry detector. A big problem with this technique is the 
interference from other metabolites. Because the sample was prepared under alkaline 
conditions, not only the glyceraldehyde-3-phosphate and dihydroxycetone phosphate 
spontaneously eliminate phosphate to form MG, but also the hydroxyacetone and 
lactaldehyde can be oxidized to form MG (Richard 1991; Thornalley 1985). These 
reactions can be avoided by acidic sample preparation. Therefore, in the improved 
method, MG was derivatized in deproteinized perchloric acid extracts in order to 
minimize the interference from glycolytic metabolites (McLellan et al. 1992). However, 
a few years later, a study carried by Chaplen’s group (Chaplen et al. 1996a) 
demonstrated that there were a few problems with the method described by McLellan et 
al (McLellan et al. 1992). Firstly, perchloric acid used to deproteinize the sample and to 
maintain an acidic pH can significantly increase MG level due to its oxidative 
degradation of nucleic acid (RNA and DNA) to MG. DNA is 12 fold more susceptible to 
degradation than RNA (Chaplen et al. 1996a). Secondly, DNA degradation can also 
form quinoxaline derivative of 2,3-butandione which was used as an internal standard. 
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Based on these problems, a new method was developed (Chaplen et al. 1996b). In this 
new method, perchloric acid-precipitated material was removed by centrifugation before 
derivatization in order to reduce the nucleic acid interference. An additional C-18 
solid-phase extraction step was added before derivatization to further reduce the amount 
of DNA and RNA in the samples. 5-methylquinoxaline was used as an internal standard 
because it cannot be formed by nucleic acid degradation and it is also commercially 
available. Sample derivatization was done at 20oC instead of 37oC because at low 
temperature the formation of MG from nucleic acid degradation was reduced and the 
rate of reaction between derivative agent, o-phenylenediamine, and MG was lower 
(Chaplen et al. 1996a). Thus, this newly developed method is widely accepted to use for 
the measurement of MG levels in biological systems. In addition, the HPLC method 
where MG was derivatized into the corresponding fluorescent pteridinic derivative with 
6-hydroxy-2,4,5-triaminopyrimidine has also been described (Espinosa-Mansilla et al. 
1998). 
Gas chromatography (GC) has been used for MG qualification. After derivatization 
with o-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine hydrochloride, MG level can be 
measured on MS/SIM detector or electron-capture detector (Bao et al. 1998; Lapolla et 
al. 2003b). Electrospray ionization liquid chromatography mass spectrometry 
(ESI/LC/MS) is also used to detect MG concentrations in human plasma or animal 
tissues (Odani et al. 1999; Randell et al. 2005). 
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4.5 Cellular toxicity of MG  
4.5.1 Modification of protein 
 Under physiological conditions, MG may reversibly and irreversibly bind and 
modify proteins. It has been showed that at physiological concentration (< 5 μM), more 
than 90% of MG is reversibly bound to protein (Lo et al. 1994c). MG reacts with protein 
by initial reversible reactions: with arginine and lysine residues it forms glycosylamine, 
with cysteine it forms hemithioacetal. Further irreversible reaction of MG with protein 
yields irreversible advanced glycation endproducts (AGEs), leading to cross-linking and 
denaturation of protein. The irreversible reaction of MG with lysine residues of protein 
forms Nε-carboxyethyl-lysine (CEL), Nε-carboxymethyl-lysine (CML) and 
1,3-di(N-lysino)-4-methyl-imidazolium (MOLD) (Ahmed et al. 1997; Degenhardt et al. 
1998; Shamsi et al. 1998). MG reacts with arginine residues of protein to form the 
non-fluorescent products 5-hydro-5-methylimidazolone and tetrahydropyrimidine, and 
the major fluorescent products argpyrimidine and hydroimidazolone (Ahmed et al. 2003; 
Oya et al. 1999; Shipanova et al. 1997) (Fig. 1-4). 
 At physiological concentrations of MG, the major irreversible modification of 
protein by MG was of arginine residues forming the hydroimidazolone (Westwood et al. 
1997). When human serum albumin was modified minimally with MG, tryptic peptide 
mapping indicated a hotspot of modification at Arg-410 located in drug-binding site II 
and the active site of albumin-associated esterase activity. Other sites of minor 
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modification were: Arg-114, Arg-186, Arg-218, and Arg-428 (Ahmed and Thornalley 
2005).There are three structural isomers of MG induced hydroimidazolone, MG-H1, 
MG-H2 and MG-H3. Among them, MG-H1 predominates in protein residues (Ahmed 
and Thornalley 2002). MG-H1 residues were found in relatively high amounts in cellular 
and excellular proteins (Thornalley et al. 2003). It is predicted that MG can modify up to 
13 percent of all proteins (Ahmed et al. 2005a), which suggests that MG derived AGEs 
have significant effects on protein structure and function, contributing to protein 
dysfunction. For example, by hydroimidazolone formation, MG modification of critical 
arginine residues could disrupt protein-ligand interactions and inactivate enzyme activity 
(Ahmed et al. 2005a).  
These glycation effects of MG on protein function are expected to be of little 
physiological significance because the glyoxalase system maintains a very low 
concentration of MG under normal physiological conditions. However, chronic exposure 
to increased concentrations of MG or impairment of the glyoxalase system may lead to 
significant deterioration of protein structure and function. MG-induced AGEs have been 
linked to microvascular and macrovascular complications of diabetes, aging and 
Alzheimer’s disease (Kuhla et al. 2005; McNulty et al. 2007; Thomas et al. 2005). 
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Fig.1- 4. MG-induced advanced glycation endproducts (AGEs) 
 CEL, Nε-carboxyethyl-lysine; CML, Nε-carboxymethyl-lysine; MOLD,  
1,3-di(N-lysino)-4-methyl-imidazolium 
 
4.5.2 Modification of nucleic acid 
MG binds to guanine and guanyl nucleosides and nucleotides. With radioactively 
labeled MG, it was found that the reactivity ratio of MG binding to poly-G, poly-A and 
poly-C was 100:7:3, but MG was not reactive with poly-U (Krymkiewicz 1973).  MG 
also binds reversibly to t-RNA, and can inhibit the translation of natural and chemically 
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decapped mRNAs (Lozano and Mezl 1984). MG has mutagenic activity, and in 
mammalian cells, MG-induced mutation mainly occurred at G:C pairs. MG also caused 
multi-base deletions and base-pair substitutions (Murata-Kamiya et al. 2000). MG can 
bind to DNA, leading to the formation of so called DNA-bound advanced glycation 
end-products (DNA-AGEs). Among the nucleobases, guanine and its derivatives readily 
react with MG (Papoulis et al. 1995). With the LC-MS/MS technique, a recent study 
(Frischmann et al. 2005) showed that in the presence of high concentrations of MG (100 
mM),  four adducts were formed which were identified to be two diastereomers of 
N2-(1-carboxyethyl)-2'-deoxyguanosine (CEdGA,B) and two diastereomers of 
N2-(1-carboxyethyl)-2'-deoxyadenosine (CEdAA,B). With physiological concentrations 
of MG, only CEdGA,B was detected. From literature, many studies have shown that 
MG-induced DNA-AGEs may contribute to the age-related decrease of genomic 
functionality, diabetes kidney dysfunction or other diseases (Baynes 2002; Roberts et al. 
2003; Thornalley 2003a). 
 
5. Advanced glycation endproducts (AGEs) 
AGEs are formed by the non-enzymatic Maillard reaction. The Maillard reaction, 
first described by Louise Camille Maillard, is also known as “browning reaction” 
because of the brown colour of its products (Maillard 1916). It begins when the reactive 
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aldehyde or ketone carbonyl group of a reducing sugar interacts with the nucleophilic 
amino group of the amino acid, protein or lipid to produce an unstable Schiff base. This 
step is dependent on the concentration of the available sugars and is reversible. In the 
late phase of the reaction, the Schiff base undergoes further chemical rearrangement to 
form a more stable Amadori product. With time, Amadori products tend to accumulate 
and undergo more complex rearrangements or oxidation or degradation to form the 
AGEs.  
 
5.1 Endogenous AGEs 
Under physiological conditions, the Maillard reaction is very slow, which means 
that AGE formation occurs mainly on long-lived proteins such as extracellular matrix 
components. The extracellular matrix and vascular basement membrane (BM) are highly 
susceptible to AGE modification. AGE-mediated crosslinks in BM are known to cause 
reduced solubility and decreased enzymatic digestion (Charonis and Tsilbary 1992). It 
has been demonstrated that AGE formation can cause structural and functional 
abnormalities of BM protein by impairing their ability to form precisely assembled three 
dimensional matrix aggregates (Vlassara and Palace 2002). Free amino groups on 
collagen fibrils are also very vulnerable to glycation. The AGE-collagen crosslinking 
causes collagen to lose its normal elasticity, strength and flexibility (Zieman and Kass 
 32
2004). In addition to the crosslinking of collagen in the vascular wall matrix, AGEs may 
crosslink elastin fibrils, further reducing arterial distensibility (Winlove et al. 1996). 
The formation of AGEs occurs at a faster rate under conditions of hyperglycemia, 
dyslipidemia and oxidative stress. For example, it has been demonstrated in vitro that the 
rate of the formation of intracellular AGEs may be 14-fold faster in 30 mM glucose 
compared to 5 mM glucose (Giardino et al. 1994). Under pathological conditions, not 
only the long-lived proteins are heavily modified, but also the short-lived molecules 
such as plasma protein and lipids, become the targets of AGE modification. AGE 
modification of short-lived molecules is involved in oxidation of proteins and lipids, 
disruption of molecular conformation, abnormal clearance by receptors, and reduction of 
degradative capacity (Zieman and Kass 2004). Take low density lipoproteins (LDL) as 
an example, AGE formation on the apoprotein part of LDL makes this molecule more 
vulnerable to crosslink formation with the collagen fraction of the vessel wall and 
reduces the ability of LDL uptaken by its receptors, thus, leading to increased serum 
LDL levels (Bucala et al. 1993).  
AGEs are a chemically heterogeneous group of compounds, most of which are 
structurally unidentified. About twenty-five AGEs have been characterized and they 
primarily are the products of reactions involving glyoxal, MG and 3-deoxyglucosone. 
Some of these identified AGE products are non-cross-linking AGEs such as CML 
(Ahmed et al. 1986), CEL (Ahmed et al. 1997), pyralline (Miyata and Monnier 1992) 
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and carboxymethylvaline (Cai and Hurst 1999). Other more complex AGEs form 
cross-links between and within modified proteins. These AGEs include MOLD 
(Degenhardt et al. 1998), glyoxal lysine dimer (GOLD) (Frye et al. 1998), pentosidine 
(Sell and Monnier 1989), argpyrimidine (Shipanova et al. 1997) and hydroimidazolone 
(Oya et al. 1999). Because many of these AGE cross-link moieties have intrinsic 
fluorescence, fluorescence can be used as a marker to detect the presence of these AGEs. 
For example, collagen-linked fluorescence has been shown to increase with age (Dyer et 
al. 1993). A recent study (Lutgers et al. 2006) found that skin autofluorescence, as a 
measure of tissue accumulation of AGEs, was significantly higher in patients who have 
type 2 diabetes with both micro- and macrovascular disease and it was associated with 
the severity of diabetes-related complications. The authors concluded that skin 
autofluorescence might serve as a rapid and useful tool in the outpatient clinic for 
identifying diabetic patients who are at risk for developing vascular complications. 
 
5.2 Exogenous sources of AGEs 
Numerous studies suggest that AGEs from exogenous sources such as diet and 
smoking may have significant impact on disease mechanisms. Diet is the major source 
of exogenous AGEs. AGEs are responsible for the brown color that develops in food 
during cooking and the toughness of food after storage. Foods of the fat group have the 
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highest amount of AGE content, followed by meat (Goldberg et al. 2004). Formation of 
AGEs in food depends on the cooking temperature, length of the cooking time, and the 
presence of moisture (Goldberg et al. 2004). A recent study found that cola drinks 
contain low concentrations of AGEs whereas pasteurised and sterilized milk are rich in 
heat-stable AGEs (Ahmed et al. 2005b). The content of CML in raw milk was 337 ± 94 
nM, but its concentration increased 3-fold during pasteurisation and 6-fold during 
sterilization. CEL content in milk was also increased 3- fold during pasteurisation and 
sterilization (Ahmed et al. 2005b). 
Conventional diets contain significant amounts of AGE-modified substances. Oral 
bioavailability studies of such substances found that approximately 10% of ingested 
AGEs are absorbed and about two-thirds of absorbed AGEs are deposited in tissues, 
where they remain biologically active and exert their pathological effects (Koschinsky et 
al. 1997). The renal excretion of AGEs in human adults is normally poor (only about 
30% of the amount absorbed) and is markedly suppressed in the presence of renal 
disease (e.g. diabetic nephropathy) (Koschinsky et al. 1997; Lin et al. 2002). It has 
becoming increasingly evident that dietary AGEs are an important source of circulating 
and tissue AGEs and manifest similar pathogenic effects to their endogenous 
counterparts. In animal models, restriction of AGEs intake provides significant 
protection against postinjury restenosis, atherosclerosis and nephrophathy and improves 
wound healing and insulin sensitivity (Hofmann et al. 2002; Lin et al. 2002; Peppa et al. 
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2003; Zheng et al. 2002). In type 2 diabetic patients, a high AGE diet over 6 weeks 
induced a significant increase in markers of inflammation including C-reactive protein, 
tumor necrosis factor-α and vascular cell adhesion molecule 1 (VCAM-1) (Vlassara et al. 
2002). Furthermore, LDL pooled from patients on a high AGE diet was more glycated 
and more oxidized and markedly stimulated NF-κB activity (Cai et al. 2004). A recent 
study also demonstrated that a single high AGE meal induces a profound impairment of 
both macro and microvascular function in type 2 diabetic patients (Negrean et al. 2007). 
The curing of tobacco involves conditions conducive to Maillard reaction. Both 
aqueous extracts of tobacco and cigarette smoke contain glycotoxins, highly reactive 
glycation products that can rapidly induce AGE formation on proteins. During the 
process of smoking, high concentrations of glycotoxins are inhaled into the alveoli, 
where they may be both absorbed into the blood stream and taken up into the lung 
parenchymal cells. Studies have shown that total serum AGEs and AGE-apoprotein B 
levels in cigarette smokers were significantly higher than in nonsmokers (Cerami et al. 
1997). In addition, smokers, especially diabetic smokers had an elevated level of AGEs 
in their arteries and ocular lens (Vlassara and Palace 2002).  
 
5.3 Precursors of AGE formation 
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5.3.1 Glucose 
In principle, all reducing sugars such as glucose, fructose, lactose, arabinose and 
maltose as well as certain molecules related to sugar, for example, ascorbic acid 
(Ortwerth and Olesen 1988) can cause non-enzymatic glycation of protein. Since 
glucose is the most abundant sugar in blood, to date, glycation by glucose is the focus of 
most studies. However, glucose has the slowest glycation rate because the reactivity of 
each sugar is dependent on the percentage of sugar in the open chain (carbonyl) structure 
(Bunn and Higgins 1981). In addition to direct glyation reactions, glucose autoxidation 
also contributes to the formation of stable AGEs (Wolff and Dean 1987). By 
metal-catalyzed reaction, glucose itself can be slowly autoxidized, resulting in the 
formation of ketoaldehyde and hydrogen peroxide. Ketoaldehyde formed by the reaction 
of ketoaldehyde and amino groups on proteins is linked to AGE formation (Hunt et al. 
1988; Wolff and Dean 1987). Hydrogen peroxide can produce highly reactive hydroxyl 
radicals, which, in turn, further induces oxidative protein degradation. It has been 
reported that the increased glucose level in diabetic patients causes accelerated 
non-enzymatic glycation that affects some proteins such as LDL apoprotein, hemoglobin 
and collagen (Thomas et al. 2005). 
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5.3.2 Fructose 
Fructose is a highly reactive reducing sugar. It also undergoes the Maillard reaction 
with proteins and amino acids, producing reactive intermediates, cross-linking of 
proteins, and forming brown and fluorescent polymeric materials (Gaby 2005). With 
respect to human health, the contribution of fructose as an effective glycating agent is 
very important for two main reasons. One is that the fructose consumption has been 
increasing steadily in the last two decades. An elevated concentration of fructose and its 
metabolites, caused by the increased fructose intake from the diet, can potentiate the 
Maillard reaction. The other reason is that fructose participates in the glycation reaction 
at a much faster rate than glucose because it is much more reactive in glycating proteins 
(Schalkwijk et al. 2004). It has been found that fructose is 7.5 times faster than glucose 
in glycation of hemoglobin, and 10 times greater in the rate of protein cross-linking 
(Bunn and Higgins 1981; McPherson et al. 1988). It was also revealed that after 
incubation with fructose, not only the intensity of fluorescent albumin but also the 
protein oxidation was 3 to 10 fold greater than that with glucose under the same 
conditions (Takagi et al. 1995). Thus, the large percentage increases in plasma fructose 
concentrations that happen after ingestion of fructose or sucrose may have clinical 
consequences, even though the circulation level of fructose is much lower than that of 
glucose (35 μmol/L fructose vs 5 mmol/L glucose). One animal study showed that long 
term consumption of fructose accelerated glycation (Levi and Werman 1998). In this 
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study, after one year treatment, levels of the early glycation products, glycated 
hemoglobin and fructosamine, were significantly higher in fructose-fed rats compared to 
glucose and sucrose treated groups. AGEs evaluated by collagen-linked fluorescence in 
bones were also significantly elevated in fructose treated rats. 
 
5.3.3 α-oxoaldehydes 
The α-oxoaldehydes include glyoxal, MG and 3-deoxyglucosone (3-DG). The 
α-oxoaldehydes are very reactive. They can react with amino groups of protein up to 100 
times more rapidly than does glucose (Beisswenger et al. 2003). They react with 
arginine and lysine residues of proteins to form AGEs, as mentioned earlier. Under 
physiological conditions, the concentrations of these AGE precursors are very low 
because they are metabolized and inactivated by enzymatic conversion. However, the 
accumulation of α-oxoaldehydes may occur when their formation is increased and/or 
their degradation is decreased. Hyperglycemia, lipid peroxidation and oxidative stress 
may increase the formation of α-oxoaldehydes (Rahbar and Figarola 2003). 
 
5.3.3.1  3-Deoxyglucosone  
3-Deoxyglucosone (3-DG) mainly comes from fructosamine 3-phosphate 
(Beisswenger et al. 2003). Other sources of 3-DG formation include decomposition of 
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fructose 3-phosphate, direct auto-oxidation of glucose and reverse aldol, rearrangement 
and hydrolysis of Amadori product (Zyzak et al. 1995). The concentration of 3-DG in 
plasma of healthy subjects is 60 nmol/L and increased two to three fold in diabetes 
mellitus and four fold in uraemia (Knecht et al. 1992). 3-DG is detoxified by both 
reductive and oxidative pathways. The reductive pathway results in the production of 
3-deoxyfructose catalyzed by NADPH-dependent aldehyde reductase and aldose 
reductase. The oxidative pathway leads to the production of 3-deoxygluconate catalyzed 
by NAD(P)-dependent 2-oxyaldehyde dehydrogenase (Abordo et al. 1999). 3-DG is a 
potent and rapidly acting glycated agent. The reaction of 3-DG with the lysine residue of 
protein forms pyrraline and the 3-DG-derived bis(lysyl)imidazolium crosslink DOLD. 
The reaction of 3-DG with arginine produces hydroimidazolone (Thornalley et al. 1999). 
 
5.3.3.2  Glyoxal 
Glyoxal is formed from several reactions such as spontaneous oxidative 
degradation of glucose, lipid peroxidation, oxidative fragmentation of Schiff’s base etc. 
(Abordo et al. 1999). Recently, a study found a new pathway for glyoxal formation, 
which is through peroxynitrite mediated oxidation of glucose (Nagai et al. 2002). 
Glyoxal is mainly detoxified by the glyoxalase system. It is converted to glycolate with 
reduce glutathione as a cofactor. Glyoxal can react with protein to form CML, GOLD 
and hydroimidazolone (Thornalley et al. 1999). 
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5.3.3.3  Methylglyoxal 
MG, a metabolite of glucose, is a highly reactive dicarbonyl compound formed 
spontaneously during glycolysis as a result of transformation of triose phosphates 
(Kalapos 1999). Other sources of MG formation include intermediates of protein 
metabolism and fatty acid metabolism (Casazza et al. 1984),(Lyles and Chalmers 1992).  
MG is detoxified by the glyoxalase system that uses glutathione as a cofactor (Phillips 
and Thornalley 1993). MG is the most reactive AGE precursor (Thornalley 1990), and it 
can react with selective proteins to yield irreversible AGEs, leading to cross-linking and 
denaturation of protein (Lo et al. 1994b) (See section 4). 
 
5.4 Agents that inhibit AGE formation 
Based on the sites of action of inhibitors in the pathways of AGEs formation, 
there are six groups of AGE inhibitors (Khalifah et al. 1999). Type A inhibitors are sugar 
competitors that compete with sugar for attachment to amino groups of protein. Aspirin 
is an example of this group of inhibitors (Reiser 1998). Type B consists of compounds 
that react with aldose and ketose sugars to inactivate them and prevent their reaction 
with proteins. These compounds inhibit AGE formation at more than one step. 
Aminoguanidine, pyridoxamine and other vitamin B6 derivatives belong to this group 
(Booth et al. 1996).  Type C inhibitors are antioxidants and metal chelators. These 
inhibitors are non-specific. Vitamins C and E are antioxidants that react with reactive 
oxygen species (ROS) generated by AGEs and their intermediates (Kutlu et al. 2005). 
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Desferoxamine and penicillamine are two examples of metal chelators (Khalifah et al. 
1999). Type D inhibitors are compounds that trap reactive dicarbonyl intermediates such 
as MG, glyoxal, glycoaldehyde and glucosones to form substituted triazines and thus 
inhibit AGE formation. This group includes aminoguanidine (Thornalley 2003b), 
metformin (Beisswenger and Ruggiero-Lopez 2003), L-arginine (Lubec et al. 1997), 
OPB-9195 (Miyata et al. 1999), D-Penicillamine (Khalifah et al. 1999) The mechanism 
of AGE inhibition by Type E group is by inhibiting products such as amadoriase 
(Vlassara et al. 1994) and human fructosamine-3-kinase (Saxena et al. 1996). Type F is 
AGE breakers or cross-link breakers. This group includes thiazolium compounds such as 
phenacylthiazolium bromide (PTB) (Vasan et al. 1996) and ALT-711 (Vasan et al. 2003). 
These compounds mostly break α-dicarbonyl cross-links. 
5.4.1 Aminoguanidine 
A variety of agents have been developed to inhibit AGEs formation. Among them, 
aminoguanidine is the best known and most widely used. It was the first agent reported 
to prevent the diabetes-induced arterial wall protein crosslinking (Brownlee et al. 1986).  
Aminoguanidine is a nucleophilic hydrazine compound. It exerts its inhibitory effect 
mostly at the Amadori stage with little effect on post-Amadori products (Khalifah et al. 
1999).  Aminoguanidine inhibits the formation of Amadori products by reacting with 
reactive carbonyl metabolites particularly α-oxoaldehydes such as MG, glyoxal and 
3-DG. Aminoguanidine is mostly efficient in scavenging MG (Thornalley 2003b). 
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Aminoguanidine is also a potent and irreversible inhibitor of semicarbazide-sensitive 
amine oxidase (SSAO), an enzyme that catalyzes aminoacetone to MG (Casazza et al. 
1984). Thus, by scavenging AGE precursors and inhibiting SSAO activity, 
aminoguanidine could decrease the formation of AGEs. The direct antioxidant effect of 
aminoguanidine provides an additional protection against the formation of AGEs. 
Aminoguanidine can not only inhibit catalase activity (Ihm et al. 1999) but also have the 
ability to scavenge peroxynitrite (Szabo et al. 1997). Amiguanidine is also a selective 
inducible nitric oxide synthase (NOS) inhibitor (Misko et al. 1993). Therefore, the use of 
aminoguanidine to inhibit AGEs formation would affect NO production and a number of 
processes associated with it.  
Numerous studies have shown that aminoguanidine has beneficial effect in 
preventing the development of diabetic complications such as nephropathy, neuropathy 
and retinopathy (Thornalley 2003b). In STZ-induced diabetic rats treated with 
aminoguanidine for 32 weeks, not only the glomerular and renal tubular fluorescence 
increase was attenuated, but also the rise of urinary albumin excretion and mesangial 
expansion were retarded (Soulis et al. 1996). In another diabetic animal model (OLEFT 
rats), aminoguanidine (1 g/l in drinking water) also prevented the development of 
albuminuria, mesangial expansion and glomerular basement membrane thickening 
(Yamauchi et al. 1997). It has been reported that aminoguanidine prevents the 
development of experimental diabetic retinopathy in both normotensive and 
hypertensive diabetic rats (Hammes et al. 1991; Hammes et al. 1994). In normotensive 
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diabetic rats, aminoguanidine prevented the accumulation of AGEs at branching sites of 
precapillary arterioles and attenuated the increase in the number of acellular capillaries 
and formed capillary microaneurysms, characteristic pathologic features of background 
diabetic retinopathy (Hammes et al. 1991). In diabetic spontaneously hypertensive rats, 
arteriolar deposition of periodic acid-Schiff (PAS)-positive material and abnormal 
microthrombus formation were completely prevented by aminoguanidine (Hammes et al. 
1994). Aminoguanidine can also prevent cardiovascular changes associated with age. 
There was a decreased level of age-induced AGE formation in cardiac, aortic and renal 
tissues of rats treated with aminoguanidine, in comparison with that from untreated rats. 
Age-related aortic stiffening and cardiac hypertrophy were also prevented by 
aminoguanidine administration (Li et al. 1996). 
 Clinical trials have also been performed to test the effect of aminoguanidine in 
overt diabetic nephropathy (ACTION): ACTION I was conducted in patients with type 1 
diabetes mellitus; and ACTION II in patients with type 2 diabetes mellitus. The results 
of ACTION I showed that aminoguanidine did not attenuate the rate of progression of 
renal disease in type 1 diabetic patients, although it reduced the levels of triglycerides, 
LDL cholesterol, and urinary protein. In ACTION II, 599 patients were enrolled. 
However, this trial was terminated early because of the lack of efficacy and the safety 
concerns (Freedman et al. 1999). Adverse effects of aminoguanidine included 
gastrointestinal disturbance, abnormalities in liver function tests and flu-like symptoms 
(Freedman et al. 1999). 
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 In another clinical study, a group of 690 patients with type 1 diabetes mellitus 
were treated with aminoguanidine to determine if it can ameliorate nephropathy. The 
study found that inhibiting AGE formation can attenuate serious complications of type 1 
diabetes mellitus (Bolton et al. 2004). A one year trial with erythropoietin and 
aminoguanidine on 12 patients on dialysis observed that the combination of 
erythropoietin and aminoguanidine restored red blood cell-deformability to nearly 
normal levels in these patients (Brown et al. 2001).  
 
5.4.2. Metformin 
Metformin (dimethylbiguanide) is widely used as an oral antihyperglycaemic 
agent for the management of type 2 diabetes mellitus. It is a guanidine compound with 
some structure similarity to aminoguanidine, which suggests that metformin may also 
inhibit the glycation process.  A number of studies have shown that metformin 
treatment may protect against diabetic complications through the mechanisms 
independent of its antihyperglycemic effect (Beisswenger and Ruggiero-Lopez 2003; 
Ruggiero-Lopez et al. 1999; Tanaka et al. 1999). In vitro studies have shown that 
metformin is able to significantly inhibit AGEs formation (Kiho et al. 2005; 
Ruggiero-Lopez et al. 1999). An in vivo study (Tanaka et al. 1999) reported that chronic 
treatment with metformin can reduce AGE levels in lens, kidney and nerves in diabetic 
animals. After 10 wks treatment of STZ-induced diabetic rats with metformin (500-650 
mg/kg/day), the AGE levels in lens, sciatic nerve and renal cortex were reduced by 72%, 
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42% and 33%, respectively. In patients with type 2 diabetes, both high dosage 
(1,500-2,500 mg/day) and low dosage (< 1,000 mg/day) of metformin significantly 
reduced MG levels by decreasing MG production or increasing MG detoxification. 
Moreover, it was found that metformin reduced MG in a dose-dependent fashion 
(Beisswenger et al. 1999). Using mass spectrometry technique, MG-metformin end 
product, triazepinone was identified in plasma and urine from type 2 diabetic patients 
treated with metformin (Ruggiero-Lopez et al. 2000). Several mechanisms by which 
metformin inhibit glycation processes have been proposed. One mechanism is suggested 
that metformin traps reactive carbonyl species like MG and glyoxal. An in vitro study 
(Ruggiero-Lopez et al. 1999) demonstrated that metformin directly reacts with MG to 
form stable triazepinone derivatives. Another mechanism is proposed that metformin 
reduces MG levels via enhancement of MG detoxification through the glyoxalase 
pathway with unclear mechanism (Beisswenger et al. 1999). Metformin may also react 
with post-Amadori products (Rahbar et al. 2000). 
 
5.4.3. AGE breakers   
Phenacylthiazolium bromide (PTB) was the first AGE breaking compound 
reported (Vasan et al. 1996). PTB was synthesized based on a hypothesis that the 
carbon-carbon bond of α-diketones can be selectively cleaved with some thiazolium 
salts. The nucleophilic centre of PTB should be able to react with a carbonyl group and 
facilitate its spontaneous cleavage at physiological pH. PTB was successfully tested as 
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an AGE breaker on 1-phenyl-1,2-propane-dione, an α-dicarbonyl compound. In diabetic 
animals, PTB reduced the accumulation of AGEs in blood vessels and attenuated the 
diabetes induced mesenteric vascular hypertrophy (Cooper et al. 2000). Because PTB is 
not stable, a more stable derivative ALT 711 (4,5-dimethylthiazolium) was developed 
(Vasan et al. 2003). A number of studies have demonstrated that ALT 711 can 
significantly improve the elasticity of large vessels and decrease the artery stiffness and 
peripheral resistance, although the mechanism of cross-link breaking is not clear (Vasan 
et al. 2003). A clinical trial has shown that ALT 711 significantly attenuated large artery 
stiffness and decreased arterial pulse pressure in patients with isolated systolic 
hypertension (Liu et al. 2003). 
 
5.5 Quantification of AGEs 
Although there is experimental evidence that AGE accumulation is associated 
with age and diabetes, it is difficult to compare results among laboratories due to 
different techniques used in the determination of AGEs in different laboratories. Since 
AGEs are structurally heterogeneous, it is difficult to ensure that the AGE detected is 
relevant to the complications observed in vivo or in vitro. Currently, there is no 
commonly accepted or widely used method to detect AGEs. Moreover, the lack of 
internal standards leaves assays open to error which require a high degree of accuracy 
and reproducibility for each sample run. 
To date, the use of immunoassay is most common to detect AGEs (Ahmed et al. 
 47
1997; Hammes et al. 1999; Horiuchi et al. 1991; Makita et al. 1992). The assessment of 
high-titer polyclonal and monoclonal anti-AGE antibodies has been applied successfully 
to ELISA and immunohistochemical studies. Although immunoassay procedures have 
provided important analytical evidence for the presence and ultrastructural location of 
AGEs, they have significant disadvantages and limitations. The first disadvantage is the 
specificity of the antibodies. For example, the conventionally prepared anti-CML 
antibody (6D12) cross-reacts with CEL (Koito et al. 2004). The second disadvantage is 
the background interference. This is because proteins containing glycation adduct are 
added in order to reduce non-specific binding of the antibody during immunoassay 
procedure. For instance, there are AGEs in the blocking solution prepared from dried 
milk powder (Ahmed et al. 2005b). The third disadvantage is temperature interference. 
The high temperatures during sample processing may cause artificial AGEs formation 
(Hayashi et al. 2002). The last disadvantage is inaccuracy. This immunoassay does not 
provide absolute concentrations or amounts but rather arbitrary units with or without 
normalization to a reference AGE protein standard (Thornalley et al. 2003). 
Total AGE fluorescence has also been used to determine AGE levels. Many 
AGEs like argpyrimidine and pentosidine crosslink have intrinsic fluorescence which 
can be measured with excitation and emission wavelengths of 350 nm and 450 nm 
respectively. The problem with this method is that major AGEs like CML and CEL are 
not fluorescent and are, therefore, not detected (Thornalley et al. 2003). Recently a new 
method has been developed to detect different AGEs in enzymic hydrolysates of protein 
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by HPLC with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate 
(AQC) (Ahmed et al. 2002). The AQC chromatographic assay was deployed 
successfully for the quantification of CML and CEL in CML-and CEL-modified human 
serum albumin. Structural isomers of hydroimidazolones derived from glyoxal, MG and 
3-DG were also determined for the first time. The limitation of this method is that it 
cannot detect AGEs in vivo because of sensitivity and/or poor chromatographic 
resolution. To date, the best analytical method available to quantify glycation adducts in 
biological systems is liquid chromatography with tandem mass spectrometric detection 
(LC-MS/MS) and quantification using stable isotope substituted standards (Lieuw-A-Fa 
et al. 2004; Thornalley et al. 2003).  
 
5.6 AGE receptors 
Many effects of AGEs are mediated by their interactions with specific 
AGE-receptors. These receptors have been discovered in macrophages, endothelial cells 
and several other cell types (Schmidt et al. 2000). Over the last decade, a number of 
specific AGE-receptors have been identified including AGE-R1, AGE-R2, AGE-R3 and 
the receptor for AGEs (RAGE). AGE-R1 (oligosaccharyl transferase-48) and AGE-R2 
(80K-H phosphoprotein) were initially identified (Yang et al. 1991). AGE-R1 is a single 
transmembrane integral protein and has a small extracellular N-terminal domain and a 
cytoplasmic C-terminal domain (Vlassara 2001). AGE-2, which contains a 
tyrosine-phosphorylated section in the plasma membrane, is involved in the intracellular 
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signaling of various receptors (Goh et al. 1996). AGE-R3, also known as Galectin-3, 
Mac-2 or carbohydrate binding protein-35, has a high-affinity binding for AGE ligands 
(Vlassara et al. 1995). Studies have found that AGE-R1 and –R3 are largely responsible 
for AGE-recognition and high-affinity binding, but they have not been shown to 
transduce cellular signals after binding with AGE. Instead, they may cause the clearance 
and possible detoxification of AGEs (Bucciarelli et al. 2002).  
RAGE, a multiligand member of the immunoglobulin superfamily, has clearly 
been demonstrated to function as a signal transduction receptor (Hudson et al. 2003).  It 
has a single transmembrane domain followed by a highly charged 43-amino acid 
cytosolic tail (Schmidt et al. 2001). In homeostasis, RAGE is expressed at a very low 
level, however, biologic stress such as mechanical vascular injury, diabetes and 
inflammation lead to striking upregulation of RAGE expression (Park et al. 1998). 
RAGE may be involved in a broad array of diseases like diabetic complications, 
inflammation and wound healing (Hudson et al. 2003). 
 
6. The association of MG and diseases  
Under physiological conditions, with its low concentration (<5 μM) (Westwood 
and Thornalley 1995), the effect of MG on biological systems are expected to be of little 
physiological significance. However, an increased formation of MG may occur when the 
availability of its precursors is increased. There is a link between overproduction of MG 
and over-consumption of food high in carbohydrates and fat and/or alcoholic drinks. 
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Accumulation of glucose, fat or alcohol, precursors of MG, may eventually cause an 
overproduction of MG. Because MG level depends on the balance of its synthesis and 
degradation, an increased MG level also occurs when the rate of its detoxification is 
decreased even with normal levels of glucose or other MG precursors. Since MG is a 
major sources of intracellular and plasma AGEs (Thornalley 1990), overproduction of 
MG gives rise to elevated level of AGEs. Increased levels of MG and AGEs have been 
linked to many diseases including diabetes mellitus, aging, and Alzheimer’s disease.  
 
6.1 Diabetic complications 
MG formation is accelerated in hyperglycemic conditions (Beisswenger et al. 
2001). Plasma MG is highly elevated, reaching ~400µmol/L in poorly controlled type 2 
diabetic patients (Lapolla et al. 2003a). Biochemical and clinical evidence shows that 
increased formation of MG is linked to the development of chronic complications of 
diabetes, such as retinopathy, nephropathy, neuropathy and also macrovascular diseases 
like atherosclerosis even though the exact role of this dicarbonyl in these processes is 
still unclear. There are three lines of evidence for the role of MG in diabetic 
complications: (i) increased MG concentration at the sites of complications development 
(Kalapos 1999); (ii) Induction of diabetes-like vascular disease by experimental 
exposure to MG (Berlanga et al. 2005); (iii) suppression of the development of diabetic 
complications by scavenging MG in experimental diabetes and clinical trial (Thomas et 
al. 2005; Thornalley 2003b). 
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The first indication that MG formation was increased in hyperglycaemia came from 
a study of human red blood cells cultured under high glucose concentration (Thornalley 
1988). The concentration of MG and the flux of MG metabolized by the glyoxalase 
system were proportional to the glucose concentration. An in vivo study showed 
increased concentrations of MG in the kidney cortex and medulla, lens and blood in 
diabetic rats (Phillips et al. 1993). Then a clinical study was initiated to survey the MG 
concentrations in patients with type 1 or 2 diabetes and healthy control subjects 
(McLellan et al. 1994). The concentration of MG was increased 2-3-fold in blood 
samples of type 1 diabetic patients and 5-6-fold in blood samples of type 2 patients.  
In endothelial cells, the hyperglycemia-induced intracellular AGE formation was 
significantly increased when glyoxalase-I was partially inhibited. In addition, 
overexpression of glyoxalase-I completely prevented hyperglycemia-induced AGE 
formation, indicating that hyperglycemia increased AGE formation primarily by 
enhancing the concentration of MG (Shinohara et al. 1998). MG-induced AGEs level is 
also increased in diabetic animal models. Studies using rats rendered diabetic after STZ 
injection found that the AGE content was increased in lens tissue, kidney, skin and 
vascular tissues after only a few weeks of the injection (Baynes and Thorpe 1999; 
Nakayama et al. 1991). A recent study (Thornalley et al. 2003) showed that in 
STZ-induced diabetic rats, the concentration of CML and CEL was increased in renal 
glomeruli, retina, sciatic nerve and plasma proteins compared to healthy controls. 
Moreover, the increased levels of MG-induced hydroimidazolones were found in renal 
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glomeruli (295%), retina (279%), nerve (211%) and plasma proteins (154%), in 
comparison with that from control group. In human diabetic subjects, levels of 
MG-induced AGEs are significantly higher compared to healthy controls.  It had been 
reported that the MOLD level was higher in diabetic plasma compared with that of 
control (273 ± 62.67pmol per milligram of protein vs 172.5 ± 32.53 pmol per milligram 
of protein) (Chellan and Nagaraj 1999). Serum hydroimidazolone level was also 
increased in diabetic patients (Fosmark et al. 2006; Kilhovd et al. 2003). With 
LC-MS/MS technique, quantitative screening of MG-induced AGEs was performed in 
diabetic patients. It was found that the level of free CML was increased approx. 4-fold in 
peritoneal dialysis (PD) subjects and 8-fold in haemodialysis (HD) subjects. The level of 
free CEL was also increased markedly, approx. 10-fold in PD subjects and 22-fold in 
HD subjects. In addition, the concentrations of MG-induced hydroimidazolone in 
plasma proteins were also increased 16-fold in PD and 50-fold in HD subjects 
(Thornalley et al. 2003). The argpyrimidine concentrations in diabetic serum proteins 
was two- to threefold higher than in nondiabetic controls (9.3 ± 6.7 vs 4.4 ± 3.4 
pmol/mg). Moreover, there is a significant correlation between serum protein 
argpyrimidine and glycosylated hemoglobin, which suggested that argpyrimidine 
synthesis in serum proteins, occurs in relation to the degree of glycemia (Wilker et al. 
2001). The increased formation of MG modified proteins may initiate processes leading 
to vascular dysfunction and development of diabetic complications. 
Oral administration of MG to mice may induce renal pathology similar to that 
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found in human diabetic nephropathy (Golej et al. 1998). After 5-month treatment with 
MG, the mice had elevated level of collagen in kidney and increased glomerular 
basement membrane thickness. Another study showed that prolonged exposure of rats to 
MG by intraperitoneal administration induces diabetes-like microvascular changes in 
rats (Berlanga et al. 2005). After 7 wk treatment with MG (50-75 mg/kg of body weight), 
serum creatinine was increased, hypercholesterolaemia was induced and vasodilation 
was impaired compared with saline controls. Degenerative changes in cutaneous 
microvessels with loss of endothelial cells, basement membrane thickening and luminal 
occlusion were also detected. There is also evidence that administration of 
AGE-modified proteins may induce diabetes-like vascular damage (Vlassara et al. 1992; 
Vlassara et al. 1994). In this study, AGE-modified albumin was administrated 
intraperitoneally in healthy nondiabetic rats. Within 2-4 weeks of AGE treatment, it was 
found that AGE administration was associated with a significant increase in vascular 
permeability, and markedly defective vasodilatory responses to acetylcholine and 
nitroglycerin, consistent with marked NO inactivation or/and downstream pathways 
(Vlassara et al. 1992). Chronic administration of in vitro prepared protein-AGE to 
normal rats also leads to advanced pathologic changes in renal glomerular structure and 
function consistent with focal glomerulosclerosis and albuminuria (Vlassara et al. 1994). 
Further support for the involvement of MG in the development of diabetic 
complications comes from the observations that the pharmaceutical agents, which 
prevent the accumulation of MG and MG-related AGEs, attenuate the development of 
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diabetic complications. Therefore, prevention of protein damage by inhibiting AGE 
formation at critical functional sites of proteins in diabetes is expected to contribute to 
the preventive therapy of diabetic complications. Many agents inhibit AGE formation by 
scavenging or trapping MG.  Aminoguanidine, one of the most widely used AGE 
inhibitor, scavenges MG and other α-oxoaldehydes and thereby prevents the formation 
of α- oxoaldehydes-modified proteins (Lo et al. 1994a). Metformin, another AGE 
inhibitor, can significantly reduce MG levels by decreasing MG production or increasing 
MG detoxification (Beisswenger and Ruggiero-Lopez 2003). Other AGE inhibitors like 
pyridoxamine, LR-90, or LR-9, have also been reported to interact with MG (Rahbar 
and Figarola 2003). 
MG also interferes with insulin action. It has been reported that intracellular MG 
can impair insulin signalling pathways by inhibiting insulin-stimulated phosphorylation 
of protein kinase B and extracellular-regulated kinase 1/2, without affecting insulin 
receptor tyrosine phosphorylation (Riboulet-Chavey et al. 2006). A recent study from 
our lab (Jia et al. 2006) found that MG modifies insulin molecule by attaching to the 
internal arginine in the β-chain of insulin. This MG-modified insulin has a significantly 
reduced capacity in stimulating [3H]-2-deoxyglucose uptake by 3T3-L1 adipocytes and 
L8 skeletal muscle cells, compared with native insulin (Jia et al. 2006). 
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6.2 Aging 
Aging is characterized by structural and functional changes of different tissues or 
organs, especially, cardiovascular and renal systems. It has been proposed that most of 
these cardiovascular and renal modifications were related to glycation of proteins 
(Vlassara et al. 1992). A recent study found that prolonged intraperitoneal administration 
of MG can induce premature aging of the animals (Berlanga et al. 2005). In this study, 
after 7-wk treatment with MG, the rats developed an emaciated and wasted phenotype 
involving the whole body and, particularly, the carcass. Cachexia was associated with a 
loss of adipose tissue and a reduction in muscle mass, along with a decrease in skeletal 
compactness.  Moreover, MG-treated rats exhibited an aged cutaneous phenotype 
characterized by thinner skin with abundant wrinkles. The formation of AGEs 
progressively increases with aging, even in the absence of disease. For example, in 
human, tissue CML concentration increased five-fold from 20 to 85 years of age (Dyer 
et al. 1993). Accumulation of AGEs may cause decreased central arterial compliance, 
increased myocardial stiffness and endothelial dysfunction (Zieman and Kass 2004).  
 
6.3 Atherosclerosis 
There is abundant in vitro and in vivo evidence that MG and AGEs play a role in 
the pathogenesis of atherosclerosis. (i) MG induced platelet-derived growth factor 
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(PDGF) β modification and altered mitogenic signaling in response to PDGF-β and 
subsequent cell proliferation, leading to fragile thin cap in atherosclerotic lesion 
(Cantero et al. 2007). (ii) AGE formation alters the functional properties of several 
important matrix molecules. For instance, AGEs can cause collagen cross-linking and 
high resistance to collagenases (Sell and Monnier 1989), enhance synthesis of 
extracellular matrix components (Sims et al. 1996) and trap circulating serum proteins, 
such as lipoproteins (Meng et al. 1998). (iii)By binding to AGE receptors on endothelial 
cells, AGEs increase vascular permeability (Wautier et al. 1996), intracellular oxidative 
stress (Yan et al. 1994), and expression of adhesion molecules (Schmidt et al. 1995). (iv) 
Tissue-bound AGEs can chemically quench cell-derived nitric oxide activity, thereby 
inhibiting the nitric oxide-dependent vascular relaxation (Bucala et al. 1991). (v) AGEs 
also increase proliferation and fibronectin production of smooth muscle cells (Sakata et 
al. 2000).  
 
7. Rationale and hypothesis 
The association of MG and AGEs with hyperglycemic states such as diabetes 
mellitus has been intensively studied. Increased MG production, which in turn gives rise 
to AGEs, has been linked to the development of diabetic complications although the 
exact role of this dicarbonyl in this process remains unclear (Goldin et al. 2006; Singh et 
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al. 2001). The association of MG and related AGEs with hypertension, however, is still 
largely unsettled. It has been reported that the systolic blood pressure was significantly 
increased after Wistar Kyoto (WKY) rats were treated with MG in drinking water. This 
increase was associated with an increase of aldehyde conjugate levels in kidney, and a 
decrease in serum levels of circulating NO (Vasdev et al. 1998). An enhanced AGE 
formation was found in the aorta of stroke-prone spontaneously hypertensive rats 
(Mizutani et al. 1999). Our previous study (Wu and Juurlink 2002) demonstrated 
increased MG and AGEs in vascular smooth muscle cells (VSMCs) from spontaneously 
hypertensive rats (SHR) in comparison with that from WKY rats. We also showed that 
MG increased NF-κB p65 and ICAM-1 expression in VSMCs from SHR (Wu and 
Juurlink 2002).  These observations lead us to hypothesize that an increased 
cellular level of MG is one of the causative factors of essential hypertension. MG 
causes the development of hypertension by enhancing AGEs formation in VSMCs, 
increasing oxidative stress, causing endothelial dysfunction and inducing vascular 
remodeling. 
 
8. Objectives and experimental approaches 
 
I. To investigate the correlation between increased intracellular MG levels and 
hypertension development in spontaneously hypertensive rats.  We investigated 
whether MG and MG-induced AGEs were increased in plasma, aorta and kidney 
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of SHR and whether an increased formation of MG and related AGEs was 
correlated with the development of high blood pressure in SHR. We used 
different ages (5-, 8, 13, and 20-weeks) of SHR and age-matched normotensive 
WKY rats to carry out this part of the study. Blood pressure in 5-week old SHR 
is still in the normal range (pre-hypertensive stage). At 8 wks of age, SHR start 
to develop hypertension and 13-week old SHR have fully developed 
hypertension.  SHR of 20-wks age represents the aged hypertension model.  
II. To investigate gender-related changes in AGEs and NOS in Sprague-Dawley (SD) 
rats and stroke-prone SHR (SHRsp). There is as yet no data on gender 
differences in regard to AGEs. Also there is no study correlating gender related 
changes in CEL, CML and NOS with hypertension development. In this part of 
the study, gender related changes in AGEs and NOS were investigated through 
an immunohistochemical characterization in Sprague-Dawley (SD) rats and 
SHRsp. 
III. To investigate whether decreased MG levels in SHR will prevent or slow down 
the development of hypertension. We chronically treated young SHR with 
aminoguanidine, an inhibitor of AGEs formation, before their blood pressure 
started to increase. We determined if aminoguanidine attenuated the increase of 
blood pressure in SHR and the possible underlying mechanisms. 
IV. To test whether accumulated MG and its AGEs in blood vessel walls may 
constitute a causative factor for hypertension development. We chronically 
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treated young SD rats with fructose, and/or metformin. Then we determined 
whether increased formation of MG and MG-induced AGEs caused blood 
pressure increase, insulin resistance and vascular remodeling.  
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ANIMALS  
All the rats were purchased from Charles River laboratories (St-Constant, 
Quebec, Canada), and housed in a temperature-regulated animal facility, exposed to a 12 
h light/dark cycle with free access to food and water. The standard lab rat chow, Prolab® 
RMH 3000, contains 60% starch, 22% crude proteins, 5% crude fat, 5% crude fiber, 6% 
ash, and 2% added minerals (PMI® Nutrition Intl., MO. USA).  Rats were treated in 
accordance with guidelines of the Canadian Council on Animal Care and the 
experimental protocols were approved by the Animal Care Committee at the University 
of Saskatchewan. Systolic blood pressure was determined weekly using a standard tail 
cuff noninvasive BP measurement system (Model 29-SSP, Harvard Apparatus, St. 
Laurent, QC, Canada). At the end of each study, rats were anaesthetized with sodium 
pentobarbital (60 mg/kg body weight) intraperitoneally. Blood was collected from the 
heart using anti-heparin coated tubes, and plasma was separated by centrifuging blood 
samples at 1,000 g for 10 min at 4ºC.  Tissues including heart, kidney, liver, aorta and 
mesenteric arteries were isolated in ice-cold phosphate buffer saline, cleaned and 
snap-frozen in liquid nitrogen immediately and stored at -80ºC until processing.  
 
 
MG MEASUREMENT 
Quantitation of MG was done by the widely accepted o-phenylenediamine 
(o-PD)-based assay (Chaplen et al. 1996) with some modifications. Earlier assays for 
MG measurement employed dinitrophenylhydrazine for derivatization of MG. This was 
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not specific since other intermediates of glycolysis also reacted with 
dinitrophenylhydrazine (Richard 1991). The method we have used is specific for MG 
and is also very sensitive. In this method the reagent, o-PD, a 1,2-diaminobenzene 
derivative, rapidly reacts with MG to form a quinoxaline which can be easily quantified 
with reverse-phase high-performance liquid chromatography.  
 
Sample preparation 
Frozen tissues were pulverized with a Mikro-Dismembrator and kept on ice. 
Then phosphate buffer was added to tissue samples. The amount of tissue and volume of 
buffer depend on the quantity of tissue and protein content. Tissues were sonicatied on 
ice (3 times, 10 seconds each), followed by addition of about 1/4 or 1/5 volume of 1 
mol/L perchloric acid (PCA) to each sample. The samples were mixed up, incubated on 
ice for 10 minutes and centrifuged at 15,000 g for 10 min at 4 oC to remove the 
PCA-precipitated material. The supernatant of the tissue homogenate or plasma were 
derivatized with 100 mmol/L o-PD (derivatizing agent) for 3 h at room temperature, 
followed by centrifuge at 15,000 g for 10 min to remove any particles. 252 µl 
supernatant was taken out and mixed up with 28 µl of the 100 µmol/L internal standard 
(5-methylquinoxaline, 5-MQ). Then 130 µl of mixture was transferred into glass inserts 
of HPLC. 
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HPLC of quinoxalines 
The quinoxaline derivative of MG (2-methylquinoxaline, 2-MQ) and the 
quinoxaline internal standard (5-MQ) were measured using a Hitachi D-7000 HPLC 
system (Hitachi Ltd., Mississauga, ON, Canada). The column was a Nova-Pak® C18 
column (3.9x15 mm, and 4 um particle diameter; Waters, MA). The mobile phase was 
composed of 80 vol% of 10 mmol/L NaH2PO4 (pH 4.5) and 20 vol% of HPLC grade 
acetonitrile. The analysis conditions were as follows: detector wavelength, 315 nm; the 
flow rate of mobile phase, 1.0 ml/min; typical sample size, 130µl; and colume 
temperature, room temperature. Duplicate injections of each sample were made. 
Samples were calibrated by comparison with 2-MQ standards. 
 
IMMUNOHISTOCHEMISTRY 
Immunostaining 
Immunostaining was performed using the method described in our previous study 
(Ndisang et al. 2003). In brief, paraformaldehyde-fixed and OCT-embedded renal tissues 
derived from WKY and SHR at different ages were prepared. Sections of 8-10 μm 
thickness were cut using cryostat. Sections on poly-l-lysine coated slides were 
permeabilized with 0.1% triton X-100 in PBS for 5 min after 3 washes in 0.1 mol/L 
phosphate buffer. Nonspecific antibody binding was blocked by incubation for 30 min 
with normal goat serum diluted 1:30. Sections were then incubated overnight at room 
temperature in a humid atmosphere in the presence of either monoclonal anti-CML 
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antibody or anti-CEL antibody (Novo Nordisk, A/S, Denmark) diluted 1:100 in PBS 
containing 0.1% bovine serum albumin. Control sections were exposed to the diluting 
solution without the primary antibody added. After the reaction with the primary 
antibody, the slides were washed 3 times with PBS and incubated with anti-mouse 
IgG-FITC (Sigma, St. Louis, USA) diluted 1:200 for 1 h at room temperature, followed 
by another 3 washes. Thereafter, the slides were mounted in PBS-glycerin (7:3 v/v), 
coverslipped and examined under a fluorescence microscope (Olympus 1×70) with the 
appropriate filters.  
Double staining 
For double immunofluorescence staining, aortic sections were incubated overnight 
in a cocktail solution containing mouse anti-CEL antibody (1:100) and rabbit anti-eNOS 
antibody (1:200; Chemicon International, Temecula, CA, USA). After multiple washes 
in PBS, sections were incubated for 2 h in goat anti-mouse IgG-FITC (1:200) and Alexa 
Fluor 568–conjugated anti-mouse secondary antibody (1:400; Invitrogen, Burlington, 
ON, Canada). Sections were mounted on gelatinized slides and coverslipped. 
Immunofluorescence images were obtained under a confocal laser-scanning microscope 
(LSM 510 META; Zeiss). 
Quantification of staining 
The intensities of staining were quantified using GeneTools image analysis 
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software (PerkinElmer®, MA, USA). For each animal, thirty spots of each micrograph, 
with 10 micrographs of each section and three sections of each animal were analyzed 
and the average value was used to express the intensity of staining.  
 
MEASUREMENT OF REDUCED GLUTATHIONE LEVELS   
The reduced glutathione (GSH) levels in plasma, aorta or kidney were 
determined by derivation with 5, 5'-dithio-bis (2-nitrobenzoic acid), and reverse-phase 
HPLC using ultra-violet detection, as described in our previous study (Wu et al. 2004). 
 
MEASUREMENT OF HYDROGEN PEROXIDE 
The formation of H2O2 was measured by a dichlorofluorescin (DCFH)-assay as 
described previously (Wu and Juurlink 2002). Briefly, cleaned aortic rings 5 mm long 
were loaded with a membrane permeable and nonflurescent probe DCFH-DA (10 
μmlo/L) in Kreb’s buffer bubbled with O2 and protected from light, for 2 hrs at 37°C. 
The washed aortic tissues were transferred to a 96-well plates containing 200 µl Kreb’s 
buffer in each well, incubated for 2 hrs at 37°C and detected. Once inside cells, 
DCFH-DA becomes the membrane impermeable DCFH2 in the presence of cytosolic 
esterases and further oxidized by H2O2 to form oxidized-DCF with detectable 
fluorescence. Oxidized-DCF was quantified by monitoring the DCF fluorescence 
intensity with excitation at 485 nm and emission at 527 nm with Fluoroskan Ascent 
plate-reader and Ascent software (Thermo Labsystem, Helsinki, Finland). The level of 
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oxidized –DCF was expressed using arbitrary units. 
 
DETECTION OF SUPEROXIDE PRODUCTION 
O2- production was measured using the lucigenin-enhanced chemiluminescence 
method as described previously (Wu et al. 2002). Briefly, cleaned aortic rings in Kreb’s 
buffer were incubated for 30 min at 37°C, and then mixed with lucigenin at 50 µmol/L 
for 15 min before subjecting to detection. MG-induced O2- was measured by the 
intensity of chemiluminescence detected with a luminometer (TD-20/20, Tunner 
Designs, CA) and expressed using arbitrary units. 
 
MEASUREMENT OF ENZYME ACTIVITIES 
The activities of GSH-Px and GSH-Red were measured according to methods 
described previously (Wu and Juurlink 2001). The measurement of GSH-Px was 
coupled to the reduction of GSSG formed in the peroxidase reaction. The activity of 
GSH-Red was determined by monitoring the decrease in absorbance at 340 nm based on 
the oxidation of NADPH which is coupled to the reduction of one GSSG back to two 
GSH. The enzyme activity for both GSH-Px and GSH-Red was expressed as nmole 
NADPH oxidized/min/mg protein. Protein concentrations were determined by 
bicinchoninic acid procedure using bovine serum albumin standards. 
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ABSTRACT 
Background: Methylglyoxal (MG), a metabolite of glucose, causes non-enzymatic 
glycation of proteins to form irreversible advanced glycation endproducts (AGEs). The 
role of MG in the development of essential hypertension is unknown though MG has 
been extensively studied in relation to diabetes.   
Methods: Blood pressure of spontaneously hypertensive rats (SHR) and paired Wistar 
Kyoto (WKY) rats was measured at 5, 8, 13 and 20 wks of age. HPLC was used to 
determine the levels of plasma and kidney MG as well as reduced or oxidized 
glutathione in the kidney. MG-induced AGEs, Nε-carboxyethyl-lysine (CEL) and 
Nε-carboxymethyl-lysine (CML), in the kidney were detected by immunohistochemistry.  
Results: Plasma MG levels were significantly elevated in SHR, but not in WKY rats, at 
8, 13 and 20 wks of age in parallel with blood pressure increase. Kidney MG levels in 
SHR were increased by 21% and 38% at 13 and 20 wks, respectively, compared to 
age-matched WKY rats. There were no differences in blood pressure and MG levels in 
plasma and kidney between SHR and WKY rats at 5 wks of age. Immunohistochemistry 
revealed more intense staining for CML and CEL in kidneys from SHR compared to 
WKY rats from 8 wks onwards. Most of the staining was localized to renal tubules with 
some staining in the glomerular vessels.  
Conclusions: MG and AGEs formation was significantly elevated in kidney from SHR, 
which may cause local vascular and tubular damage, contributing to the development 
and complications of hypertension. 
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INTRODUCTION 
 Methylglyoxal (MG), a metabolite of glucose, is a highly reactive dicarbonyl 
compound formed spontaneously during glycolysis as a result of transformation of triose 
phosphates1. This dicarbonyl molecule can be also formed during various metabolic 
processes including metabolism of acetone from lipolysis and metabolism of threonine 
from protein catabolism2,3.  MG is detoxified by the glyoxalase system that uses 
glutathione (GSH) as a cofactor1. MG is the most reactive AGE precursor4 and can react 
with selective proteins to yield irreversible advanced glycation endproducts (AGEs), 
leading to cross-linking and denaturation of protein5. The irreversible reaction of MG 
with lysine residues of protein forms Nε-carboxyethyl-lysine (CEL) and 
Nε-carboxymethyl-lysine (CML). 
 MG and related AGEs such as CEL have been recognized as indicators of carbonyl 
overload in vivo6,7, and their formations are correlated with age8,9.  The association of 
MG and AGEs with hyperglycemic states such as diabetes mellitus has been intensively 
studied. Increased MG production, which in turn gives rise to AGEs, has been linked to 
the development of nephropathy in diabetes although the exact role of this dicarbonyl in 
this process remains unclear10. The associations of MG and related AGEs with 
hypertension, however, are still largely unsettled. It has been reported that the systolic 
blood pressure was significantly increased after Wistar Kyoto (WKY) rats were treated 
with MG in drinking water. This increase was associated with an increase of aldehyde 
conjugate levels in kidney, not in heart or liver11. An enhanced AGE formation was 
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found in the aorta of stroke-prone spontaneously hypertensive rats12. Our previous 
study13 demonstrated increased MG and AGEs in vascular smooth muscle cells 
(VSMCs) from spontaneously hypertensive rats (SHR) in comparison with that from 
WKY rats. We also showed that MG increased NF-κB p65 and ICAM-1 expression in 
VSMCs from SHR13.  
The aim of the present study was to investigate whether MG and MG-induced 
AGEs were increased in plasma or kidney of SHR and whether an increased formation 
of MG and related AGE was correlated with the development of high blood pressure in 
SHR.  To this end, MG levels in plasma and kidney were determined in SHR and 
WKY at different hypertension development stages.  The MG-induced CML and CEL 
in kidney were evaluated in both strains. Since glutathione (GSH) plays a role in the 
metabolism of MG, GSH levels, oxidized glutathione (GSSG) and related enzyme 
activities including glutathione peroxidase (GSH-Px) and glutathione reductase 
(GSH-Red) were also evaluated.  
  
MATERIALS AND METHODS 
Animals  
Male SHR and WKY rats were purchased from Charles River laboratories 
(St-Constant, Quebec, Canada), and were treated in accordance with guidelines of the 
Canadian Council on Animal Care and the experimental protocols were approved by the 
Animal Care Committee at the University of Saskatchewan. SHR and paired WKY rats 
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were compared at 4 different time points ranging from 5 to 20 wks of age. Systolic blood 
pressure was determined weekly using a standard tail cuff noninvasive BP measurement 
system (Model 29-SSP, Harvard Apparatus, St. Laurent, QC, Canada). At the end of the 
study, rats were anaesthetized with sodium pentobarbital (60 mg/kg body weight) 
intraperitoneally. Blood was collected from the heart, and plasma was separated by 
centrifuging blood samples at 1,000 g for 10 min at 4ºC.  Kidney was isolated in 
ice-cold phosphate buffer saline (PBS), cleaned and snap-frozen in liquid nitrogen 
immediately and stored at -80ºC until processing.  
 
MG Measurement  
Quantitation of MG was done by the widely accepted o-phenylenediamine 
(o-PD)-based assay as described by Chaplen et al.14 with some modifications. Briefly, 
the supernatant of kidney homogenate or plasma was incubated with 100 mmol/L o-PD 
(derivatizing agent) for 3 h at room temperature. The quinoxaline derivative of MG 
(2-methylquinoxaline) and the quinoxaline internal standard (5-methylquinoxaline) were 
measured using a Hitachi D-7000 HPLC system (Hitachi Ltd). The column was a 
Nova-Pak® C18 column (3.9x15 mm, and 4 μm particle diameter; Waters, MA). The 
mobile phase was composed of 80% (vol) of 10 mmol/L NaH2PO4 (pH 4.5) and 20% 
(vol) of HPLC grade acetonitrile. Duplicate injections of each sample were made. 
Samples were calibrated by comparison with a 2-MQ standard. 
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Measurement of reduced and oxidized glutathione levels   
The reduced glutathione (GSH) and oxidized glutathione (GSSG) levels in 
kidney were determined by derivation with 5, 5'-dithio-bis (2-nitrobenzoic acid), and 
reverse-phase HPLC using ultra-violet detection, as described in our previous study.15 
 
Measurement of enzyme activites 
The activities of GSH-Px and GSH-Red were measured according to methods 
described previously16. The measurement of GSH-Px was coupled to the reduction of 
GSSG formed in the peroxidase reaction. The activity of GSH-Red was determined by 
monitoring the decrease in absorbance at 340 nm based on the oxidation of NADPH 
which is coupled to the reduction of one GSSG back to two GSH. The enzyme activity 
for both GSH-Px and GSH-Red was expressed as nmole NADPH oxidized/min/mg 
protein. Protein concentrations were determined by bicinchoninic acid procedure using 
bovine serum albumin standards. 
 
Immunohistochemistry  
Immunostaining was performed using the method described in our previous 
study17. In brief, paraformaldehyde-fixed and OCT-embedded renal tissues derived from 
WKY and SHR at different ages were prepared. Sections of 7-10 μm thickness were cut 
on a cryostat and picked up on poly-l-lysine coated slides.  Sections were 
permeabilized with 0.1% triton X-100 in PBS for 5 min after 3 washes in 0.1 mol/L PBS. 
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Nonspecific antibody binding was blocked by incubation for 30 min with normal goat 
serum diluted 1:30. Sections were then incubated overnight at room temperature in a 
humid atmosphere in the presence of either monoclonal anti-CML antibody or anti-CEL 
antibody (Novo Nordisk, A/S, Denmark) diluted 1:100 in PBS containing 0.1% bovine 
serum albumin. Control sections were exposed to the diluting solution without the 
primary antibody added. After the reaction with the primary antibody, the slides were 
washed 3 times with PBS and incubated with anti-mouse IgG-FITC (Sigma, St. Louis, 
USA) diluted 1:200 for 1 h at room temperature, followed by another 3 washes. 
Thereafter, the slides were mounted in PBS-glycerin (7:3 v/v), coverslipped and 
examined under a fluorescence microscope with the appropriate filters. The sections 
were independently scored by two observers in a blinded fashion. Staining intensities of 
the renal tissue were graded semiquantitatively as follows: (-) negative staining, (−/+) 
occasional, (+) weak, (++) moderate, (+++) intense staining. 
 
Data Analysis  
Data are expressed as mean±SEM and analyzed using Student’s t-test in 
conjunction with the Newman-Keuls test where applicable. Significant difference 
between treatments was defined at a level of P<0.05. 
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RESULTS 
Basal parameters of SHR 
As shown in Table 1, the systolic blood pressure was significantly higher in SHR 
at 8 wks and onwards, compared to age-matched WKY. During the observation period, 
blood pressure increased significantly above the initial value recorded at 5 wks in SHR 
but remained unchanged in WKY rats. In young rats at 5 wks of age there was no 
difference in the blood pressure and body weights between SHR and WKY rats. The 
body weight of SHR was significantly lower than age-matched WKY rats from 8 wks 
onward. No significant difference was found in kidney weight and the ratio of kidney 
weight to body weight in both groups of rats at different ages.  The plasma glucose 
levels (mean±SEM) of 7 and 12 wks old SHR were 4.1±0.1 mM (n=5) and 5.2±0.2 mM 
(n=10), respectively, which were comparable to those in age-matched WKY rats, 
4.2±0.1 mM (n=5) at 7 wks and 5.1±0.1 mM (n=6) at 12 wks. 
 
Increased MG levels in plasma and kidney of SHR 
As shown in Figure 1A, plasma MG level was age-dependent and progressively 
increased in SHR, compared to WKY rats.  The plasma levels (nmol/ml) of WKY rats / 
SHR at 5, 8, 13 and 20 wks were 11.2±0.44 / 11.3±0.65 (n=3), 9.1±0.81 / 13.8±0.72 
(n=4), 18.5±2.71 / 30.3±2.05 (n=5), and 14.2±3.48 / 33.6±2.16 (n=4), respectively.  
In young WKY and SHR rats (5 and 8 wks old), there was no significant 
difference in kidney MG levels. However, from 13 wks onwards the renal MG level was 
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significantly higher in SHR than in age-matched WKY rats (Figure 1B). The renal MG 
levels (nmol/mg protein) in WKY rats / SHR were 0.67±0.15 / 0.67±0.12 (n=3) at 5 wks, 
0.79±0.20 / 0.82±0.10 (n=4) at 8 wks, 0.71±0.06 / 0.91±0.09 (n=5) at 13 wks, and 
0.22±0.04 / 0.30±0.06 (n=4) at 20 wks, respectively. 
 
Increased MG-induced CEL and CML in kidney of SHR 
With immunohistochemical staining method, we further investigated whether 
MG-induced AGEs were increased in kidney from SHR.  Figure 2 shows more intense 
or positive staining for CEL in kidney from SHR, compared to WKY rats at 8, 13 and 20 
wks of age (n=3 for each age group), respectively (Table 2).  Positive CEL staining in 
kidney of SHR was observed occasionally even at the age of 5 wks (Table 2).  Most of 
the positive staining was localized to renal tubules in both strains. There was some 
staining observed in glomerular vessels, too. Staining for CML was also more marked in 
kidney from SHR as opposed to WKY rats at 8, 13 and 20 wks of age (n=3 for each 
group) (Figure 3 and Table 2). The control sections revealed no staining. 
 
GSH and related enzyme activities in the kidney of SHR 
 As shown in Figure 4A, GSH level in kidney was significantly decreased by 16.5% 
in SHR at the age of 20 wks (50.7±4.3 nmol/mg protein) in comparison with that from 
age-match WKY rats (60.7±3.0 nmol/mg protein). The GSH levels (nmol/mg protein) in 
WKY rats / SHR at 5, 8, and 13 wks of age were 95.9± 9.9 / 94.6±6.1, 82.5±6.2 / 
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76.6±2.6, and 67.6±11.0 / 62.0±11.0, respectively. The ratio of GSH/GSSG was also 
significantly decreased in 20 wks old SHR than that in age-matched WKY rats (Figure 
4B). There was no significant difference in renal GSH levels and GSH/GSSG ratio 
between SHR and WKY rats at the relatively younger age (Figure 4).   
The renal GSH-Px activity was significantly decreased by 14% in SHR at the age 
of 20 wks (1.62±0.1 nmol/mg protein), compared with age-matched WKY (1.87±0.18 
nmol/mg protein) (n=3 for each group, P<0.05). There was no significant change in 
renal GSH-Px activities between SHR and WKY rats at the age of 5, 8, and 13 wks (n=3 
for each group, P>0.05).  No significant difference in GSH-Red activity was observed 
between these two strains in different age groups (data not shown).   
 
DISCUSSION 
Studies on MG and AGEs have been mainly focused on their roles in diabetes 
mellitus and its complications. A state of hyperglycemia as a precedent for MG and AGE 
formation stimulates such studies. However, an association of MG and AGEs with 
disease conditions with an apparently normoglycemic state has not been investigated 
intensively. Our study shows a strong association of MG and its AGE products, CML 
and CEL, with hypertension in SHR. The blood pressure of SHR was not different from 
that of WKY rats at 5 wks of age. From 8 wks onwards, it was significantly elevated 
compared to age-matched WKY rats. Importantly, this increase was associated with a 
progressive increase in plasma MG levels, which was significantly higher in SHR than 
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in WKY rats. MG levels in SHR kidney were also significantly higher than in WKY rats 
from 13 wks onwards. Moreover, the levels of MG-induced AGEs, CML and CEL, in 
the kidney were higher in SHR than in WKY from 8 wks onwards, in parallel with 
increased plasma MG levels and blood pressure in SHR. On the other hand, no 
hyperglycemia developed in SHR at different ages.  It has been shown that the glucose 
levels and insulin sensitivity in SHR and WKY rats are comparable18.  Our study 
suggests that in addition to diabetes/hyperglycemic or hyperlipidemic conditions19, MG 
is associated with the development of high blood pressure in SHR, and indeed MG may 
be a causative factor for the development of hypertension or its complications in this 
non-diabetic model. This hypothesis is supported by the evidence, including coincidental 
increase in plasma MG level with blood pressure development, observed in our current 
study and the induction of hypertension in WKY rats by chronic MG feeding reported 
previously11.  However, further studies are needed to clarify the causative role of MG 
in hypertension. In comparison with glucose-induced glycation that undergoes a 
reversible Maillard reaction with N-terminal amino groups or lysyl chains to form 
fructosamine, an early glycation adduct, MG induces glycation through an oxidation 
process. This reaction is also called glycoxidation and it generates irreversible end 
glycation adducts6 including CEL and CML.  With their stable chemical property, CEL 
and CML have been interpreted as a measure of the status of oxidative stress and of 
cumulative oxidative damage to proteins induced by MG in aging and diabetes4,20. In our 
study, antibodies against CEL and CML were used. The antibody against MG-induced 
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CML is less selective since this antibody can also react with glyoxal (another dicarbonyl 
compound)-induced AGE20. In contrast, anti-CEL antibody is specifically against 
MG-induced CEL and has been suggested to be a good indicator for MG-induced AGE 
or glycoxidation product21.   
The kidney plays a major role in blood pressure homeostasis22 and possibly the 
pathogenesis of hypertension in SHR23 and other models of hypertension such as 
DOCA-salt sensitive hypertension24. The afferent and efferent arterioles and the 
glomerular capillaries along with the renal proximal tubules and the thick ascending 
limb of the loop of Henle regulate salt and water absorption as part of the homeostatic 
mechanism. A number of enzymes including the cytochrome P450s and various ion 
pumps are involved. An alteration in the function of one or more of these 
enzymes/proteins can readily disturb the homeostatic mechanisms operating within the 
kidney and lead to increased blood pressure. AGE-induced renal injury was 
demonstrated in vivo when diabetic mice were randomized to receive either a regular 
diet or diet that had less AGE content. Mice on the regular diet developed changes 
typical of diabetic nephropathy, while mice on the low AGE diet did not, even in the 
face of persistent hyperglycemia25. Immunohistochemical studies of kidney from normal 
and diabetic rats have suggested that glomerular basement membrane, mesangium, 
podocytes, and renal tubular cells accumulate high levels of AGEs. Ultrastructural 
studies have indicated that AGE peptides may be reabsorbed by the renal proximal 
tubular cells26,27. AGE deposition can lead to glomerulosclerosis and widespread 
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dysfunction, independent of diabetes. This is evidenced by the development, in 
nondiabetic animals infused with AGE-albumin, of glomerular pathology resembling 
diabetic nephropathy, including glomerular hypertrophy, BM thickening, mesangial 
extracellular matrix expansion, and albuminuria28. Our immunohistochemical studies 
revealed a strong staining for CML and CEL in the renal tubules and the glomerular 
vessels of SHR compared to WKY rats from 8 wks onwards. This suggests that an 
increased renal MG level and MG-glycated proteins in kidney may induce local 
micro-vascular and tubular damage, consequently impairing renal function. A 
chronically increased MG and related AGE formation may lead to the development of 
high blood pressure in SHR. 
MG levels in plasma or tissues including kidney are dependent on the balance 
between its anabolism and catabolism.  When the formation of MG exceeds its 
degradation, accumulation of MG occurs even with normal glucose levels. As mentioned 
earlier, the main source of MG in mammals is glycolysis. The estimated rate of MG 
formation in normal tissues is approximately 125 μM/day, largely resulting from the 
fragmentation of triosephosphates1.   Approximately 0.1-0.4% of glucose is 
metabolized to D-lactate in human red blood cells and promyelocytic leukaemia cells, 
which represents the maximum flux of MG formation29.  Other sources of MG are 
aminoacetone or acetone catalyzed by semicarbadize-sensitive amine oxidase (SSAO) or 
acetol mono-oxygenase (AMO)2,3, with former enzyme found in high amounts within 
VSMC and in human plasma30,31. Increased activities of plasma SSAO and AMO have 
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been suggested to be responsible for the increased circulating MG and endothelial 
dysfunction in diabetes patients30. Moreover, SSAO enzyme levels have been shown to 
be significantly elevated in nondiabetic patients with congestive heart failure32 and 
obesity33, compared to controls. In our study, MG levels in plasma and kidney were 
significantly and age-dependently increased in SHR at different ages in comparison with 
the age-matched WKY (Fig.1). A lower MG level in kidney, but not in plasma, was also 
observed from both SHR and WKY rats at the age of 20 wks in comparison with their 
relative younger age groups tested.  The exact mechanism for this age-dependent 
difference is unclear yet. One possible explanation for this might be a reduced MG 
formation in kidney in the aged rats.  MG formation in plasma is more complicated, 
linked to different circulating enzymes such as SSAO and AMO.  An age-dependent 
change in SSAO and AMO might be responsible for the alteration in circulating MG at 
different ages in diabetes30 as well as in hypertension. These speculations need to be 
validated in future.    
Normal catabolism of MG is largely dependent on the availability of cellular 
GSH and the related enzyme activities including GSH-Px and GSH-Red. In our study, 
the elevated levels of MG in plasma or kidney and MG-induced CEL and CML in 
kidney of SHR were observed at as early as the age of 8 wks. These changes preceded 
the decreased GSH level and suppressed activity of GSH-Px in kidney of SHR, which 
appeared at the age of 20 wks. At the same time the GSH-Red activity also increased, 
albeit not significant. This increase may be a compensatory response to increased GSSG 
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levels. The delayed decrease of GSH in SHR indicates that the primary reason for the 
early onset of MG increase could be the abnormally increased MG production rather 
than a dysfunctional MG degradation. Blood pressure of young SHR begins to increase 
as MG level and its associated oxidative stress level are progressively increased and the 
anti-oxidant GSH system fails to compensate.  Eventually, GSH level will drop and 
hypertension in aged SHR enters a sustained stage. 
In conclusion, MG levels in the plasma and kidney of SHR, but not WKY rats, 
increased in an age-dependent manner associated with the development of hypertension. 
Increased MG and AGE formation in kidney may cause local damage, contributing to 
both development and complications of hypertension. 
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Table 3-1. Basal parameters of SHR and WKY at different ages. 
 
Age 
(wks) 
Rats 
BP 
(mmHg) 
BW 
(g) 
KW 
(g) 
KW/BW 
(mg/g) 
WKY 123±1 107±3 1.33±0.08 12.43±0.30 
5 
SHR 131±2 98±2 1.27±0.01 12.96±0.17 
WKY 121±1 197±6 1.91±0.09 9.64±0.40 
8 
SHR 190±3 ** 180±4 * 1.81±0.01 10.1±0.08 
WKY 120±1 339±5 2.45±0.05 7.23±0.08 
13 
SHR 203±1 ** 281±7 ** 2.36±0.02 8.4±0.30 
WKY 119±1 353±11 2.22±0.03 6.3±0.10 
20 
SHR 202±1 ** 308±4* 2.52±0.08 8.15±0.20 
 
BP: systolic blood pressure, BW: body weight, KW: kidney weight.  *P<0.05, SHR vs. 
WKY of the same age group. **P<0.001, SHR vs. WKY of the same age group. 
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Table 3-2. CEL and CML staining in kidney from SHR and WKY at different ages 
(n=3 for each group). 
 
 Rats 5 wks 8 wks 13 wks 20 wks 
CEL 
WKY 
SHR 
- 
-/+ 
++ 
+++ 
+ 
+++ 
+ 
++ 
CML 
WKY 
SHR 
- 
- 
+ 
++ 
-/+ 
++ 
-/+ 
+ 
 
Staining:  (-) negative, (-/+) occasional, (+) weak, (++) moderate, (+++) intense 
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     Figure 3-1. MG levels in kidney and plasma from WKY and SHR at different 
ages.  MG levels were measured in plasma (A), and kidney (B) from SHR and 
age-matched WKY rats at 5 wks (n=3), 8 wks (n=4), 13 wks (n=5) and 20 wks 
(n=4) of age. MG levels in SHR are presented as the percentage of that in 
age-matched WKY.  *P<0.05, SHR vs. WKY of the same age group.  
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Figure 3-2. Immunohistochemical detection of CEL in kidney from WKY rats and 
SHR at different ages. Kidney sections from SHR (right panel) show more 
extensive staining than age-matched WKY rats (left panel). Big arrows indicate the 
representative immunoreactivity in renal tubules, and small arrows show staining 
in the glomerulus. 
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Figure 3-3. Immunohistochemical detection of CML in kidney from WKY rats and 
SHR at different ages. Kidney sections from SHR (right panel) show more staining 
than age-matched WKY rats (left panel). Big arrows indicate representative 
immunoreactivity in renal tubules, and small arrows show staining in the 
glomerulus. 
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     Figure 3-4. GSH levels and oxidative stress in kidney from WKY rats and 
SHR at different ages. A. Renal levels of GSH.   n=4 for 5 and 20 wks and n=7 
for 8 and 13 wks. GSH levels in SHR are presented as the percentage of that in 
age-matched WKY. B. Oxidative stress in kidney.   n=3 in each group. *P<0.05, 
SHR vs. WKY of the same age group. 
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ABSTRACT 
An age- and blood pressure-associated increase in methylglyoxal (MG) and 
MG-induced advanced glycation endproducts (AGEs), including Nε-carboxyethyl-lysine 
(CEL) and Nε-carboxymethyl-lysine (CML), in the kidney of spontaneously 
hypertensive rats (SHR) has been shown.  In the present study, gender-related changes 
in AGEs and NOS were investigated in Sprague-Dawley (SD) rats and stroke-prone 
SHR (SHRsp).  Immunohistochemical analyses were conducted on kidneys from 
24-week old male and female SD rats as well as SHRsp. The systolic blood pressure of 
SHRsp was significantly higher than that of SD rats. Male SD rats had more intense 
kidney staining for CEL than female SD rats. Both male and female SHRsp had more 
marked CEL and CML staining localized to kidney tubules, as opposed to SD rats. 
Female rats showed more staining in glomerular vessels than male rats in both SD and 
SHRsp. Nuclei containing NF-κB p65 and activated macrophages were seen in the 
kidney from SHRsp, not so much in SD rats, localized to renal tubules in male and 
glomerular vessels in female SHRsp. Higher protein level of NF-κB p65 was found in 
SHRsp than in SD rats.  SD rats had more intense kidney nNOS staining than SHRsp. 
Intensity of iNOS staining was significantly higher in SHRsp than in SD rats with no 
gender differences in either strain.  SHRsp and male rats exhibit higher AGEs and 
oxidative stress than SD and female rats, respectively. These differences might partly 
account for development of hypertension in SHRsp and higher vulnerability of male 
animals to renal pathology. 
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INTRODUCTION  
The kidney plays a major role in blood pressure homeostasis (1) and possibly the 
pathogenesis of hypertension in spontaneously hypertensive rats (2) (SHR) and other 
models of hypertension such as DOCA-salt sensitive hypertension (3). A number of 
enzymes including the nitric oxide synthase (NOS) isoforms, cytochrome P450s and 
various ion pumps are involved in the modulation of renin secretion and 
secretion/absorption of ions. An oxidative stress-induced alteration in the function of one 
or more of these enzymes/proteins can readily disturb the homeostatic mechanisms 
operating within the kidney and lead to increased blood pressure. Nitric oxide (NO), 
synthesized by NOS is an important vasodilator (4) and renin secretion modulator (5) 
and can be considered as an anti-hypertensive mediator. The gender of the animal has 
been shown to have an important influence on the expression/activity of endothelial 
nitric oxide synthase (eNOS) in the blood vessels (6-8) and the kidney (9), conferring 
protection to the female gender against development of hypertension, atherosclerosis and 
cardiovascular mortality (10,11). It has been shown in humans and animals that NO 
level is greater in females than in males because estrogens not only stimulate NO 
production (6,7) but also decrease inactivation of NO by oxygen radicals (12). 
Post-menopausal females and males have reduced arterial NO activity which was 
restored to premenopausal levels in females after two weeks of estrogen replacement 
therapy (13).  
The impact of gender on renal disease has also been observed in rats. Aging male 
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rats show a reduction in renal NOS compared to females (14) and develop 
age-dependent kidney damage, proteinuria and glomerulosclerosis, whereas females and 
orchidectomized males are resistant to the development of renal injury (15). Male rats 
have a greater tendency, an androgenic effect, than female rats, to develop proteinuria 
after chronic NOS inhibition (16). Also, male stroke-prone spontaneously hypertensive 
rats (SHRsp) have more frequent renal lesions and more severe renal damage compared 
to female rats (17). The incidence and prevalence of end-stage renal disease are higher in 
men than in women (18).  
The expression/activity of NOS are also altered in hypertensive animal models 
such as SHR. Earlier studies have shown increased reactive oxygen species, enhanced 
NOS expression and NO production in SHR. These findings support the role of 
oxidative stress in the genesis and/or maintenance of hypertension and compensatory 
upregulation of the expression of eNOS, iNOS (19) and nNOS (20) in SHR.  
There is evidence that oxidative stress is enhanced in males compared with 
females (21-23). Plasma thiobarbituric acid-reactive substances and urinary 
8-isoprostaglandin F2α were higher in men than in women (22) and male rats produced 
more superoxide anions than females (23). We have recently shown an age and blood 
pressure-associated increase in methylglyoxal (MG), a metabolite of glucose, and 
MG-induced irreversible advanced glycation endproducts (AGEs), 
Nε-carboxyethyl-lysine (CEL) and Nε-carboxymethyl-lysine (CML), in the plasma and 
kidney of SHR (24). However, gender differences in regard to these AGEs are not 
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known. 
There is as yet no data on gender related changes in CEL and CML, which are 
precursors of oxidative stress (25). Also there is no study correlating gender related 
changes in CEL, CML and NOS with hypertension development. In the present study, 
gender related changes in AGEs and NOS were investigated through an 
immunohistochemical characterization in Sprague-Dawley (SD) rats and SHRsp. 
 
MATERIALS AND METHODS 
 
Animals  
Male and female Sprague-Dawley (SD) rats and SHRsp (24 wks old) were used 
to carry out this work.  SD rats were used to fulfill our primary aim to investigate 
gender differences within a given strain with a normal blood pressure profile that was 
not genetically related to SHRsp. SHRsp were used instead of SHR because the SHRsp 
strain develops a severe form of hypertension and shows a high incidence of injuries in 
different vascular beds, especially in renal vasculature and parenchyma. Such lesions are 
milder or even absent in the closely related SHR. Moreover, male SHRsp have more 
frequent lesions and more severe renal damage compared to female rats (17). These 
animals were housed in a temperature-regulated animal facility and exposed to a 12 h 
light/dark cycle with free access to food and water.  Rats were treated in accordance 
with guidelines of the Canadian Council on Animal Care, and the experimental protocols 
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were approved by the Animal Care Committee at the University of Saskatchewan.  
Systolic blood pressure was determined weekly using a standard tail cuff noninvasive 
BP measurement system (Model 29-SSP, Harvard Apparatus, St. Laurent, QC, Canada).  
 
Tissue preparation 
At the end of the study, rats were anaesthetized with sodium pentobarbital (60 
mg/kg body weight) intraperitoneally. Rats were perfused with heparinized phosphate 
buffered saline (PBS) followed by PBS containing 4% paraformaldehyde. Kidney 
tissues were dissected out immediately and kept in the same fixative solution overnight. 
Samples were then incubated in a 30% sucrose solution for 3 days at 4°C for 
cryoprotection. After embedding in O.C.T. compound (Somagen Diagnostics, Edmonton, 
AB, Canada), 8 µm thick cross sections were cut using a cryostat, collected on 
gelatin-chrome alum-coated slides, and stored at -20°C until further processing. 
 
Immunohistochemistry 
CEL and CML Staining 
Immunostaining was performed using the method described in our previous 
study (26). In brief, frozen sections were permeabilized with 0.1% triton X-100 in PBS 
for 5 min after 3 washes in 0.1 M PBS. Nonspecific antibody binding was blocked by 
incubation for 30 min with normal goat serum diluted 1:30. After overnight incubation 
with either monoclonal anti-CML antibody or anti-CEL antibody (Novo Nordisk, A/S, 
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Denmark) diluted 1:100, the slides were washed 3 times and incubated with anti-mouse 
IgG-FITC (Sigma, Oakville, ON, Canada) diluted 1:200 for 1 h at room temperature, 
followed by another 3 washes. The slides were mounted in PBS-glycerin (7:3 v/v), 
coverslipped and examined under a fluorescence microscope with the appropriate filters.  
 
ED-1 and NF-κB 
Frozen sections were immunostained by using primary antibody ED-1 (Serotec, 
Raleigh, NC), a marker for activated macrophages, or anti-NF-κB p65 (Transduction 
Laboratories, Lexington, KY, USA) that recognized the nuclear localization signal on 
p65. ED-1 staining was detected by Cy3-conjugated affiniPure goat antimouse IgG 
(Jackson ImmunoResearch, WestGrove, PA, USA), and NF-κB staining was 
demonstrated by the avidin–biotin–peroxidase (Vector Laboratories, Burlington, ON, 
Canada) detection system.  
 
NOS Staining 
Kidney tissue sections (8 μm) were incubated with either monoclonal nNOS 
antibody or polyclonal iNOS antibody (Calbiochem, San Diego, CA, USA) diluted at 
1:200. Anti-rabbit or anti-mouse IgG-FITC diluted 1:200 was the secondary antibody.  
 
Quantification of staining 
The intensities of staining were quantified using GeneTools image analysis 
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software (PerkinElmer®, MA, USA). For each animal, thirty spots of each micrograph, 
with 10 micrographs of each section and three sections of each animal were analyzed 
and the average value was used to express the intensity of staining.  
 
Western Blot Analysis 
Proteins were separated on polyacrylamide gels by using a minivertical 
electrophoresis system (Bio-Rad) and transblotted onto polyvinyldifluoridene 
membranes, and membranes were then incubated with the appropriate primary 
antibodies, followed by incubation with a horseradish peroxidase-conjugated secondary 
antibody (Bio-Rad) as done before (27). Proteins were visualized by using 
chemiluminescence substrate kit (Amersham Biosciences) and quantified by using the 
UN-SCAN-IT GEL automated digitizing system (version 5.1, Silk Scientific, Orem, UT). 
The membrane was reprobed with anti-8-actin (Sigma). Quantification was relative to 
the 8-actin. For quantification of nuclearly localized NF-κB p65, nuclear extracts were 
obtained by using the NE-PER nuclear and cytoplasmic extraction kit (Pierce) as 
described (28).  
Data analysis  
Data are expressed as mean ± SEM and analyzed using Student’s t-test or 
one-way analysis of variance (ANOVA) in conjunction with the Newman-Keul’s test 
where applicable. Significant difference between treatments was defined at a level of 
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P<0.05. 
 
RESULTS 
Basal parameters 
The systolic blood pressure of SHRsp was significantly higher than that of 
age-matched SD rats (Table 1). There is no difference in blood pressure between male 
and female rats of the same strain. Body weight of males was more than that of females 
within each strain (p < .001). In addition, SD rats weighed more than age-matched 
SHRsp of the same gender (p < .001). The plasma glucose levels of male and female 
SHRsp were 5.4±0.3 mM (n=10) and 5.1±0.2 mM (n=6), respectively, which were 
comparable to those in age-matched SD rats, 4.9±0.1 mM (n=10) of male and 5.8±0.6 
mM (n=6) of female. 
 
Increased MG-induced CEL and CML in kidney of SHRsp 
With immunohistochemical staining method, we investigated whether 
MG-induced AGEs were increased in kidney from SHRsp.  Figure 1A shows more 
intense or positive staining for CEL in kidney from male and female SHRsp, compared 
to age-matched SD rats of the same gender (n = 3 for each age group).  The staining 
intensity in male SD rats was significantly higher than that in female SD rats (Figure 1B). 
There was no difference between male and female SHRsp. Both male and female SHRsp 
had more marked CML staining in kidney as opposed to SD rats of the same gender 
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(Figure 2). Most of the positive staining for CEL or CML was localized to renal tubules 
in both strains. There was very little staining observed in glomerular vessels of male rats, 
and female rats had more positive staining in glomerular vessels than male rats for both 
SD and SHRsp. The negative (no primary antibody) and positive (control immune 
globulin) control sections revealed no staining (not shown). 
 
ED-1 and NF-κB 
In SHRsp activated macrophages could be identified in the kidney, indicating an 
inflammatory state in its structure. Positive staining of ED-1 was only detected in the 
renal tubules of male SHRsp. As to female SHRsp, ED-1 staining was only observed in 
glomerular vessels (Figure 3A). Activated macrophages were not detectable in the 
kidney from SD rats. Immunohistochemical staining revealed nuclei containing NF-κB 
p65 in the kidney from SHRsp, and very little staining was detected in the kidney from 
SD rats (Figure 3B). Positive staining was localized in the renal tubules of male SHRsp, 
while in the female SHRsp it was localized to the glomerular vessels. 
 Western blot analysis demonstrated that nuclearly localized NF-κB p65 was 
significantly higher in male SD rats and SHRsp than female rats of the same gender 
(Figure 4). 
 
nNOS  immunoreactivity 
SD rats had more intense kidney nNOS staining than age-matched SHRsp (n = 3 
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for each age group) (Figure 5). Intensity of nNOS staining was significantly higher in 
female rats than in age-matched male rats of the same strain for both SD rats and SHRsp. 
Positive staining was localized to the glomerular vessels in female SD rats and SHRsp, 
whereas in male rats of both strains the staining was only observed in renal tubules. 
Negative and positive control sections revealed no staining (data not shown). 
iNOS immunoreactivity 
 
Both male and female SHRsp had more iNOS staining than age-matched SD rats 
of the same gender, but there was no gender difference within either strain (Figure 6).  
Most of positive staining was localized to renal tubules in SHRsp. There was very little 
staining observed in glomerular vessels. 
 
DISCUSSION 
Here we show gender differences in markers of oxidative stress and enzymes 
involved in blood flow regulation and renin secretion in the kidneys of male and female 
SD rats and SHRsp. These differences possibly contribute to the reported greater 
protection of the female gender against development of hypertension, atherosclerosis, 
renal damage and disease, and cardiovascular mortality (10,11, 15-18).  
SHRsp showed marked staining for AGEs, CEL and CML, in the kidney, despite 
normal blood glucose levels. AGEs are precursors of oxidative stress (25) and our 
findings support elevated oxidative stress levels in SHRsp and SHR (24). More 
importantly, male SD rats had an elevated level of CEL compared to age-matched 
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female. This gender difference of CEL formation has not been reported before. This also 
supports findings of elevated superoxide anion levels and oxidative stress in male Wistar 
rats (23) and gender differences in terms of oxidative stress levels in humans, using 
plasma thiobarbituric acid-reactive substances and urinary 8-isoprostaglandin F2α as 
markers (21,22). An elevated oxidative stress has been associated with hypertension 
(19,28,29) and can readily disturb the homeostatic mechanisms in the kidney which 
contribute to blood pressure regulation (1). In our study, antibodies against CEL and 
CML were used. The antibody against MG-induced CML is less selective since this 
antibody can also react with glyoxal (another dicarbonyl compound)-induced AGE (30). 
In contrast, anti-CEL antibody is specifically against MG-induced CEL and has been 
suggested to be a good indicator of MG-induced AGE or glycoxidation product (31).  
Gender difference in CEL and CML staining was lost in SHRsp with an associated 
severe hypertension in both male and female SHRsp (Table1, Figures 1,2).  
NF-κB p65, a marker of inflammation was detected in SHRsp but not in SD rats. 
However, Western blot analysis demonstrated gender differences in nuclearly localized 
NF-κB p65, even though significantly less in SD than in SHRsp. Thus, NF-κB p65 was 
significantly higher in male SD rats and SHRsp than female rats of the same strain 
(Figure 3B) and may be one of the reasons for greater susceptibility of the male gender 
to cardiovascular and kidney disease, including male SHRsp (17). Moreover, activated 
macrophages were detected in the kidney of SHRsp but not in SD rats. These findings 
are consistent with the possibility that activation of NF-κB p65 and renal interstitial 
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infiltration of immune cells play a part in the pathophysiology of hypertension (32). We 
have previously shown that oxidative stress is likely involved in MG-induced activation 
of NF-κB in vascular smooth muscle cells of SHR (28). However, gender differences in 
this regard were not known. An association of inflammation and hypertension has been 
reported by elevated C-reactive protein, another marker of inflammation (33). Lack of 
NF-κB p65 staining and hypertension in the SD rats supports this association. Gender 
differences in terms of the localization of NF-κB p65 and ED-1, a marker of activated 
macrophages, in the renal tubules of male SHRsp and in the glomerular vessels of 
female SHRsp, are notable and can be speculated to indicate a more progressed 
inflammation in the males, having originated from the blood vessels.  
iNOS is normally associated with inflammatory states (4) and this is supported 
by our observation of more intense iNOS staining in SHRsp compared to SD rats. 
Increased expression of iNOS in the kidney of SHR has been reported (34). Also, AGEs 
induce iNOS in glomerular mesangial cells (35). An association of iNOS and 
hypertension is strongly supported by our results.  
Level of nNOS was higher in SD rats compared to SHRsp. Increased (36) as well 
as decreased (37) expression of nNOS in the kidney of SHR, compared to Wistar rats, 
has been reported. While the role of nNOS in renin secretion is controversial, a number 
of studies have implicated NO, derived from nNOS, stimulating renin secretion, 
especially after chronic sodium restriction (5,38,39). Staining intensity of nNOS was 
greater in female compared to male rats for both SD and SHRsp. Moreover, SHRsp had 
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lower levels of nNOS compared to SD rats for both male and female, which supports a 
previous report of reduced nNOS in the SHR (37). This can be speculated as a feedback 
inhibition of nNOS expression due to high blood pressure in SHRsp. In the study by 
Kumar et al. (37) gender differences were not reported. The reason for gender difference 
in nNOS within a strain is not clear at present.  Another important difference between 
male and female rats, noted in our study, was localization of nNOS staining. Most of the 
staining in male rats was in the tubules whereas in female rats it was in the glomerular 
vessels. While tubular expression of nNOS has been reported (20,36,37) localization of 
nNOS to the glomerular vessels in female rats was a surprise and is intriguing. 
Functional significance of this difference needs to be determined by separate studies. 
Gender differences in expression of eNOS in the kidney and the vasculature are well 
established and increased vascular NO production has been proposed as affording more 
protection to females against cardiovascular morbidity and mortality (6-11). 
While differences in the NOSs have been described above it might be worth 
pointing out that the age of rats used in our study, 24 weeks, is within the reproductive 
age and an influence of menopause, reportedly occurring after 18 months or about 72 
weeks of age, can be ruled out (40). 
In conclusion, increased expression of CEL, NF-κB p65, ED-1, and iNOS in 
male rats compared to female rats, or in SHRsp compared to SD rats, strongly supports 
the contention that female gender has better biochemical protection against 
cardiovascular and renal morbidity and mortality.  
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Table 4-1. Systolic blood pressure and body weight of SHRsp and age-matched SD 
rats  
 
Rats Gender BP  (mmHg) BW (g) 
Male 120  ± 3 583 ± 10    
SD 
Female 116  ± 2 452 ± 8# # 
Male 184  ± 5*** 386 ± 5***  
SHRsp 
Female 180  ± 3*** 275 ± 4***# # 
 
Values are mean ± SEM. BP, systolic blood pressure; BW, body weight. 
***P < 0.0001, SHRsp vs. SD rats of the same gender, # #P < 0.001, Female vs. male of 
the same strain. (n = 6 each group) 
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 Figure 4-1. Immunohistochemical detection of CEL in the kidney from SHRsp and 
age-matched SD rats. (A). CEL staining was detected in kidney sections from male (left 
panel) and female (right panel) SHRsp and SD rats. Big arrows indicate the 
representative immunoreactivity in renal tubules, and small arrows show staining in the 
glomerulus. (B). Intensity of CEL staining (n = 3 in each group). *P < 0.05, male 
compared to female rats of the same strain.  #P < 0.05, SHRsp compared to SD rats of 
the same gender. 
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Figure 4-2.  Immunohistochemical detection of CML in the kidney from SHRsp and 
age-matched SD rats. (A). CML staining was detected in kidney sections from male (left 
panel) and female (right panel) SHRsp and SD rats. Big arrows indicate the 
representative immunoreactivity in renal tubules, and small arrows show staining in the 
glomerulus. (B). Intensity of CML staining (n = 3 in each group).  #P < 0.05, SHRsp 
compared to SD rats of the same gender. 
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 Figure 4-3.  Immunohistochemical detection of ED-1 (A) and NF-κB (B) in the 
kidney from SHRsp and age-matched SD rats. Positive staining of ED-1 was only 
detected in the renal tubules of male SHRsp. In female SHRsp, the staining was only 
observed in glomerular vessels (A).  Micrographs show that positive nuclear NF-κB 
p65 signal was observed in male and female SHRsp; and very little staining was 
detected in the kidney from SD rats (B). (n = 3 for each group). 
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Figure 4-4.  Western blot showing the localization of activated NF- B in the kidney 
from SHRsp and age-matched SD rats. (A). A representative Western blot of nuclearly 
localized NF-κB p65. (B). Quantification of NF-κB p65 relative to 8-actin (y axis depicts 
relative units). Data were taken from kidney tissues of 3-4 animals. *P < 0.05, male 
compared to female rats of the same strain. #P < 0.05,   SHRsp compared to SD rats of 
the same gender. 
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Figure 4-5. Immunoreactivity of nNOS in renal tissues from male and female SHRsp 
and age-matched SD rats. (A). Immunostaining of nNOS. Female rats (right panel) show 
more positive nNOS staining than age-matched male rats of the same strain (left panel). 
Big arrows indicate representative immunoreactivity in renal tubules, and small arrows 
show staining in the glomerulus. (n = 3 for each group). (B). Intensity of nNOS staining. 
*P < 0.05, male compared to female rats of the same strain.  #P < 0.05, SHRsp 
compared to SD rats of the same gender. 
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Figure 4- 6.  Immunohistochemical detection (A) and intensity (B) of iNOS staining in 
renal tissues from male and female SHRsp and age-matched SD rats. Big arrows 
indicate the representative immunoreactivity in renal tubules, and small arrows show 
staining in the glomerulus. (n = 3 for each group). *P < 0.05, male compared to female 
rats of the same strain.     #P < 0.05, SHRsp compared to SD rats of the same gender. 
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ABSTRACT 
Objectives: The pathogenic process of diabetes mellitus is associated with increased 
methylglyoxal (MG). MG causes non-enzymatic glycation of proteins to form 
irreversible advanced glycation endproducts (AGEs). However, the correlation between 
MG and essential hypertension is unknown. The aim of the present study was to 
investigate whether MG, MG-induced AGEs, and oxidative stress were increased in the 
aorta of SHR and whether an increased formation of MG and related AGEs was 
correlated with the development of high blood pressure in spontaneously hypertensive 
rats (SHR). 
Methods: HPLC was used to determine MG and reduced glutathione levels in plasma 
and aorta.  MG-induced AGEs, Nε-carboxyethyl-lysine (CEL) and 
Nε-carboxymethyl-lysine (CML), in aorta were determined using immunohistochemistry. 
Hydrogen peroxide and superoxide levels in aorta and glutathione peroxidase and 
reductase activities were also determined.  
Results: Aortic and plasma MG levels were significantly elevated in SHR, but not in 
Wistar Kyoto (WKY) rats, at 8, 13 and 20 wks of age in parallel with blood pressure 
increase. Immunohistochemistry revealed more intense staining for CML and CEL in 
aorta from SHR than that of WKY rats from 8 wks onwards. Most of the staining was 
localized to endothelial cells. Superoxide and hydrogen peroxide levels were 
significantly elevated in aorta of SHR at 13 wks whereas reduced glutathione levels, 
glutathione peroxidase and glutathione reductase activities were significantly decreased 
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compared to WKY rats.  
Conclusions:  Increased aortic MG, AGEs formation and oxidative stress were 
associated with blood pressure increase in SHR, which may cause endothelial 
dysfunction and altered vascular reactivity.  
Key Words: methylglyoxal ■ advanced glycation endproducts ■ aorta ■ hypertension
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INTRODUCTION  
 One of the by-products of glucose metabolism during glycolysis is methylglyoxal 
(MG), a highly reactive dicarbonyl compound formed spontaneously due to the 
transformation of triose phosphates [1].  MG is also generated from primary amines 
and from acetone during lipolysis, catalyzed by semicarbazide-sensitive amine oxidase 
(SSAO) or acetol mono-oxygenase (AMO) [2,3].  SSAO are capable of deaminating 
primary amines to produce aldehyde, ammonia, and hydrogen peroxide. Under 
physiological conditions vascular endothelial cells are a major source of circulating 
SSAO [4]. Increased activities of plasma SSAO and AMO have been suggested to be 
responsible for the increased circulating MG levels and diabetic vascular complications 
in animals [2,5]. Increased SSAO in transgenic mice are associated with an increased 
endothelial cell capacity for lymphocyte binding and altered expression of 
redox-sensitive proteins [4]. 
MG is detoxified by the glyoxalase system that uses glutathione (GSH) as a 
cofactor [1]. MG can react with selective proteins to yield irreversible advanced 
glycation endproducts (AGEs), leading to cross-linking and denaturation of protein [6]. 
The irreversible reaction of MG with lysine residues of protein forms 
Nε-carboxyethyl-lysine (CEL) and Nε-carboxymethyl-lysine (CML) [7].  
 MG and related AGEs such as CEL are inducers of the increased oxidative stress in 
vivo [7,8], and their levels are correlated with tissue damage and aging [9].  The 
hyperglycaemic state in diabetes mellitus is strongly and causatively associated with 
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increased MG and AGEs, potentially contributing to the development of nephropathy, 
retinopathy, neuropathy and other complications of diabetes [7,8].  The associations of 
MG and related AGEs with the development and maintenance of hypertension, however, 
are still largely unsettled. Systolic blood pressure was significantly increased after 
Wistar Kyoto (WKY) rats were treated with MG in drinking water, with an increase in 
aldehyde conjugate levels in kidney, but not heart or liver [10]. An enhanced AGE 
formation was found in the aorta of stroke-prone spontaneously hypertensive rats [11]. 
In our previous studies on the spontaneously hypertensive rats (SHR) we have shown 
elevated MG and AGEs levels as well as increased NF-κB p65 and ICAM-1 expression 
in cultured vascular smooth muscle cells (VSMCs) [12].   
The aim of the present study was to investigate whether MG, MG-induced 
AGEs, and oxidative stress were increased in the aorta or plasma of SHR and whether an 
increased formation of MG and related AGEs was correlated with the development of 
high blood pressure in SHR.  To this end, MG levels and SSAO activity in the aorta 
and plasma were determined in SHR and WKY rats at different hypertension 
development stages.  The MG-induced CML and CEL in the aorta were evaluated in 
both strains. Since glutathione plays a role in the metabolism of MG, and MG can 
increase oxidative stress by inactivating antioxidant enzymes such as glutathione 
reductase [13] and glutathione peroxidase [14], we also measured the levels of GSH, 
superoxide anion (O2-.) and hydrogen peroxide (H2O2), and the activities of glutathione 
peroxidase (GSH-Px) and glutathione reductase (GSH-Red) in the aorta. 
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 MATERIALS AND METHODS 
Animals  
A total of 36 rats, including 18 male SHR and 18 male WKY rats, were 
purchased from Charles River laboratories (St-Constant, Quebec, Canada). Rats were 
treated in accordance with guidelines of the Canadian Council on Animal Care, and the 
experimental protocols were approved by the Animal Care Committee at the University 
of Saskatchewan. Systolic blood pressure was determined weekly using a standard tail 
cuff noninvasive BP measurement system (Model 29-SSP, Harvard Apparatus, St. 
Laurent, QC, Canada). At the end of the study, rats were anaesthetized with sodium 
pentobarbital (60 mg/kg body weight) intraperitoneally. Blood was collected from the 
heart, and plasma was separated by centrifuging blood samples at 1,000 g for 10 min at 
4ºC.  Tissues cleaned in ice-cold phosphate buffer saline (PBS) were snap-frozen in 
liquid nitrogen immediately and stored at -80ºC until processing.  
 
MG measurement 
Quantitation of MG was done by the widely accepted o-phenylenediamine 
(o-PD)-based assay as described previously [15]. Earlier assays for MG employed 
dinitrophenylhydrazine for derivatization of MG. This was not specific since other 
intermediates of glycolysis also reacted with dinitrophenylhydrazine [16]. The method 
we have used is specific for MG and is also very sensitive. In this method the reagent, 
o-PD, a 1,2-diaminobenzene derivative, rapidly reacts with MG to form a quinoxaline 
 125
which can be easily quantified with reverse-phase high-performance liquid 
chromatography [15]. For the assay, the supernatant of the aortic homogenate or plasma 
was incubated with 100 mmol/L o-PD (derivatizing agent) for 3 h at room temperature. 
The quinoxaline derivative of MG (2-methylquinoxaline) and the quinoxaline internal 
standard (5-methylquinoxaline) were measured using a Hitachi D-7000 HPLC system 
(Hitachi Ltd., Mississauga, ON, Canada). Samples were calibrated by comparison with 
2-MQ standards. 
 
Measurement of reduced glutathione levels   
The reduced glutathione (GSH) levels in the aorta were determined by derivation 
with 5, 5'-dithio-bis (2-nitrobenzoic acid), and reverse-phase HPLC using ultra-violet 
detection, as described in our previous study [17]. 
 
Measurement of hydrogen peroxide levels 
The formation of H2O2 was measured by a DCFH-assay as described previously 
[12]. The membrane permeable and nonfluorescent probe DCFH-DA was used to load 
aortic rings. H2O2 oxidized-DCF was quantified by monitoring the DCF fluorescence 
intensity with excitation at 485 nm and emission at 527 nm with Fluoroskan Ascent 
plate-reader (Thermo Labsystem, Franklin, MA, USA) using Ascent software and 
expressed using arbitrary units. 
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Measurement of superoxide production 
O2-. production was measured using the lucigenin-enhanced chemiluminescence 
method as described previously [18]. Chemiluminescence intensity was detected with a 
luminometer (TD-20/20, Tunner Designs, CA, USA) and expressed using arbitrary 
units. 
 
Measurement of Enzyme Activities   
The activities of GSH-Px and GSH-Red were measured according to methods 
described previously [19]. The enzyme activity for both GSH-Px and GSH-Red was 
expressed as nmol NADPH oxidized/min/mg protein. Protein concentrations were 
determined by bicinchoninic acid procedure. 
 
Fluorometric measurement of SSAO 
SSAO activity was measured according to methods described by Storer et al. [20] 
with some modifications. Briefly, an aliquot of aorta homogenate or plasma was 
incubated with 0.5 mmol/L homovanillic acid and 0.5 mmol/L clorgyline. To this 0.5 
mmol/L benzylamine and 30 U/ml horseradish peroxidase were added in a total volume 
of 250 μl. After incubation fluorescence was recorded at excitation/emission 
wavelengths of 310/440 nm using H2O2 standards.  
  
Immunohistochemistry  
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Immunostaining was performed using the method described in our previous 
study [21]. In brief, paraformaldehyde-fixed and OCT-embedded 8 μm aortic tissue 
sections were incubated with either monoclonal anti-CML antibody or anti-CEL 
antibody (Novo Nordisk, A/S, Denmark) diluted 1:100. Anti-mouse IgG-FITC (Sigma, 
Oakville, ON, Canada) diluted 1:200 was the secondary antibody. The sections were 
quantified using GeneTools image analysis software (PerkinElmer®, Wellesley, MA, 
USA). Twenty fields along the endothelium of each section were analyzed and the 
average value was used to express the intensity of staining. 
 
Data Analysis  
Data are expressed as mean ± SEM and analyzed using Student’s t-test. 
Significant difference between treatments was defined at a level of P < 0.05. 
 
RESULTS 
Basal parameters of SHR 
As shown in Table 1, in young rats at 5 wks of age there was no difference in the 
systolic blood pressure and body weights between SHR and WKY rats. However, the 
blood pressure increased in the subsequent wks in SHR but remained unchanged in 
WKY rats. At 8, 13 and 20 wks of age the blood pressure was significantly higher in 
SHR than that of age-matched WKY rats, while the body weight of SHR was 
significantly lower than that of age-matched WKY rats. No significant difference was 
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found in the heart and kidney weights between the two strains at different ages.   
 
MG levels in plasma and tissues from SHR 
Plasma MG level was age-dependently and progressively increased in SHR, 
compared to WKY rats (Figure 1A).   Between young 5-wk old SHR and WKY rats 
there was no significant difference in aortic MG levels. However, from 8 wks onwards 
the aortic MG level was significantly higher in SHR than in age-matched WKY rats 
(Figure 1B).  The MG levels in the kidney and the liver, but not in the heart, were 
significantly higher in the SHR compared to age-matched WKY rats at 13 wks (Figure 
1C). No significant change in renal, hepatic and heart MG levels was observed between 
SHR and age-matched WKY rats at 8 wks of age (data not shown). 
 
Increased MG-induced CEL and CML in aorta of SHR 
With immunohistochemical staining method, we further investigated whether 
MG-induced AGEs were increased in the aorta from SHR.  Figure 2 shows more 
intense or positive staining for CEL in the aorta from SHR, compared to WKY rats at 8, 
13 and 20 wks of age (n = 3 for each age group). Positive CEL staining in the aorta of 
SHR was observed occasionally even at the age of 5 wks.  From 8 wks onwards, the 
intensity of CEL staining was significantly higher in SHR than in age-matched WKY 
rats (Table 2). Most of the positive staining was localized to the endothelial layer in both 
strains. Some staining was observed in smooth muscle cells too.  Staining for CML was 
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also more intense in the aorta from SHR as opposed to WKY rats at  8, 13 and 20 wks 
of age (n = 3 for each group) (Figure 3 and Table 2). The negative (no primary antibody) 
and positive (control immune globulin) control sections revealed no staining (not 
shown). 
 
Increased superoxide and hydrogen peroxide levels in the aorta, and 
semicarbazide-sensitive amine oxidase (SSAO) activity in plasma of SHR 
Superoxide anion (O2-.) level was significantly higher in the aorta of SHR at 13 
wks of age (Figure 4A). Hydrogen peroxide (H2O2) level was also significantly elevated 
in the aorta of SHR at 13 wks of age (Figure 4B).   The SSAO activity was 
significantly elevated in the plasma, but not in the aorta, of SHR at 8 and 13 wks 
compared to age-matched WKY rats (Figure 5).   There was no significant difference 
in SSAO activity between 5 wk-SHR and age matched WKY rats.  
 
GSH level and the activities of the related enzymes in the aorta of SHR 
As shown in Figure 6A, GSH level in the aorta was significantly decreased by 
34% in SHR at the age of 13 wks compared to age-matched WKY rats. There was no 
difference between the plasma GSH levels between SHR and WKY rats at 5, 8 and 13 
wks (Figure 6B).  
The aortic GSH-Px activity was significantly decreased by 38% in SHR at the 
age of 13 wks compared to age-matched WKY rats (Figure 7A). The GSH-Red activity 
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was also significantly reduced by 16% in SHR at 13 wks, compared to WKY rats 
(Figure 7B).  
 
DISCUSSION 
The pathogenesis of essential hypertension has been under ongoing intensive 
investigations by clinicians and basic science researchers. The aorta, a common site for 
atherosclerotic changes, is frequently the focus of such studies [11]. The aortic 
endothelium and smooth muscle host a number of mediators involved in a delicate 
homeostatic balance. Amongst the factors that upset this balance is oxidative stress. MG 
and AGEs are precursors of oxidative stress, and potently alter the structure and 
functions of proteins and nucleic acids [7,13,14,22]. Elevated MG and AGEs are 
commonly associated with hyperglycemic conditions such as diabetes mellitus.  The 
role of MG and AGEs in hypertension under an apparently normoglycemic state has not 
been investigated widely. Our present study showed that the age-dependent increase in 
blood pressure was associated with a progressive increase in the aortic and plasma MG 
levels in SHR, whereas the MG levels remained unchanged in age-matched WKY rats. 
The levels of MG-induced AGEs, CML and CEL, in the aorta were higher in SHR than 
in WKY rats from 8 wks onwards, in parallel with increased plasma MG levels and 
blood pressure in SHR. These changes in MG and AGEs in SHR are clearly not due to 
increased glucose metabolism since the latter shows no hyperglycemia and the glucose 
levels and insulin sensitivity in SHR and WKY rats are comparable [23]. Thus, in 
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addition to diabetes/hyperglycemic or hyperlipidemic conditions [24], essential 
hypertension is associated with abnormal MG metabolism.  MG may play an important 
role in the development of hypertension in this non-diabetic model. This hypothesis is 
supported by our current study showing synchronized increases in aortic and plasma MG 
levels and blood pressure in SHR. Moreover, chronic MG feeding induces hypertension 
in WKY rats [10]. Given these important advances in our understanding of the putative 
pathogenic role of MG, however, further studies are needed to substantiate a causative 
role of MG in hypertension development. 
While glucose induces glycation via a reversible Maillard reaction with 
N-terminal amino groups or lysyl chains to form fructosamine, MG induces glycation 
through an oxidation process. This reaction is also called glycoxidation and it generates 
irreversible end glycation adducts [7], including CEL and CML.  With their stable 
chemical property, CEL and CML have been interpreted as a measure of the status of 
oxidative stress and of cumulative oxidative damage to proteins induced by MG in aging 
and diabetes [25]. In our study, antibodies against CEL and CML were used. The 
antibody against MG-induced CML is less selective since this antibody can also react 
with glyoxal (another dicarbonyl compound)-induced AGE [25]. In contrast, anti-CEL 
antibody is specifically against MG-induced CEL and has been suggested to be a good 
indicator of MG-induced AGE or glycoxidation product [26].   
When the formation of MG exceeds its degradation, accumulation of MG occurs 
even with normal glucose level. As mentioned earlier, the main source of MG in 
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mammals is glycolysis. Other sources of MG are aminoacetone or acetone catalyzed by 
semicarbadize-sensitive amine oxidase (SSAO) or acetol mono-oxygenase (AMO) [2,3], 
with the former enzyme found in high amounts in the serum, endothelium, adipose tissue 
and vascular smooth muscle cells in mammals [4,27]. SSAO in smooth muscle cells 
mediates MG formation in rat aorta  and may be responsible for diabetic vascular 
complications [5]. A recent paper pinpointed the endothelium as being the major source 
of circulating plasma SSAO in mice [4]. In our study, MG levels in plasma and the aorta 
were significantly and age-dependently increased in SHR at different ages in comparison 
with the age-matched WKY (Figure 1).  An age-dependent change in the activities of 
SSAO and AMO might be responsible for the alteration in circulating MG at different 
ages in diabetes [5] as well as in hypertension. We have found an age-related increase in 
plasma SSAO activity at 8 and 13 wks in SHR, possibly coming from the endothelium 
[4], even though the aortic SSAO activity did not change in SHR and WKY rats. 
Immunocytochemistry revealed most of the staining for CEL and CML in the 
endothelium and very little in the smooth muscle of the aorta, indicating the plasma or 
the endothelium itself to be the source of the elevated MG.  
Normal catabolism of MG is largely dependent on the availability of cellular 
GSH and the activities of the GSH-related enzymes, including GSH-Px and GSH-Red. 
In our study, the elevated levels of MG in plasma or the aorta and MG-induced CEL and 
CML in the aorta of SHR were observed as early as 8 wks of age. These changes 
preceded the decreased GSH level and suppressed activities of GSH-Px and GSH-Red in 
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the aorta of SHR, which appeared at the age of 13 wks. The delayed decrease of GSH in 
SHR indicates that the primary reason for the early onset of MG increase could be an 
abnormally increased MG production rather than a dysfunctional MG degradation.  
Blood pressure of young SHR begins to increase as the levels of MG and its 
associated oxidative stress are progressively increased and the anti-oxidant GSH system 
fails to compensate.  The latter event could also putatively result from the action of MG 
to inactivate antioxidant enzymes such as glutathione reductase [13] and glutathione 
peroxidase [14].  Eventually, GSH level will drop and hypertension in aged SHR enters 
a sustained stage.  
In conclusion, MG, AGEs, and oxidative stress in the aorta and plasma of SHR, 
but not WKY rats, increased in an age-dependent manner associated with the 
development of hypertension. Increased MG and AGEs formation in the aorta may cause 
endothelial dysfunction and altered vascular reactivity, contributing to the development 
of hypertension in the SHR.  
 
 
 
 134
  Table 5-1. Basal parameters of SHR and WKY at different ages 
 
Age 
(wks) 
Rats 
BP 
(mmHg) 
BW 
(g) 
HW 
(g) 
KW 
(g) 
WKY 123 ± 1 107 ± 3 0.66 ± 0.10 1.33 ± 0.08 
5 
SHR 130 ± 2 98 ± 2 0.49 ± 0.01 1.27 ± 0.01 
WKY 121±1 202 ± 5 1.13 ± 0.20 1.91 ± 0.09 
8 
SHR 168 ± 1*** 180 ± 4** 0.93 ± 0.01 1.81 ± 0.01 
WKY 121 ± 1 315 ± 6 1.06 ± 0.03 2.45 ± 0.05 
13 
SHR 204 ± 1*** 282 ± 4** 1.03 ± 0.02 2.36 ± 0.02 
WKY 119 ± 1   361 ± 5 1.17 ± 0.06 2.22 ± 0.03 
20 
SHR 202 ± 1*** 308 ± 4*** 1.37 ± 0.10 2.52 ± 0.08 
 
Values are mean ± SEM. BP, systolic blood pressure; BW, body weight; HW, heart 
weight; KW, kidney weight; WKY, Wistar Kyoto rats; SHR, spontaneously hypertensive 
rats.  
**P < 0.01, ***P < 0.001 SHR vs. WKY rats. 
 
 
 
 
 135
                                                                                   
                                                                                   
            
 
Table 5-2. Intensity of CEL and CML staining in the aorta from SHR and WKY at 
different ages   (n = 3 for each group) 
 
 Rats 5 wks 8 wks 13 wks 20 wks 
CEL 
WKY 
SHR 
5545 ± 528 
6849 ± 93 
8525 ± 664 
11316 ± 478* 
8391 ± 664 
14678 ± 521** 
6977 ± 320 
11175 ± 258** 
CML 
WKY 
SHR 
5589 ± 86 
6288 ± 339 
7519 ± 327 
11248 ± 690** 
7768 ± 550 
12065 ± 795** 
6938 ± 410 
10349 ± 987* 
  CEL, Nε-carboxyethyl-lysine; CML, Nε-carboxymethyl-lysine; WKY, Wistar Kyoto 
rats; SHR, spontaneously hypertensive rats. 
  The intensity of staining was quantified using GeneTools image analysis software  
  and expressed using arbitrary units. 
 *P < 0.05, **P < 0.01 SHR vs. WKY rats. 
 
 
 
 
 
 
 
 
 
 
 
 136
010
20
30
40
A
**
**
**
201 385
M
G
 le
ve
ls
 in
 p
la
sm
a 
(n
m
ol
/m
l)
A g e  (w eek s )
 W K Y
 S H R
 
0
1
2
3
B
201385
**
***
M
G
 le
ve
ls
 in
 a
or
ta
(n
m
ol
/m
g 
pr
ot
ei
n)
A ge  (w eeks )
 W K Y
 S H R
 
0
1
2
3
C
 
*
*
K id n e yL iv e rH e a rt
M
G
 le
ve
ls
(n
m
ol
/m
g 
pr
ot
ei
n)
 W K Y
 S H R
 
 137
                                                                                    
  
 
Figure 5- 1. Methylglyoxal (MG) levels in spontaneously hypertensive rats (SHR).  
MG levels were measured in plasma (A), and the aorta (B) from SHR and age-matched 
Wistar Kyoto (WKY) rats at 5 wks (n = 3), 8 wks (n = 4), 13 wks (n = 4-5) and 20 wks 
(n = 4) of age. MG levels in other tissues (C) were measured in SHR and WKY rats at 
13 wks of age (n = 4-5). *P <0.05, **P < 0.01 SHR vs. WKY rats.  
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Figure 5-2. Immunohistochemical detection of Nε-carboxyethyl-lysine (CEL) in rat 
aortic tissues.  CEL staining was detected in the aorta from spontaneously hypertensive 
rats (SHR) and Wistar Kyoto (WKY) rats. Aortic sections from SHR (right panel) show 
more intense staining than age-matched WKY rats (left panel) (n = 3 to each group). 
Arrows indicate the representative immunoreactivity in the endothelium. Scale bar: 
25µm 
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Figure 5-3.  Immunohistochemical detection of Nε-carboxymethyl-lysine (CML) in rat 
aortic tissues.  CML staining was detected in the aorta from spontaneously 
hypertensive rats (SHR) and Wistar Kyoto (WKY) rats. Aortic sections from SHR (right 
panel) show more intense staining than age-matched WKY rats (left panel) (n = 3 to 
each group). Arrows indicate the representative immunoreactivity in the endothelium. 
Scale bar: 25µm 
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Figure 5-4. Oxidative stress levels in aorta of SHR.  Superoxide anion (O2-. ) (A) and 
hydrogen peroxide (H2O2) (B) levels were measured in spontaneously hypertensive rats 
(SHR) and Wistar Kyoto (WKY) rats at 13 wks of age. (n = 4). O2-. production was 
measured using the lucigenin-enhanced chemiluminescence method, and H2O2 
production was determined by a DCFH-assay. *** P < 0.001 SHR vs. WKY rats. 
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Figure 5-5.  Increased semicarbazide-sensitive amine oxidase (SSAO) activity in 
spontaneously hypertensive rats (SHR).  A. Aortic SSAO activity was measured from 
SHR and Wistar Kyoto (WKY) rats at 8 wks and 13 wks (n = 4 each group). B. SSAO 
activity was measured in plasma from SHR and WKY rats at 5 wks (n = 4), 8 wks (n = 5) 
and 13 wks (n = 4). *P < 0.05, **P < 0.01  SHR vs. WKY rats. 
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Figure 5-6. Reduced glutathione (GSH) levels in the aorta and plasma of spontaneously 
hypertensive rats (SHR) and Wistar Kyoto (WKY) rats at different ages. GSH levels 
were measured in the aorta (A), and plasma (B) from SHR and WKY at 5 wks (n = 3), 8 
wks (n = 4), and 13 wks (n = 4). *P < 0.05, **P < 0.01  SHR vs. WKY rats.  
 143
010
20
30
40
A
1385
**
G
SH
-P
x 
ac
tiv
ity
(n
m
ol
/m
in
/m
g 
pr
ot
ei
n)
Age (weeks)
 WKY
 SHR
                   
0
20
40
60
80
100
120
B
*
1385
G
SH
-R
ed
 a
ct
iv
ity
(n
m
ol
/m
in
/m
g 
pr
ot
ei
n)
Age (weeks)
 WKY
 SHR
 
Figure 5-7.  The activities of the enzymes in the aorta of spontaneously hypertensive 
rats (SHR) and Wistar Kyoto (WKY) rats at different ages. Glutathione peroxidase (A) 
and reductase (B) activities in the aorta of SHR and WKY rats (n = 3-4 for each group). 
*P < 0.05, **P < 0.01  SHR vs. WKY rats.  
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ABSTRACT 
Objectives: Methylglyoxal (MG), a metabolite of glucose, and MG-induced advanced 
glycation endproducts (AGEs) are causatively associated with vascular complications of 
diabetes mellitus. We have previously reported elevated levels of MG and MG-induced 
AGEs in spontaneously hypertensive rats (SHR). The purpose of this study was to 
investigate the causative role of MG and MG-induced AGEs in the pathogenesis of 
hypertension in SHR.   
Methods: Young SHR were treated with an AGE inhibitor; aminoguanidine, for 9 wks. 
HPLC was used to determine plasma and aortic MG and reduced glutathione levels. 
MG-induced AGEs, Nε-carboxyethyl-lysine (CEL) and argpyrimidine, in the aorta were 
determined by immunohistochemistry. Vascular relaxation of small mesenteric arteries 
was measured using myograph.   
Results: Chronic treatment with aminoguanidine attenuated age-dependent blood 
pressure increase in SHR. Plasma and aortic MG levels, and aortic levels of MG-induced 
AGEs were significantly reduced after aminoguanidine treatment, which were 
comparable to those from age-matched Wistar Kyoto rats. Free radical level was 
significantly lowered, while reduced glutathione level was significantly increased by 
aminoguanidine treatment in the aortic tissues from SHR. Moreover, aminoguanidine 
therapy prevented the morphological damage of vascular tissues in SHR, and restored 
the endothelium-dependent relaxation to acetylcholine. Chronic aminoguanidine 
treatment also increased aortic eNOS expression and reduced iNOS expression.  
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Conclusion:  MG and MG-induced AGEs contribute to the pathogenesis of 
hypertension by altering the redox balance, causing vascular eutrophic inward 
remodeling, and inducing endothelial dysfunction in SHR. 
Key Words: methylglyoxal ■ advanced glycation endproducts ■ hypertension 
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INTRODUCTION 
Advanced glycation end products (AGEs) are a heterogeneous group of 
compounds formed by the non-enzymatic reaction of aldehydes and ketones with amino 
groups of proteins via the Maillard reaction1. AGEs are characterized by brown color 
and intra-or inter-molecular cross-linking. AGEs accumulate slowly in aging vascular 
and renal tissues, but this process accelerates with diabetes2. AGEs can be formed by 
glucose, reactive α-oxoaldehydes and other saccharide derivatives with methyglyoxal 
(MG) being the most reactive precursor for AGE formation3. MG is a highly reactive 
dicarbonyl compound that originates from dephosphorylation of the glycolytic 
intermediates4. MG reacts with arginine residues of proteins to form the major 
fluorescent product, argpyrimidine, and the irreversible reaction of MG with lysine 
residues of proteins forms Nε-carboxyethyl-lysine (CEL) 5. 
 
MG and the related AGEs have been recognized as indicators of carbonyl 
overload in vivo1. Numerous studies have shown that increased MG and AGE formation 
under conditions of hyperglycemia has a causative association with diabetes mellitus and 
its complications6. However, the role of MG and AGEs in hypertension with an 
apparently normoglycemic state has not been investigated systematically. An enhanced 
AGE formation was found in stroke-prone spontaneously hypertensive rats7,8. Our 
previous study9 demonstrated increased MG and AGEs in vascular smooth muscle cells 
(VSMCs) from spontaneously hypertensive rats (SHR) in comparison with those from 
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Wistar Kyoto (WKY) rats. We have also shown that MG and MG-induced AGEs 
increase in an age-dependent manner associated with the development of hypertension in 
SHR10,11.  
The purpose of this study was to determine whether increased MG and 
MG-induced AGEs caused blood pressure increase in SHR. We chronically treated 
young SHR with aminoguanidine, an inhibitor of AGEs formation, before their blood 
pressure started to increase, and found that reduction of MG and MG-AGEs attenuated 
the development of hypertension in SHR. This finding has important implications for 
devising new preventive approaches for hypertension management.  
 
MATERIALS AND METHODS 
Animals 
A total of 24 4-week old male rats, including 16 SHR and 8 WKY rats, were 
purchased from Charles River laboratories (St-Constant, Quebec, Canada). At this age 
the SHR are normotensive. In order to avoid inter-batch variability the rats were all 
ordered at the same time in a single batch. The rats were treated in accordance with the 
guidelines of the Canadian Council on Animal Care, and the experimental protocols 
were approved by the Animal Care Committee at the University of Saskatchewan. After 
one week of adaptation, SHR were divided into 2 groups:  untreated group (n = 8) and 
aminoguanidine treated group (1 g/L in drinking water for 9 wks, n = 8). Systolic blood 
pressure was determined weekly using a standard tail cuff noninvasive blood pressure 
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(BP) measurement system (Model 29-SSP, Harvard Apparatus, St. Laurent, QC, Canada). 
At the end of the 9-wk treatment, rats were anaesthetized with sodium pentobarbital (60 
mg/kg body weight) given intraperitoneally. Blood was collected from the heart, and 
plasma was separated by centrifuging blood samples at 1,000 g for 10 min at 4ºC.  
Tissues cleaned in ice-cold phosphate buffer saline (PBS) were snap-frozen in liquid 
nitrogen immediately and stored at -80ºC until processing.  
 
MG measurement 
Aortic tissues were pulverized with a Mikro-Dismembrator (B. Braun Biotech. 
Int., Bethlehem, PA, USA). Samples prepared in 10 mmol/L PBS were sonicated on ice 
twice for 10 s each and thereafter, processed by the addition of 1 mol/L perchloric acid 
(PCA). Then the samples were incubated on ice for 10 min and centrifuged at 15,000 g 
to remove the PCA-precipitated material. The supernatants were used freshly for MG 
measurement. MG was quantitated by the o-phenylenediamine-based assay as described 
previously10,12.  
 
Measurement of reduced glutathione levels   
The reduced glutathione (GSH) level in the aorta was determined by derivation 
with 5, 5'-dithio-bis (2-nitrobenzoic acid), and reverse-phase HPLC using ultra-violet 
detection as described in our previous study13.  
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Measurement of oxidized 2,7-dichlorofluorescein 
 The formation of oxidized 2,7-dichlorofluorescein (DCF) was measured by a 
dichlorofluorescin (DCFH)-assay, as described previously9. The membrane permeable 
and nonfluorescent probe DCFH-DA was used to load aortic tissues. Oxidized-DCF was 
quantified by monitoring the DCF fluorescence intensity with excitation at 485 nm and 
emission at 527 nm with Fluoroskan Ascent plate-reader (Thermo Labsystem, Franklin, 
MA, USA), expressed in arbitrary units. 
 
Measurement of superoxide level 
O2-. production was measured using the lucigenin-enhanced chemiluminescence 
method as described previously14. Chemiluminescence intensity was detected with a 
luminometer (TD-20/20, Tunner Designs, CA, USA). 
 
Measurement of nitric oxide production 
 Nitric oxide (NO) concentration was measured by a newly developed reagent, 
4-amino-5-methylamino-2’,7’-difluorofluorescein diacetate (DAF-FM)15. To detect the 
production of NO, aortic tissues were preloaded with membrane permeable and 
nonfluoresecent DAF-FM (5 µmol/L) in Kreb’s buffer for 2 h at 37°C. DAF-FM is 
deacetylated by intracellular esterases and further reacts with NO to form a fluorescent 
benzotriazole (DAF fluorescence). The intensity of DAF-fluorescence was determined 
by Fluoroskan Ascent plate-reader with excitation at 495 nm and emission at 515 nm. 
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Morphometric analyses 
Morphological examinations were performed by the method described by 
DeBlois et al.16 with some modifications. Briefly, aorta and mesenteric arteries from rats 
were dissected and fixed by immersion in 4% paraformaldehyde for 16-18 h. The 
samples were then incubated in 30% sucrose at 4ºC for 3 days. After embedding in 
O.C.T. compound (Somagen Diagnostics, AB, Canada), 8 µm thick sections were cut 
using a cryostat. After amplifying the images on the slides using a microscope (Olympus 
1×70), the circumferences of the vessels were measured. Diameter (D) was calculated 
from the equation C = π D, where C is the circumference.  Arterial cross-sectional area 
(CSA) was calculated from CSA = π (ro2-ri2), where ro is the external radius of the media 
layer and  ri is the radius of the lumen. 
Immunohistochemistry  
Immunostaining was performed using the method described in our previous 
study10. In brief, paraformaldehyde-fixed and OCT-embedded 8 μm aorta and mesenteric 
artery sections were incubated overnight at 4°C with primary antibodies diluted 1:100 
against the following proteins: CEL (Novo Nordisk, A/S, Denmark); argpyrimidine (Gift 
from Dr. Uchida, Japan); endothelial nitric oxide synthase (eNOS) and inducible nitric 
oxide synthase (iNOS) (BD Bioscience, Mississauga, Canada). Anti-mouse and 
anti-rabbit IgG-FITC (Sigma, Oakville, ON, Canada) diluted 1:200 was the secondary 
antibody. The sections were quantified using GeneTools image analysis software 
(PerkinElmer®, Wellesley, MA, USA). For each animal  thirty spots of each picture 
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with 10 pictures of each section and three sections from each animal were analyzed and 
the average value was used to express the intensity of staining.  
Vascular contractility determination 
Third-order branches of the superior mesenteric artery were isolated and 
transferred to cold physiological saline solution (PSS) containing (in mmol/L): 119 NaCl, 
4.7 KCl, 1.18 KH2PO4, 1.17 MgSO4·7H2O, 2.5 CaCl2·2H2O, 25 NaHCO3, and 5.5 
glucose (pH 7.4). Mesenteric arteries were mounted on a four-channel wire myograph 
(Multi myograph, Model 610M, Denmark) and equilibrated for 1 hour in PSS (bubbled 
with 95% air, 5% CO2, pH 7.4) at 37°C.  The passive tension-internal circumference 
was determined by stretching arteries to achieve an internal circumference equivalent to 
90% of that of the blood vessel under a transmural pressure of 100 mmHg. 
Phenylephrine at a concentration of 3x10-6 mol/L that induced 60-70% of maximal 
contraction was used to pre-contract vessel. After that the endothelium-dependent 
vasodilator acetylcholine (10-10 to 3×10-6 mol/L) or the endothelium-independent 
vasodilator sodium nitroprusside (10-10 to 3×10-6 mol/L) were cumulatively added to 
generate dose-dependent relaxation responses.  Myodaq-Myodata software (Multi 
myograph, Model 610M, Denmark) was used for collecting and analyzing data.  
 
Data analysis 
Data are expressed as mean ± SEM and analyzed using Student’s t-test or one 
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way analysis of variance (ANOVA) in conjunction with the Newman-Keul’s test where 
applicable. Significant difference between treatments was defined at a level of P< 0.05. 
 
RESULTS  
As shown in Table 1, the initial body weight was very comparable among the 
groups. At the end of the study, WKY rats weighed more than untreated SHR and 
aminoguanidine-treated SHR, while aminoguanidine treatment did not alter the body 
weight of SHR. No significant difference was found in the ratios of kidney and heart 
weight to body weight, respectively, among animal groups. Aortic cross-section area was 
comparable in all groups. But aortic media-to-lumen ratio was significantly increased in 
SHR compared with age-matched WKY rats. 
  
Anti-hypertensive effects of aminoguanidine and changes in MG-induced AGEs in 
aorta of SHR 
At the age of 5 wks, there was no difference in the blood pressure between WKY 
rats and SHR, which were 121± 2 and 123 ± 1, respectively. During the observation 
period, systolic blood pressure remained unchanged in WKY rats. But the blood pressure 
of untreated SHR increased gradually and significantly from age 5 to 14 wks (Fig. 1A). 
Aminoguanidine administration significantly attenuated the increase of blood pressure in 
the treated group.  At the end of 9-wk treatment, systolic blood pressures of SHR were 
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175 ± 1 mmHg for aminoguanidine-treated (n = 8) SHR and 202 ± 1 mmHg for 
untreated SHR (n = 8, P < 0.001). 
Plasma MG level significantly increased in untreated SHR from 11.3 ± 0.6 
nmol/ml at 5 wks to 25.9 ± 4.1 nmol/ml at 14 wks. After chronic treatment of SHR with 
aminoguanidine, plasma MG level was significantly decreased to that of WKY rats at 
the same age, which were 16.6 ± 3.7 and 14.2 ± 3.5 nmol/ml, respectively (Fig. 1B).  
MG level in the aorta of untreated SHR was increased 3 times at the age of 14 
wks (2.71 ± 0.44 nmol/mg protein) compared with that at 5 wks (0.92 ± 0.12 nmol/mg 
protein). The MG level in the aorta from aminoguanidine-treated SHR was significantly 
reduced to 1.33 ± 0.14 nmol/mg protein at the age of 14 wks, which was comparable to 
that in WKY rats at the same age (Fig. 1C).  
Using immunohistochemical staining method, we further investigated whether 
MG-induced AGEs were decreased in the aorta and mesenteric artery from SHR with 
aminoguanidine treatment.  Figure 2 shows reduced intensity of argpyrimidine and 
CEL staining in the aorta from aminoguanidine-treated SHR, compared with untreated 
controls (n = 3-5 for each group). Chronic treatment with aminoguanidine also 
normalized the intensities of argpyrimidine and CEL in SHR to that of WKY rats (Fig. 
2C & D). Table 2 shows that intensity of argpyrimidine and CEL staining in the 
mesenteric artery was also significantly decreased after aminoguanidine treatment. Most 
of the positive CEL and argpyrimidine staining was localized to the endothelial layer in 
all the animal groups. The negative (no primary antibody) and positive (control immune 
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globulin) control sections revealed no staining (not shown).   
 
Decreased oxidative stress in the aorta of AG-treated SHR 
Superoxide anion (O2-.) level was significantly reduced in the aorta of 
aminoguanidine-treated SHR at the end of 9-wk treatment period (P < 0.001) (Table 3). 
Compared with untreated SHR, DCF-fluorescence intensity was also significantly 
reduced by aminoguanidine treatment (Table 3).  Using a NO sensitive probe DAF-FM, 
NO production was directly measured. As shown in Table 3, DAF fluorescence was 
significantly decreased by chronic aminoguanidine treatment in comparison with 
untreated SHR. The GSH level in the aorta from aminoguanidine-treated SHR was 
significantly increased, as opposed to untreated SHR (Table 3). 
 
Effects of chronic aminoguanidine treatment on nitric oxide synthase expression in 
aortic tissues 
To investigate possible mechanisms for effect of aminoguanidine treatment on 
blood pressure in vivo, aortic iNOS and eNOS expressions were measured. As shown in 
Fig. 3A, compared with untreated SHR, the aorta of aminoguanidine-treated SHR had 
more eNOS staining. (Fig 3C). Immunofluorescence revealed more intense iNOS 
staining in the untreated SHR than in SHR treated with aminoguanidine and WKY rats 
(Fig. 3B & D). Both eNOS and iNOS levels in the aorta from aminoguanidine-treated 
SHR were comparable to those from WKY rats at the same age. 
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Morphological changes in mesenteric arteries of SHR 
Morphological damage of vascular tissues was prevented in SHR treated with 
aminoguanidine (Table 4). The lumen diameter of the mesenteric arteries from 
aminoguanidine-treated SHR was significantly enlarged, the wall thickness was reduced, 
and the media/lumen ratio was decreased (P < 0.05) in comparison with those of 
untreated SHR (Table 4).  On the other hand, there was no significant change in 
cross-section area of the mesenteric arteries (Table 4) (n = 3-4 for each group). These 
results suggest that long-term exposure to aminoguanidine prevents the development of 
eutrophic inward vascular remodeling in SHR. 
 
Aminoguanidine treatment improves endothelium-dependent relaxation in 
mesenteric arteries of SHR 
Acetylcholine (0.1 nmol/L to 3 µmol/L)-induced relaxations were significantly 
increased in small mesenteric arteries from adult SHR treated with aminoguanidine, 
which was very comparable to that from WKY rats of the same age (Fig. 4A). The 
sensitivity of small mesenteric arteries to acetylcholine was also significantly enhanced 
after chronic treatment with aminoguanidine compared with untreated SHR (EC50, 1.80 
± 0.15 vs. 13.23 ± 1.67 nmol/L with or without aminoguanidine treatment). There was 
no difference in sodium nitroprusside mediated relaxation of vascular tissues from WKY 
rats and SHR treated with or without aminoguanidine (Fig. 4B), which indicates that 
acetylcholine-induced relaxation is endothelium-dependent.    
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DISCUSSION 
Our previous studies10,11 showed that an age-dependent increase in blood 
pressure was associated with a progressive increase in the aortic and kidney MG and 
MG-induced AGE levels in SHR. These earlier observations suggested that MG may 
play an important role in the development of hypertension. In the present study, we show 
that administration of aminoguanidine, a non-specific inhibitor of AGE formation, to 
male SHR from 5 to 14 weeks significantly reduced plasma and aortic MG levels, 
decreased the levels of MG-induced AGEs, CEL and argpyrimidine, in the aorta and 
prevented the morphologic damage in the SHR, leading to a significant attenuation of 
blood pressure increase. Thus, we provide evidence for the first time for a role of MG 
and MG-induced AGEs in the development and progression of hypertension in the SHR. 
Recently, it was shown that aminoguanidine17, used as an inhibitor of collagen 
cross-linking, reduced increase in blood pressure and inflammatory changes in the left 
ventricle in DOCA-salt hypertensive rats. The role of MG was however, not investigated 
in this study. 
Retarded development of diabetic complications by chronic aminoguanidine 
treatment for experimental diabetes was the initial evidence that AGE accumulation is a 
risk factor for diabetic complications18,19. Recent studies have also demonstrated that 
aminoguanidine treatment of rats decreased age-related cardiovascular damage20. 
Aminoguanidine, a nucleophilic hydrazine compound, is a prototype α,β-dicarbonyl 
scavenger that prevents the formation of AGEs from α,β-dicarbonyl precursors18. 
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Aminoguanidine is mostly efficient in scavenging MG21. AG is also a potent and 
irreversible inhibitor of semicarbazide-sensitive amine oxidase (SSAO)22. Besides 
glycolysis, MG is also generated from primary amines and from acetone during lipolysis, 
catalyzed by SSAO or acetol mono-oxygenase22 and increased activities of SSAO might 
be responsible for the enhanced circulating MG levels in diabetes23 as well as in 
hypertension10. Thus, prevention of formation or scavenging of MG by aminoguanidine 
would decrease the formation of AGEs. Moreover, aminoguanidine also blocks the 
formation of a de novo crosslink by irreversibly binding to glycated proteins24.  
Oxidative stress is one of the pathogenic factors in the development of 
hypertension in experimental models6,25. Our previous study demonstrated that MG 
increased the generation of O2.- and NO in rat aortic SMCs, which in turn enhanced 
ONOO- formation15. As shown in Table 3, administration of aminoguanidine 
significantly reduced O2.-, ONOO- and H2O2 generation in SHR. This effect of 
aminoguanidine could be an indirect one, through inhibition of AGE formation, as well 
as a direct one, through an effect on free radicals themselves. Moreover, GSH level was 
significantly higher after aminoguanidine treatment than that in the untreated SHR group. 
These antioxidant properties of aminoguanidine are in agreement with other studies26. 
Aminoguanidine is a known inhibitor of iNOS27. Our results confirm these findings and 
we show decreased NO production (Table 3), probably derived from iNOS, as well as 
reduced iNOS staining (Fig. 3) after aminoguanidine-treatment in SHR. Chronic 
aminoguanidine treatment in cirrhotic rats has been shown to reduce aortic iNOS mRNA 
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and protein while having no effect on eNOS28.   
NO is a primary vasodilator derived from the endothelium. Recently, Rojas et 
al.29 found that AGEs can decrease eNOS expression by increasing the rate of eNOS 
mRNA degradation. This effect can contribute to reduced endothelium-dependent 
relaxation, as observed by us (Fig. 4). Our previous study10 revealed most of the staining 
for MG-induced AGEs, CEL and CML, in the endothelium and very little in the smooth 
muscle of the aorta. After aminoguanidine therapy, the endothelial levels of MG-induced 
CEL and argpyrimidine were normalized to the levels found in WKY rats at the same 
age. The expression of eNOS was also increased by aminoguanidine treatment. 
Moreover, the small mesenteric arteries from aminoguanidine-treated SHR showed 
restored endothelium-dependent relaxation to acetylcholine and unaltered 
endothelium-independent relaxation to sodium nitroprusside (Fig. 4). 
It is well established that essential hypertension is associated with structural 
changes in the resistance vessels, a process known as vascular remodeling. Mulvany30 
has proposed that essential hypertension is associated only with eutrophic remodeling in 
small arteries. In our study, chronic aminoguanidine administration prevented 
AGEs-induced morphological damage in mesenteric arteries from SHR, as evidenced by 
increased lumen diameter and decreased media/lumen ratio without changes of CSA, 
which indicate that AGEs-induced eutrophic inward remodeling. Aminoguanidine, a 
known inhibitor of collagen cross-linking17, may be reducing aortic stiffness, like 
β-aminopropionitrile31, although such an effect on resistance vessels that regulate blood 
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pressure needs to be proved in future studies. 
In summary, plasma and aortic MG levels in SHR were significantly reduced by 
aminoguanidine treatment. Aortic levels of MG-induced AGEs in SHR after 
aminoguanidine treatment were normalized to the levels found in age-matched WKY 
rats. Free radical production was significantly lowered while reduced glutathione level 
was significantly increased after aminoguanidine treatment in the aortic tissues from 
SHR. Moreover, aminoguanidine treatment prevented the morphological damage of 
vascular tissues in SHR, and restored endothelium-dependent relaxation to acetylcholine. 
Chronic treatment of SHR with aminoguanidine significantly increased aortic eNOS 
levels and reduced iNOS expression.  All these beneficial effects of aminoguanidine 
lead to reduced age-dependent development of hypertension in SHR. Although further 
studies are needed to substantiate the causative roles of MG and MG-mediated AGEs in 
the progression of hypertension, our study strongly suggests that MG and MG-induced 
AGEs are involved as a factor in the pathogenesis of hypertension by modulating the 
redox state and inducing endothelial dysfunction and vascular remodeling in the SHR. 
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Table 6-1.  Gross indications of animal growth and morphology of the aorta  
 
 
 WKY SHR - Untreated SHR -Aminoguanidine 
Initial (5 wks) 
body weight (g) 
107 ± 2 94 ± 2 92 ± 3 
Final (14 wks) 
body weight (g) 
335 ± 10 300 ± 10* 302 ± 4* 
Kidney weight/ 
Body weight (%) 
0.67 ± 0.02 0.77 ± 0.05 0.77 ± 0.03 
Heart weight/ 
Body weight (%) 
0.33 ± 0.005 0.4 ± 0.01 0.38 ± 0.01 
Aorta CSA (mm2) 0.402 ± 0.01 0.456 ± 0.08 0.393 ± 0.04 
Aorta media/lumen ratio 
(%) 6.03 ± 0.12 6.73 ± 0.02* 6.12 ± 0.4 
 
n =  4-8 for each group. 
Values are mean ± SEM.  CSA, cross-section area.  
*P< 0.05, SHR vs. WKY rats of the same age group 
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Table 6-2. Intensity of advanced glycation endproducts immunofluorescence 
staining in mesenteric arteries. 
 
 
 Argpyrimidine CEL 
WKY 498 ± 22 534 ± 51 
SHR - Untreated 731 ± 25* 801 ± 19* 
SHR -Aminoguanidine 508 ± 37# 544 ± 26# 
 
Intensity of argpyrimidine and CEL staining was quantified using GeneTools image 
analysis software (n = 3-5 in each group). *P < 0.05, SHR vs. WKY rats of the same age 
group.  #P < 0.05, aminoguanidine-treated vs. untreated SHR of the same age group. 
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Table 6-3. Free radical and reduced glutathione levels in aortic tissues of rats. 
 
 
 WKY SHR - Untreated 
SHR 
-Aminoguanidine
Superoxide anion production 
(% of WKY rats) 100 ± 16 220 ± 9** 136 ± 8
## 
DCF-fluorescence intensity 
(% of WKY rats) 100 ± 4 122 ± 2 * 107 ± 4
# 
NO production 
 (% of WKY rats) 
100 ± 6 155 ± 6* 105 ± 5# 
GSH levels in aorta 
(% of WKY rats) 
100 ± 16 63.8 ± 5.9* 96.2 ± 8.6# 
 
n = 5-8 in each group. O2-. production was measured using the lucigenin-enhanced 
chemiluminescence method, oxidized DCF production was determined by a 
DCFH-assay, NO concentration was measured by DAF-FM reagent, and reduced GSH 
was quantified by HPLC. *P < 0.05, **P< 0.001, SHR vs. WKY rats of the same age 
group.  #P < 0.05, ## P < 0.001, aminoguanidine -treated vs. untreated SHR of the same 
age group. 
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Table 6-4.  Morphological characteristics of the mesenteric arteries of rats (14 
wks) 
 
 
 
WKY SHR- Untreated 
SHR - 
Aminoguanidine
Lumen diameter (mm) 0.601 ±0.02 0.46 ± 0.01* 0.576 ± 0.03# 
Wall thickness (µm) 42.39 ± 1.16 71.32 ± 2.26* 56.30 ± 4.25# 
Media/lumen ratio (%) 7.09 ± 0.37 15.52 ± 0.7* 9.76 ± 0.45# 
Cross-section area (mm2) 0.085 ± 0.04 0.119 ± 0.04 0.112 ± 0.01 
 
n = 3-4 for each group 
*P< 0.05,  SHR vs. WKY rats of the same age group 
#P<0.05,  aminoguanidine-treated vs. untreated SHR of the same age group 
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Figure 6-1. Effect of aminoguanidine on systolic blood pressure and methylglyoxal 
(MG) levels in SHR. Systolic blood pressure was measured by tail-cuff (A). SHR were 
treated with aminoguanidine from 5 wks to 14 wks (n = 8).  MG levels were measured 
in the plasma (B), and the aorta (C) from aminoguanidine-treated SHR, untreated SHR 
and WKY rats (n = 5-6). *P < 0.05, **P < 0.001, SHR vs. WKY rats of the same age 
group.  #P < 0.05, ##P < 0.001, aminoguanidine-treated vs. untreated SHR of the same 
age group. 
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 Figure 6-2. Immunohistochemical detection of AGEs in rat aortic tissues.  
Argpyrimidine (A) and Nε-carboxyethyl-lysine (CEL) (B) staining was detected in the 
aorta from aminoguanidine-treated SHR, untreated SHR and WKY rats. Aortic sections 
from untreated SHR showed more intense argpyrimidine and CEL staining than 
age-matched SHR treated with aminoguanidine. Arrows indicate the representative 
immunoreactivity in the endothelium. Scale bar: 25µm.  Intensity of argpyrimidine (C) 
and CEL (D) staining was quantified using GeneTools image analysis software (n = 3-5 
in each group). *P < 0.05, SHR vs. WKY rats of the same age group.  #P < 0.05, 
aminoguanidin -treated vs. untreated SHR of the same age group. 
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Figure 6-3.  Immunoreactivities of eNOS and iNOS in aortic tissues of SHR.  Staining 
of eNOS (A) and iNOS (B) were detected in the aorta from aminoguanidine-treated SHR, 
untreated SHR and WKY rats. Aminoguanidine-treated SHR and WKY rats show more 
positive eNOS staining than age-matched controls, while untreated SHR has more 
positive iNOS staining than WKY rats and aminoguanidine-treated SHR. The positive 
staining was only localized in the endothelium. Scale bar: 25µm. Intensity of eNOS (C) 
and iNOS (D) staining was quantified using GeneTools image analysis software.  n = 
3-5 for each group. *P < 0.05, SHR vs. WKY rats of the same age group.  #P < 0.05, 
aminoguanidine-treated vs. untreated SHR of the same age group. 
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Figure 6-4.  Vasorelaxation of the third branches of the mesenteric arteries in SHR 
treated with aminoguanidine. A. The mesenteric arteries were precontracted with 
phenylephrine (3x10-6 mol/L) followed by administration of acetylcholine and 
endothelium-dependent vasorelaxation was measured in aminoguanidine-treated SHR, 
untreated SHR and WKY rats.  B. The mesenteric arteries were precontracted with 
phenylephrine (3x10-6 mol/L) and endothelium-independent vasorelaxation was 
measured in the presence of various concentrations of sodium nitroprusside, a NO donor. 
n = 7-8 for each group.  *P < 0.05, ** P < 0.001, SHR vs. WKY rats of the same age 
group.  #P < 0.05, ## P < 0.001, aminoguanidine-treated vs. untreated SHR of the same 
age group.  
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 ABSTRACT 
Objectives: Methylglyoxal (MG) is a reactive dicarbonyl intermediate of metabolism 
produced in the body. MG reacts with certain proteins and forms damaging advanced 
glycation endproducts (AGEs) such as Nε-carboxyethyl-lysine (CEL) and 
Nε-carboxymethyl-lysine (CML). Increased MG levels are found in diabetes mellitus 
and associated with hypertension development in the SHR. The purpose of this study 
was to investigate whether increased endogenous formation of MG and MG-induced 
olorofluorescin assay. Immunohistochemistry 
l changes in fructose-fed rats were attenuated 
in metformin and fructose cotreated rats.  
AGEs caused hypertension development in normotensive Sprague Dawley (SD) rats.  
Methods: The rats were fed chronically for 16 wks with fructose, a known precursor of 
MG formation. One group of rats was cotreated with fructose and metformin, an AGEs 
formation inhibitor. MG and reduced glutathione (GSH) were measured by HPLC, while 
hydrogen peroxide was measured by a dich
was performed for eNOS, CEL and CML. 
Results: Fructose-fed rats had elevated blood pressure, serum MG, insulin and 
triglycerides, and reduced serum levels of GSH. MG, hydrogen peroxide and CEL were 
increased in the aorta while the endothelial eNOS was reduced. CEL and CML were also 
increased in the mesenteric artery endothelium along with media/lumen ratio, signifying 
structural remodelling. Fructose-fed rats also had reduced insulin-stimulated glucose 
uptake in adipose tissue. All of the harmfu
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Conclusion: Increased MG, AGEs, oxidative stress and reduced endothelial nitric oxide 
synthase along with structural remodelling of the vessel wall in the aorta and mesenteric 
artery likely play a role in the pathogenesis of hypertension.  
Key Words: methylglyoxal ■ advanced glycation endproducts ■ hypertension ■ 
oxidative stress 
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INTRODUCTION 
Methylglyoxal (MG), a highly reactive dicarbonyl compound, is an intrinsic 
component of anaerobic glycolysis. It is also formed during other metabolic processes 
including the breakdown of threonine from protein catabolism and acetone from 
lipolysis [1]. MG is detoxified by the glyoxalase system that uses reduced glutathione 
(GSH) as a cofactor. An overproduction of MG may be caused by an increased 
availability of its precursors such as glucose and fructose; for example, in vascular 
smooth muscle cells, fructose increased MG formation in a concentration and time 
dependent manner [2]. MG can react with selective proteins to yield irreversible 
advanced glycation endproducts (AGEs), and it is one of the most reactive AGE 
precursors [3].  The irreversible reaction of MG with lysine residues of proteins forms 
Nε-carboxymethyl-lysine (CML) and Nε-carboxyethyl-lysine (CEL) [4].  
  Clinical and biochemical evidences suggest that increased formation of MG and its 
induced AGEs in diabetes mellitus is a causative factor for the development of diabetic 
complications such as retinopathy or nephropathy [5]. High MG levels may also play an 
important role in non-diabetic conditions such as hypertension. An enhanced AGE 
formation was found in stroke-prone spontaneously hypertensive rats (SHR) [6]. Our 
previous studies [7, 8] showed that an increase in blood pressure of SHR closely 
paralleled with an age-dependent increase in MG, CEL and CML levels in the kidney 
and aorta, which was not seen in age-matched Wistar Kyoto rats, despite similar blood 
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glucose levels between these two strains [9]. We also found that treatment of young 
SHR with an AGE inhibitor, aminoguanidine, attenuated the increase of blood pressure 
[10]. 
The aim of this study was to determine whether increased formations of MG and 
MG-induced AGEs caused blood pressure increase in young normotensive Sprague 
Dawley (SD) rats. We chronically treated young SD rats with fructose, a precursor of 
MG, and metformin, an inhibitor of AGEs. We found that fructose treatment 
significantly increased MG and MG induced AGEs formation. Metformin cotreatment 
attenuated the increase of blood pressure in fructose-fed SD rats by scavenging MG and 
AGEs. This finding implies that the increased level of MG may be a causative factor for 
hypertension development.  
 
MATERIALS AND METHODS 
Animals  
A total of 79 4-week old male SD rats were purchased from Charles River 
Laboratories (St-Constant, Quebec, Canada). The rats were treated in accordance with 
the guidelines of the Canadian Council on Animal Care, and the experimental protocols 
were approved by the Animal Care Committee at the University of Saskatchewan. After 
one week adaptation, SD rats were divided into 4 groups:  untreated control group (n = 
17); 60% fructose (in chow) treated group (n = 25); metformin (500mg/kg/day in 
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drinking water) treated group (n = 18); and fructose plus metformin (60% fructose in 
chow, metformin 500mg/kg/day in drinking water) treated group (n = 19). Body weight, 
blood glucose levels, and systolic blood pressure were measured weekly. Blood glucose 
was determined using the OneTouch® blood glucose monitoring system (LifeScan 
Canada). Systolic blood pressure was determined weekly using a standard tail cuff 
noninvasive BP measurement system (Model 29-SSP, Harvard Apparatus, St. Laurent, 
QC, Canada). After 9 wks treatment, some rats were sacrificed to test the insulin 
resistance status.  At the end of the 16-wk study, rats were anaesthetized with sodium 
pentobarbital (60 mg/kg body weight) given intraperitoneally. Blood was collected from 
the heart, and serum was separated by centrifuging blood samples at 1,000 g for 10 min 
at 4ºC.  Tissues cleaned in ice-cold phosphate buffer saline (PBS) were snap-frozen in 
liquid nitrogen immediately and stored at -80ºC until processing.  
 
Biochemical Measurements 
The serum levels of hemoglobin A1C, triglycerides, total cholesterol and high 
density lipoprotein (HDL) cholesterol were assayed in the Laboratory of Biochemistry 
and Hematology, Royal University Hospital, University of Saskatchewan, Saskatoon, 
Canada. Serum insulin concentration was measured with a rat-specific insulin ELISA kit 
(Mercodia, Uppsala, Sweden). 
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Glucose tolerance test and the determination of insulin stimulated glucose uptake 
An intraperitoneal glucose tolerance test (IPGTT) was carried out after 12-14 h 
fasting. After basal glucose level was measured, conscious rats were injected 
intraperitoneally with 1.5 g/kg body weight of 50% (w/v) glucose solution in 0.9% (w/v) 
saline. Blood was then collected from the tail vein and blood glucose was measured 
using OneTouch® blood glucose monitoring system (LifeScan, Canada) at 0, 10, 15, 30, 
60, and 120 min after the glucose injection. [3H]-2-deoxyglucose ([3H]-2-DOG, 
PerkinElmer) was used for glucose uptake experiments in abdominal adipose tissue as 
described previously [11].   
 
MG measurement 
Aortic and serum MG levels were quantified by the widely accepted 
o-phenylenediamine (o-PD)-based assay as described previously [7] with some 
modification. Briefly, the supernatant of the aortic homogenate or serum was incubated 
with 100 mmol/L o-PD (derivatizing agent) for 3 h at room temperature. The 
quinoxaline derivative of MG (2-methylquinoxaline) and the quinoxaline internal 
standard (5-methylquinoxaline) were measured using a Hitachi D-7000 HPLC system 
(Hitachi Ltd., Mississauga, ON, Canada). Samples were calibrated by comparison with 
2-MQ standards. 
 
Measurement of reduced glutathione levels   
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The GSH levels in the aorta and serum were determined by derivation with 5, 
5'-dithio-bis (2-nitrobenzoic acid), and reverse-phase HPLC using ultra-violet detection 
as described in our previous study [12].  
Measurement of hydrogen peroxide levels 
 The formation of H2O2 was measured by a dichlorofluorescin (DCFH)-assay, as 
described previously [13]. The membrane permeable and nonfluorescent probe 
DCFH-DA was used to load aortic tissues. Oxidized-DCF was quantified by monitoring 
the DCF fluorescence intensity with excitation at 485 nm and emission at 527 nm with 
Fluoroskan Ascent plate-reader (Thermo Labsystem, Franklin, MA, USA), expressed in 
arbitrary units. 
 
Morphometric analyses 
Morphological examinations were performed by the method described by 
DeBlois et al. [14] with some modifications. Briefly, aorta and mesenteric arteries from 
rats were dissected and fixed by immersion in 4% paraformaldehyde for 16-18 h. The 
samples were then incubated in 30% sucrose at 4ºC for 3 days. After embedding in 
O.C.T. compound (Somagen Diagnostics, AB, Canada), 8 µm thick sections were cut 
using a cryostat and picked up on poly-l-lysine coated slides. After amplifying the 
images on the slides using a microscope (Olympus 1×70), the circumferences of the 
vessels were measured. Diameter (D) was calculated from the equation C = π D, where 
C is the circumference.  Arterial cross-sectional area (CSA) was calculated from CSA = 
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π (ro2-ri2), where ro is the external radius of the media layer and ri is the radius of the 
lumen. 
 
Immunohistochemistry  
Immunostaining was performed using the method described in our previous 
study [8]. In brief, paraformaldehyde-fixed and OCT-embedded 8 μm mesenteric artery 
sections were permeabilized and incubated overnight with primary antibodies against the 
following proteins: CEL and CML (Novo Nordisk, A/S, Denmark); diluted 1:100. 
Anti-mouse IgG-FITC (Sigma, Oakville, ON, Canada) diluted 1:200 was the secondary 
antibody.  
For double immunofluorescence staining, aortic sections were incubated overnight 
in a cocktail solution containing mouse anti-CEL antibody (1:100) and rabbit anti-eNOS 
antibody (1:200; Chemicon International, Temecula, CA, USA). After multiple washes 
in PBS, sections were incubated for 2 h in goat anti-mouse IgG-FITC (1:200) and Alexa 
Fluor 568–conjugated anti-mouse secondary antibody (1:400; Invitrogen, Burlington, 
ON, Canada). Sections were mounted on gelatinized slides and coverslipped. 
Immunofluorescence images were obtained under a confocal laser-scanning microscope 
(LSM 510 META; Zeiss). 
The sections were quantified using GeneTools image analysis software 
(PerkinElmer®, Wellesley, MA, USA). For each animal  thirty spots of each picture, 
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with 10 pictures of each section and three sections from each animal were analyzed and 
the average value was used to express the intensity of staining.  
 
Data analysis  
Data are expressed as mean ± SEM and analyzed using Student’s t-test or one 
way analysis of variance (ANOVA) and post hoc analysis (Tukey test) where applicable. 
Significant difference between treatments was defined at a level of P< 0.05. 
 
 
RESULTS 
 
The development of insulin resistance in fructose-fed rats  
After 9 weeks’ treatment with fructose, the rats showed a significant increase in 
serum insulin (Figure 1A), and enhanced serum triglyceride levels (Table 1). As shown 
in Figure 1A, the serum insulin level was enhanced significantly from 2.80±0.12 µg/L in 
control group to 4.87 ± 0.18 µg/L in fructose-fed group. Likewise, serum triglycerides 
increased from 0.35 ± 0.04 mM to 0.84 ± 0.05 mM by fructose feeding (Table 1). 
However, total cholesterol, HDL-cholesterol and HbA1c in serum were not changed 
(Table 1). In all groups of rats treated with or without MG and/or metformin, the fasting 
blood glucose level was maintained at 5 - 6 mM. At the end of the 9 wks treatment, 
IPGTT was performed and a notable difference was observed in metformin-treated rats, 
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compared with the control rats (P<0.05, n = 4 for metformin treated group, n = 7 for 
other groups; Figure 1B).  
A decreased insulin-stimulated glucose uptake in insulin targeted tissues has been 
identified as a key indicator of insulin resistance. We observed that the insulin-induced 
glucose uptake by abdominal adipose tissue dropped dramatically in fructose-fed rats, in 
comparison with that from untreated control rats (P<0.05). With insulin (100 nM) 
stimulation, as shown in Figure 1C, glucose uptake by adipose tissue is 198% of the 
basal glucose uptake without insulin stimulation, in the control group (n = 6), and 117% 
of the basal uptake in fructose-fed rats (n = 6, P<0.05). The lowered glucose uptake in 
adipose tissue induced by fructose feeding was restored significantly by co-treatment 
with metformin (Figure 1C).  
 
Increased endogenous accumulation of MG in fructose-fed rats 
Blood pressure was significantly increased after only two weeks of the fructose 
feeding, while metformin cotreatment attenuated the increase of blood pressure in the 
treated group (Fig 2A). Metformin alone did not change the blood pressure compared to 
control SD rats.  
As shown in Fig 2B, 9-week fructose treatment caused a significant increase in 
serum MG concentration in SD rats. Serum MG level in fructose-fed rats was increasing 
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with time. At the end of the study, serum MG level was significantly increased by 72.5% 
in fructose treated SD rats to 4.28 ± 0.5 μM compared to 2.48 ± 0.3 μM in control SD 
rats (n = 5-6). MG level in aorta was also significantly increased after fructose treatment 
(Fig 2C). This increased endogenous MG accumulations in aorta as well as in serum 
were significantly reduced by metformin co-treatment.  
 
Effects of chronic fructose treatment on CEL and eNOS expression in aortic tissues 
Using immunohistochemical double-staining method, we further investigated the 
effect of fructose on CEL and eNOS in the aorta from SD rats.  Figure 3 shows 
increased intensity of CEL staining in the aorta from fructose-treated SD rats, compared 
with untreated controls (n = 3-5 for each group). Chronic co-treatment with metformin 
normalized the intensities of CEL in fructose-fed SD rats to that of control SD rats (Fig. 
3B).  Aortic eNOS expression was measured in order to investigate possible 
mechanisms for the effect of fructose treatment on blood pressure in vivo. As shown in 
Fig. 3A, compared with untreated SD rats, the aorta of fructose-treated SD rats had less 
eNOS staining. The intensity of eNOS staining was significantly increased by chronic 
treatment with metformin in fructose-fed rats (Fig 3C). Metformin alone had no effect 
on CEL and eNOS expression compared to control SD rats. Most of the positive CEL 
and eNOS staining was localized to the endothelial layer in all the animal groups. The 
negative (no primary antibody) and positive (control immune globulin) control sections 
revealed no staining (not shown).   
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Increased oxidative stress in fructose-treated SD rats 
Compared with untreated SD rats, hydrogen peroxide production in aorta measured 
with DCF-fluorescence intensity was significantly increased more than two times by 
fructose treatment, from 8.7 ± 1.3 to 21.6 ± 4.3 (arbitrary units) respectively (Fig. 4A). 
DCF-fluorescence was significantly reduced in fructose plus metformin treated group 
compared to fructose alone treated group. The reduced GSH level in the serum from 
fructose-fed rats was significantly decreased, as opposed to untreated SD rats (Fig. 4B). 
In the fructose plus metformin treated group, serum GSH level was very comparable to 
that in control group. There was no significant difference in aortic GSH levels among all 
groups (data not shown). 
 
Morphological changes in mesenteric arteries of SD rats 
The lumen diameter of the mesenteric arteries from fructose-treated SD rats was 
significantly decreased, the wall thickness was enlarged, and the media/lumen ratio was 
increased (P < 0.05) in comparison with those of untreated SD rats (Fig. 5A).  
Morphological damage of vascular tissues was prevented by co-treatment with 
metformin. On the other hand, there was no significant change in cross-section area of 
the mesenteric arteries among the groups (Fig. 5B) (n = 3-4 for each group). These 
results suggest that long-term exposure to fructose induces the development of eutrophic 
inward vascular remodeling in SD rats. 
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Enhanced expression of AGEs in mesenteric arteries by fructose treatment 
 
Figure 6 shows more intense or positive staining for CEL in the mesenteric artery 
from fructose-fed SD rats, compared to control SD rats. The intensity of CEL staining 
was significantly higher in fructose-treated rats than in age-matched control rats (Fig 6 
A&B). Most of the positive staining was localized to the endothelial layer in both strains. 
Staining for CML was also more intense in the mesenteric artery from fructose-treated 
rats as opposed to control rats (n = 3 for each group) (Fig. 6 A&C). CEL and CML 
expression was significantly decreased by chronic metformin cotreatment. 
 
DISCUSSION 
In the present study we show that chronic administration of fructose to SD rats 
significantly increased serum and aortic MG levels, enhanced the MG-induced AGEs 
formation in the aorta and the mesenteric artery, and caused morphological damage in 
the arterial wall, leading to a significant increase in blood pressure. Our previous study 
[8] showed that an age-dependent increase in blood pressure was associated with a 
progressive increase in the aortic MG and MG-induced AGE levels in SHR. More 
importantly, chronic treatment with aminoguanidine, a non-specific inhibitor of AGEs 
formation, significantly reduced MG and MG-induced AGEs in the aorta and attenuated 
the blood pressure increase in SHR [10].  The SHR is a genetic model of hypertension 
with multiple pathogenetic factors which have not been clearly defined. To define the 
role of MG and MG-induced AGEs more clearly in the pathogenesis of hypertension we 
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used fructose, a precursor of MG formation [15], to treat SD rats for 4 months and 
follow changes in blood pressure, MG, AGEs and other parameters. 
During the last two decades, the consumption of fructose has increased 
considerably. Excessive fructose consumption has been shown to cause obesity, diabetes 
mellitus and hypertension [16]. Endogenous fructose is metabolized by hexokinase or 
ketohexokinase to dihydroxyacetone phosphate (DHAP) and 
glyceraldehydes-3-phosphate (G3P), both of which can be further metabolized in the 
glycolytic pathway. Although the circulation level of fructose is lower than that of 
glucose, fructose is much more reactive in glycating proteins. It is reported that fructose 
was 7.5 times more reactive than glucose in causing glycation of hemoglobin, and 10 
times more reactive in the rate of protein cross-linking [17, 18]. Fructose feeding did not 
impair the glucose tolerance significantly but the serum insulin levels were elevated 
indicating development of insulin resistance. Metformin reversed insulin levels back to 
normal values and improved insulin-stimulated glucose uptake in fructose treated rats. 
As mentioned earlier, the main source for MG formation is anaerobic glycolysis. 
Both DHAP and G3P can be converted to MG. Increased intracellular level of fructose, 
which gives rise to G3P and DHAP levels, increases intracellular MG concentration. In 
vascular smooth muscle cells, formation of MG induced by fructose occurred in a 
concentration and time dependent manner [2]. Our results showed that serum and aortic 
MG levels were significantly increased after chronic treatment with fructose.  
Metformin is widely used as an oral antihyperglycaemic agent for the management 
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of type 2 diabetes mellitus. It is a guanidine compound with some structural similarity to 
aminoguanidine, one of the best characterized and commonly used AGEs inhibitor [19], 
which suggests that metformin may also inhibit the glycation processes.  Recently, a 
number of studies [20, 21] have shown that metformin is an anti-glycation agent. It was 
found that metformin can reduce tissue MG levels in diabetic patients [22]. Tanaka et al. 
[21] showed that chronic treatment with metformin can reduce AGE levels in lens, 
kidney and nerves in diabetic animals. Several mechanisms by which metformin can 
inhibit glycation processes have been proposed. One mechanism suggests that 
metformin traps reactive carbonyl species like MG and glyoxal. An in vitro study [20] 
showed that metformin directly reacts with MG to form stable triazepinone derivatives. 
Another mechanism proposes that metformin reduces MG level via enhancement of MG 
detoxification through the glyoxalase pathway [22]. Metformin may also react with 
post-Amadori products [23]. Our present study demonstrated that metformin 
significantly reduced aortic and serum MG levels and dramatically decreased 
MG-induced AGEs in vascular tissues. 
Our present study showed that the increase of blood pressure induced by chronic 
administration of fructose was attenuated by metformin, which implies that fructose 
induces blood pressure elevation partially via the enhanced formation of MG and 
MG-induced AGEs. Increased MG and MG-induced AGEs in fructose-fed rats can cause 
the increase of blood pressure mainly by two mechanisms. One is oxidative stress and 
the other is increased vascular contractility. From literature, a number of studies [24-26] 
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have shown that there is a synergistic relationship between MG, AGEs and oxidative 
stress. Oxidative stress is one of the pathogenic factors in the development of 
hypertension in experimental models [27]. Our previous study showed that MG 
increased the formation of superoxide, H2O2 and peroxynitrite in rat aortic SMCs [13]. 
As shown in figure 4, administration of metformin significantly attenuated the increase 
in H2O2 in fructose-fed SD rats. Moreover, the reduced serum level of the antioxidant 
GSH in fructose-fed rats was significantly increased after cotreatment with metformin. 
Regarding increased vascular contractility, a number of studies [28, 29] have shown that 
the endothelium-dependent vascular relaxation is impaired in fructose-fed rats while the 
mechanisms are not clear. In the present study, we found not only increased formation of 
MG-induced AGE, CEL, and decreased level of eNOS in the aorta, but also increased 
CEL and CML, another AGE product of MG, in the mesenteric arteries where they were 
mainly localized in the endothelium (Fig. 6). These changes possibly cause endothelial 
dysfunction observed in fructose-fed rats. Our results showed that chronic fructose 
treatment causes a eutrophic inward remodeling in mesenteric arteries from SD rats, as 
evidenced by decreased lumen diameter and increased media/lumen ratio without 
changes of cross-sectional area. This remodeling was restored by metformin which 
implies that this vascular morphological damage was likely caused by MG-induced 
AGEs. Moreover, it was reported that AGEs can not only reduce eNOS activity [30] but 
also deactivate this enzyme [31]. 
In summary, our present study provides further evidence for MG as one of the 
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causative factors in the pathogenesis of hypertension. The study shows that chronic 
fructose treatment in normotensive SD rats significantly enhanced MG and MG-induced 
AGEs formation. An overproduction of MG and MG-induced AGEs induced an 
elevation of blood pressure most likely by increasing oxidative stress and vascular 
contractility. Increasing consumption of fructose in the Western diet is a health concern.    
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Table 7-1.  Biochemical parameters of serum from rats with different treatment. 
 
Test Control (n=7) 
Fructose 
(n=10) 
Fruc +Met 
(n=8) 
Metformin 
(n=4) 
Total cholesterol (mM) 0.85 ± 0.09 0.88 ± 0.07 0.77 ± 0.1 0.70 ± 0.07 
Triglyceride (mM) 0.35 ± 0.04 0.84 ± 0.05* 0.72 ± 0.06 0.16 ±0.03*# 
HDL-cholesterol (mM) 0.77 ± 0.07 0.66 ± 0.06 0.63 ± 0.04 0.61 ± 0.08 
Hemoglobin A1C(mM) 4.3 ± 0.21 4.4 ± 0.07 4.41 ±0.16 4.6 ±0.16 
 
Fruc: fructose, Met: metformin, *P<0.05 vs. control, # P<0.05 vs. fructose-treated group. 
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Figure 7-1.   Effect of fructose, methylglyoxal (MG) and metformin on the 
development of insulin resistance.  A. Serum insulin levels in different treated rats. 
Blood samples from rats were collected after 9 weeks of treatment with fructose (n=10), 
fructose plus metformin (n=8), or metformin (n=4), respectively.  B. Intraperitoneal 
glucose tolerance test. The blood glucose was determined using OneTouch® blood 
glucose monitoring system at 0, 10, 15, 30, 60, and 120 min after the glucose injection. 
C. Insulin-stimulated glucose uptake by adipose tissues from different treated rats. The 
glucose uptake in insulin-treated cells was presented as % of the basal glucose uptake 
level in untreated cells (n= 4-5 in each group).  *P<0.05 vs. control rats; #P<0.05 vs. 
fructose-treated rats.  
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Figure 7-2. Effects of fructose on systolic blood pressure and methylglyoxal (MG) 
levels in SD rats. Systolic blood pressure was measured by tail-cuff noninvasive BP 
measurement system (A). MG levels were measured in the serum at 13 and 20 weeks of 
age (B). At the end of the study, MG levels were measured in the aorta (C) from SD rats 
with different treatments (n = 5-6). *P<0.05 vs. control rats; #P<0.05 vs. fructose-treated 
rats.  
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Figure 7-3.    Immunohistochemical detection of CEL and eNOS in the aorta from SD 
rats. A. Double immunofluorescence staining was used to detect CEL (green color) and 
eNOS (red color). Both CEL and eNOS staining were mainly localized in the 
endothelium of aorta. Intensity of CEL (B) and eNOS (C) staining was quantified using 
GeneTools image analysis software (n = 3-5 in each group). *P<0.05 vs. control rats; 
#P<0.05 vs. fructose-treated rats.  
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Figure 7-4.    Oxidative stress levels in SD rats with different treatments. Hydrogen 
peroxide formation was measured in the aorta at the end of the study (A). Hydrogen 
peroxide (H2O2) production was determined by a DCFH-assay. Reduced glutathione 
(GSH) level was detected in the serum by HPLC method (B). *P < 0.05, vs. control rats.  
#P < 0.05, vs. fructose-treated rats. 
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Figure 7-5.     Morphological characteristics of the mesenteric arteries of rats. *P < 
0.05, vs. control rats.  #P < 0.05, vs. fructose-treated rats. 
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  Figure 7-6. Immunohistochemical detection of AGEs in mesenteric arteries.  CEL 
and CML staining was detected in the mesenteric arteries from control and treated SD 
rats (A). Scale bar: 25µm.  Intensity of CEL (B) and CML (C) staining was quantified 
using GeneTools image analysis software (n = 3-5 in each group). *P < 0.05, vs. control 
rats.  #P < 0.05, vs. fructose-treated rats. 
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General discussion 
Since the discussions related to specific results have been given in chapter 3-7, the 
general association of the results, therefore, is only discussed in this chapter. 
 
Elevated MG and AGEs are commonly associated with hyperglycemic conditions 
such as diabetes mellitus.  The role of MG and AGEs in hypertension has not been 
investigated widely. Our present studies show a strong association of MG and its AGE 
products, CML and CEL, with hypertension in SHR. The blood pressure of SHR was not 
different from that of WKY rats at 5 wks of age. From 8 wks onwards, it was 
significantly elevated compared to age-matched WKY rats. MG levels were increased in 
plasma and aorta, but not in kidney or heart, in SHR at an early age of 8 weeks. 
Importantly, the blood pressure increase was associated with a progressive increase of 
MG levels in plasma and aorta of SHR. MG level in SHR kidney was also significantly 
higher compared to WKY rats from 13 wks onwards. Moreover, the levels of 
MG-induced AGEs, CML and CEL, in the aorta and kidney were significantly higher in 
SHR than in WKY from 8 wks onwards, in parallel with the increased blood pressure in 
SHR. These changes in MG and AGEs in SHR are clearly not due to increased glucose 
metabolism since the latter shows no hyperglycemia (Natalucci et al. 2000; Wang et al. 
2005). Our studies suggest that in addition to diabetes/hyperglycemic or hyperlipidemic 
conditions (Alderson et al. 2003), MG may be one of the causative factors for the 
development of hypertension or its complications in this non-diabetic model.  
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To determine whether decreased MG and MG-induced AGEs could prevent 
vascular damage/remodeling and the development of hypertension, we chronically 
treated young SHR at the age of 5 weeks with aminoguanidine, an inhibitor of AGE 
formation. We found that administration of aminoguanidine to male SHR from 5 to 14 
wks significantly reduced plasma and aortic MG levels, decreased the levels of 
MG-induced AGEs (CEL and argpyrimidine) in the aorta, and prevented the 
morphologic damage in mesenteric artery, thus leading to a significant attenuation of 
blood pressure increase. Therefore, we provide evidence, for the first time, for a role of 
MG and MG-induced AGEs in the development of hypertension in SHR. 
SHR is a genetic hypertension model with multiple pathogenetic factors which 
have not been clearly defined. To further determine the role of MG and MG-induced 
AGEs in the pathogenesis of hypertension, we used fructose, a precursor of MG 
(Thornalley 2002), to treat normotensive SD rats for 4 months. Chronic administration 
of fructose to SD rats significantly increased serum and aortic MG levels, enhanced 
MG-induced AGE formation in the aorta and the mesenteric artery, and caused 
morphological damage in the arterial wall, leading to a significant increase in blood 
pressure. Metformin cotreatment attenuated the increase of blood pressure in 
fructose-fed SD rats by scavenging MG and AGEs. This finding further confirmed that 
the increased level of MG may be one of the causative factors for the development of 
hypertension.  
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Possible mechanisms for MG-induced hypertension 
Our present studies demonstrated, for the first time, that MG plays a very important 
role in the development of hypertension. The following mechanisms by which MG 
induces blood pressure increase are proposed. 
 
1. MG and oxidative stress 
Oxidative stress is a situation of imbalance between the production of reactive 
oxygen species (ROS) and antioxidant defense mechanisms. ROS are highly reactive 
byproducts of various metabolic processes and they are associated with cumulative 
damage and many disease conditions (Davies 1995; Finkel and Holbrook 2000). The 
primary sources of ROS include the mitochondrial electron transport chain and oxidase 
enzymes such as NADPH oxidase and xanthine oxidase. Vascular ROS are produced in 
endothelial, adventitial, and VSMCs. Under physiological condition, the generation of 
ROS is proportional to the rate of cellular metabolism and ROS function as signaling 
molecules (Finkel and Holbrook 2000). However, over generation of ROS may lead to 
endothelial dysfunction, VSMC remodeling and changes in vascular contractility, which 
are important factors in vascular dysfunction and hypertension (Chang and Wu 2006; de 
Champlain et al. 2004). 
 MG has been shown to increase production of ROS. The reaction of MG with 
alanine produces three free radical species: the cross-linked methylglyoxal dialkylimine 
radical cation, the enediol radical anion of methylglyoxal and the superoxide radical 
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anion (Yim et al. 1995).  MG induces hydrogen peroxide production in platelets 
(Leoncini and Poggi 1996). A recent study has shown that MG enhanced the production 
of hydrogen peroxide and superoxide anion in neutrophils through a process involving 
p38 MAPK-dependent exocytosis of intracellular storage granules (Ward and McLeish 
2004). Our previous study (Wu and Juurlink 2002) showed that increased MG level in 
VSMCs from SHR was correlated with elevated oxidative stress which was 
demonstrated by an enhanced ability to oxidize DCFH and decreased GSH/GSSG ratio, 
compared with that from WKY rats. Our recent study (Chang et al. 2005) found that MG 
induced NO and O2- production in a concentration and time-dependent manner which 
was inhibited by N-acetyl-L-cysteine, superoxide dismutase and NAD(P)H oxidase 
inhibitor in rat VSMCs. In addition, oxidized DCF, reflecting H2O2 and ONOO− 
production, was also significantly increased by MG. Our present study showed that 
administration of aminoguanidine significantly reduced the generation of O2.-, ONOO- 
and H2O2 in SHR. The GSH level in the aorta from aminoguanidine-treated SHR was 
significantly increased, as opposed to untreated SHR. In normotensive SD rats, 
administration of fructose significantly increased H2O2 production, which was reduced 
by metformin cotreatment.  
In addition to directly increasing ROS production, MG can also increase oxidative 
stress by inducing AGE formation. In diabetic animals, oxidative stress is elevated in 
proportion to the accumulation of AGEs (Forbes et al. 2002). On one hand, AGEs 
increase ROS production by enhancing the expression and activity of NADPH oxidase 
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(Christ et al. 2002). On the other hand, AGEs are able to inactivate antioxidant enzymes 
such as glutathione reductase (Blakytny and Harding 1992; Morgan et al. 2002) and 
glutathione peroxidase (Paget et al. 1998). In addition, AGEs enhance ROS generation 
by binding to AGE receptors, therefore, inducing receptor-mediated production of ROS 
(Brownlee 2001). A recent study reported that MG modifies Cu, Zn-superoxide 
dismutase by covalent crosslinking, which leads to the loss of enzymatic activity and 
release of copper ions from the protein (Kang 2003). Aminoguanidine, an AGE inhibitor 
by scavenging MG, can increase the activities of catalase, gluthathione reductase and 
gluthathione peroxidase in insulin-dependent diabetic rats (Stoppa et al. 2006). The 
previous study from our laboratory demonstrates that MG decreases activities of 
glutathione peroxidase and reductase (Wu and Juurlink 2002). Our present study further 
confirms that increased MG level in aortic tissues is accompanied with decreased 
activities of these two antioxidant enzymes. 
 
2. MG and vascular contractility 
The impairment of vascular relaxation was observed in MG-treated rats (Berlanga 
et al. 2005). After rats were treated with MG for 7 wks, photoplethysmography study 
showed that there was completely no vasodilatory response to nitroglycerine, while in 
normal control rats, the nitroglycerine increased the response more than 2-fold of the 
basal level. MG can also decrease vasodilation via AGEs. Increased MG level gives rise 
to elevated formation of AGEs, contributing to vascular dysfunction. It has been 
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suggested that the formation of cross links increases the accumulation of vascular 
collagen, and reduces the elastic properties of the arterial wall, contributing to the 
development of hypertension (Dart and Kingwell 2001). 
Large amount of evidence from clinical and animal studies indicates that increased 
vascular contractility or impaired endothelial-dependent vascular relaxation is associated 
with progressive elevation of blood pressure (Koller 2002; Oparil et al. 2003). NO is a 
primary vasodilator derived from the endothelium. Bucala R et al. (Bucala et al. 1991) 
first reported that acceleration of the advanced glycation process impaired 
endothelium-dependent relaxation by inactivating NO in diabetic rats. This observation 
was further confirmed by Sanchez-Ferrer’s group. They (Angulo et al. 1996) reported 
that an impairment of endothelium-dependent vasoregulation correlated with the 
presence of nonenzymatic glycation of hemoglobin, and this effect was caused by 
interference with NO by means of superoxide anion production. We observed reduced 
acetylcholine-induced relaxation in mesenteric arteries of SHR was significantly 
restored after 9 wks treatment with aminoguanidine, which indicates that reduced 
endothelium-dependent relaxation in SHR is linked to the AGE formation.   
AGEs impair endothelial-dependent vascular relaxation mainly by reducing the 
bioavilability and activity of NO. Several mechanisms by which AGEs block or reduce 
NO activity have been proposed. The first mechanism is that AGEs quench and 
inactivate NO via a rapid chemical reaction (Bucala et al. 1991). The second mechanism 
proposes that AGEs reduce not only eNOS protein expression but also the half-life of 
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eNOS mRNA through an increased rate of mRNA degradation (Rashid et al. 2004; Rojas 
et al. 2000). The third mechanism suggests that AGEs impair NO production by binding 
to endothelial AGE receptors, which causes a decrease in serine phosphorylation of 
eNOS, resulting in deactivation of this enzyme (Xu et al. 2003). In addition, other 
mechanisms may be also involved since it has been observed that AGEs decreased 
vasodilator PGI2 production (Yamagishi et al. 1998) and increased vasoconstrictor 
endothelin-1 expression (Quehenberger et al. 2000) in endothelial cells.  
Our data revealed most of the staining for MG-induced AGEs was localized in the 
endothelium of vessel wall. After aminoguanidine therapy, the MG-induced CEL and 
argpyrimidine in endothelium were normalized in comparation with that from age 
matched WKY rats. The expression of eNOS was also significantly recovered by 
aminoguanidine treatment. Moreover, the small mesenteric arteries from 
aminoguanidine-treated SHR showed restored endothelium-dependent relaxation to 
acetylcholine. A number of studies (Takagawa et al. 2001; Verma et al. 1996) have 
shown that the endothelium-dependent vascular relaxation is impaired in fructose-fed 
rats with unclear mechanisms. In the present study, we demonstrated an increase in MG 
and MG-induced CEL with a decreased level of eNOS in the aorta of fructose-fed rats. 
We also found increased AGEs (CEL and CML) in the mesenteric arteries, especially 
localized in the endothelium (Fig. 7-6). Therefore, these changes possibly cause 
endothelial dysfunction observed in fructose-fed rats. 
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3. MG and vascular remodeling 
It is well established that essential hypertension is associated with structural 
changes in the resistance vessels, a process known as vascular remodeling (Baumbach 
and Heistad 1989). At the cellular level, vascular remodeling involves changes in VSMC 
growth, cell migration, inflammation and fibrosis. Vascular remodeling in hypertension 
involves two processes. One is hypertrophic remodeling, in which media cross section is 
increased and encroaches on the lumen, indicating the presence of growth (Dao et al. 
2001; Zhou et al. 2005). The other one is eutrophic remodeling characterized by 
rearrangement of wall material around a reduced lumen without evidence of net growth 
(Intengan et al. 1999).  Mulvany M (Mulvany 2002) suggests that essential 
hypertension is associated only with eutrophic remodeling in small arteries. Chronic 
aminoguanidine administration restored AGEs associated morphological changes in 
mesenteric arteries from SHR, as evidenced by increased lumen diameter and decreased 
media/lumen ratio without changes of cross-sectional area. These data indicate that 
AGEs may play an important role in eutrophic inward remodeling in SHR.  Our results 
also showed that chronic fructose treatment caused a eutrophic inward remodeling in 
mesenteric arteries of SD rats. This vascular remodeling was restored by metformin, 
suggesting the vascular morphological change was likely caused by MG-induced AGEs. 
The mechanisms by which AGEs induce vascular remodeling are unclear. The possible 
mechanisms are the following; (1) Increased proliferation and fibronectin production of 
VSMCs (Sakata et al. 2000). (2) Promotion of endothelial cell adhesion and 
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transendothelial migration (Thomas et al. 2005). (3) Enhanced synthesis of extracellular 
matrix components (Sims et al. 1996). (4) Synthesis and release of cytokines, in 
particular IL-1β and TNF-α, and growth factors like insulin-like growth factor I 
(Kirstein et al. 1992), which are involved in SMC growth, migration and apoptosis. 
 
4. MG and vascular stiffening 
Systolic blood pressure increases with age mainly because of increased stiffness of 
the large conduit arteries. The stiffness of the arteries primarily involves two major 
structural proteins, collagen and elastin. Because collagen contains large amounts of 
lysine and arginine residues, it is very vulnerable to glycation. Once glycation occurs, 
collagen loses its normal elasticity, strength and flexibility in the vessel walls (Bailey 
2001). It has been found that glycated collagen is directly increased by AGEs in a 
concentration- and time-dependent manner, both in the presence (Basta et al. 2004) or 
absence (Kim et al. 2001) of hyperglycemia. This increase in glycated collagen is 
associated with a thicker and less distensible vessel wall matrix (Kim et al. 2001). 
AGE-collagen crosslinking is accelerated in response to increased mechanical stress in 
hypertension (Bishop and Lindahl 1999). In addition to glycated collagen, elastin fibrils 
in the vascular wall matrix may be also vulnerable to glycation, therefore, further 
reduces arterial distensibility (Bailey 2001). Large artery stiffness was reversed by AGE 
breaker ALT-711 in diabetic rats (Wolffenbuttel et al. 1998). In old SHR, ALT-711 
treatment not only reduced aortic mass, but also improved systolic pressure (Susic et al. 
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2004). A recent study (McNulty et al. 2007) reported that AGEs contribute to aortic 
stiffness independent of age and blood pressure in untreated hypertensive patients. 
 An increased AGE formation was found in the aorta of stroke-prone 
spontaneously hypertensive rats (Mizutani et al. 1999). Our results also showed that 
MG-induced AGEs, CEL and argpyrimidine levels in the aorta from SHR were 
significantly higher compared to age-matched WKY rats, which were reduced by AGE 
inhibitor aminoguanidine. Moreover, the CEL level was significantly increased in the 
aorta from SD rats after chronic fructose treatment. Increased AGE levels in aorta may 
contribute to the decreased aortic distensibility and mechanical strength in rats. 
 
5. MG and inflammation 
Inflammation is one of the causative factors in the pathogenesis of hypertension 
(Vaziri and Rodriguez-Iturbe 2006). AGEs trigger the inflammatory effectors like 
cytokines and chemokines by multiple intracellular signal transduction pathways, 
including MAP kinase, p21ras and NAD(P)H oxidase (Goldin et al. 2006). Activated 
macrophage can be induced by the interaction of AGEs with mononuclear phagocytes, 
manifested by the induction of insulin-like growth factor-1 and proinflammatory 
cytokines (Basta et al. 2004). AGE-RAGE interaction causes activation and 
translocation of NF-κB, leading to a transcriptional activation of many genes. Indeed, 
many of those genes are highly relevant to inflammation such as IL-1α, IL-6 and TNF-α.  
It was found that MG treated rats had enhanced expression of TNF-α and IL-1β, 
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two pro-inflammatory cytokines, in granulation tissue cells (Berlanga et al. 2005). Our 
previous studies have shown that MG treatment activated NF-κB in cultured VSMCs 
from aorta (Wu and Juurlink 2002) and mesenteric artery (Wu 2005). MG increased 
activation of NF-κB, indicated by an enhanced nuclear localized NF-κB p65 (Wu and 
Juurlink 2002). Recently, we found that MG significantly increased the generation of 
cytokines such as TNF-α, IL-6 and IL-8, in neutrophils from non-diabetic subjects 
(Wang et al. 2007). Moreover, our present study showed increased expression of NF-κB 
and activated macrophages, together with enhanced AGEs, CML and CEL, in kidney of 
stroke-prone SHR. 
 
6. MG and the kidney 
The kidney plays an important role in blood pressure homeostasis (Cowley and 
Roman 1996) and possibly the pathogenesis of hypertension in SHR (Roman 1987) and 
other models of hypertension such as DOCA-salt sensitive hypertension (Hall et al. 
1984). A number of enzymes including the nitric oxide synthase (NOS) isoforms, 
cytochrome P450s and various ion pumps are involved in the modulation of renin 
secretion and secretion/absorption of ions. An oxidative stress-induced alteration in the 
function of one or more of these enzymes/proteins can readily disturb the homeostatic 
mechanisms operating within the kidney and lead to increased blood pressure.  
AGE-induced renal injury was demonstrated in vivo when diabetic mice were 
randomized to receive either regular diet or diet containing low AGEs. Mice on the 
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regular diet, but not those on the low AGE diet, developed typical diabetic nephropathy 
(Zheng et al. 2002). Immunohistochemical data showed an accumulation of AGEs in 
glomerular basement membrane, mesangium, podocytes, and tubular cells of kidney 
from diabetic rats. Ultrastructural studies have indicated that AGE peptides may be 
reabsorbed by the renal proximal tubular cells (Bendayan 1998; Gugliucci and Bendayan 
1995). AGE deposition can lead to glomerulosclerosis, which is independent of diabetes 
(Vlassara et al. 1994). Our immunohistochemical studies revealed positive staining for 
CML and CEL in the renal tubules and the glomerular vessels of SHR compared to 
WKY rats from 8 wks onwards. This suggests that an increased MG level and 
MG-glycated proteins in kidney may induce local micro-vascular and tubular damage, 
consequently impairing renal function, thus contributing to the development of 
hypertension in SHR. 
  
7. MG and renin-angiotensin system 
Renin-angiotensin-aldosterone is primarily responsible for the long-term control of 
blood pressure. Angiotensin II (Ang II) increases blood pressure by various mechanisms, 
including stimulating aldosterone synthesis and release, enhancing renal tubular sodium 
reabsorption, constricting resistance vessels, and stimulating antidiuretic hormone 
release. AGEs have been shown to interact with the renin-angiotensin system. It was 
observed that AGEs increased Ang II production in a time- and concentration-dependent 
manner in rat mesangial cells (Fukami et al. 2004). Inhibition of angiotensin converting 
enzyme (ACE) also attenuates the formation and accumulation of AGEs in experimental 
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diabetes. ACE inhibitor captopril was found to reverse AGE-induced collagen 
production, probably by attenuating RAGE expression and JAK2-STAT1/STAT3 
activities (Huang et al. 2001).  Ramipril, another ACE inhibitor, was reported to reduce 
renal and serum AGEs in STZ-induced type 1 diabetic animals (Forbes et al. 2002). 
Even though further studies are needed, it is possible that AGEs increase blood pressure 
partially by stimulating renin-Ang II system. 
 
CONCLUSIONS 
Our present studies show a strong association of MG and its AGE products with 
hypertension in SHR. The blood pressure of SHR was not different from that of WKY 
rats at 5 wks of age. From 8 wks onwards, blood pressure was significantly elevated 
compared to age-matched WKY rats. Importantly, this increase in blood pressure was 
associated with an elevated MG levels in plasma and aorta of SHR in an age-dependent 
fashion compared to age-matched WKY rats. Moreover, immunohistochemistry revealed 
more intense staining of MG-induced AGEs (CML and CEL), in the aorta from SHR 
compared to WKY rats from 8 wks onwards, in parallel with blood pressure increase in 
SHR. These changes in MG and AGEs in SHR are not due to increased glucose 
metabolism since the glucose levels and insulin sensitivity in SHR and WKY rats are 
comparable. In addition, we observed that both male and female stroke-prone SHR at the 
age of 24 weeks had more positive CEL and CML staining in kidney compared to 
age-matched male and female SD rats. Our data suggest that in addition to 
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hyperglycemic or hyperlipidemic conditions, the accumulation of MG and MG-induced 
AGEs in blood vessel walls plays an important role in the development of hypertension 
or its complications in SHR.  
We also observed that the blood pressure increase in SHR was attenuated and the 
mesenteric artery remodeling was reversed after inhibiting MG and its AGE formation 
by aminoguanidine. Moreover, the blood pressure of normotensive SD rats was 
increased, along with vascular remodeling, after chronic treatment with fructose to 
increase endogenous MG and its related AGE generation.  
In conclusion, our studies strongly indicate that increased MG and AGE 
formation may be a causative factor in the development of hypertension. MG and 
MG-induced AGEs may increase blood pressure by modulating the redox state, inducing 
endothelial dysfunction, and causing vascular remodeling and arterial stiffening.  
 
SIGNIFICANCE OF THE STUDY 
Despite some prevention and treatment successes over the past twenty-five years, 
the largest mortality rate in Canada is still linked to cardiovascular diseases. According 
to the latest statistics, 37% of all deaths are due to cardiovascular diseases. The annual 
economic burden of hypertensive conditions in Canada has been estimated at $20 billion. 
Each year, 80,000 Canadians die from hypertension and related cardiovascular diseases. 
Moreover the situation appears to be worsening with earlier onsets of hypertensive states 
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and rising incidences.  
The importance of MG in regulating cellular function has only been recognized 
in diabetes and a few other rare diseases with abnormal glucose metabolisms. Clarifying 
the role of MG in the development of essential hypertension has fundamental 
significance and may lead to the discoveries of new mechanism and methods for the 
management and prevention of hypertension as well as its complications. The derived 
novel discoveries can be directly transformed to pharmaceutical anti-hypertension drugs 
and to new diagnostic method and standard for early detection and follow-up the 
progression/regression of hypertension.  
 
 
FUTURE DIRECTIONS 
To extend and expand our findings reported in this thesis, we are planning to carry 
out the following experiments in the future. 
 
1. To further investigate the mechanism for increased MG production in SHR. The 
activities and expression levels (mRNA and protein) of different enzymes that are 
involved in MG generation and catabolism, such as glyoxalase I and II, will be 
determined and quantified using Real-Time PCR and Western blot analysis.  
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2. To investigate the mechanisms for MG-induced changes in vascular functions, 
including enhanced vascular contractility or reduced endothelium-dependent 
relaxation. These mechanisms include altered calcium levels and ion channel 
functions, and altered signal transduction pathways such as cAMP and cGMP. 
 
3. To examine the effect of MG on vascular remodeling. We will test whether MG can 
directly induce vascular smooth muscle cell proliferation. The mRNA (Real time 
RT-PCR) and protein (Western blot) levels of mitogen-activated protein kinases 
(MAPK, including ERK1/2, p38, JNK), activator protein-1 and NF-κB in vascular 
tissues will be investigated for their involvement in cell proliferation process.  
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